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1. General 
West Nile virus (WNV) is a neurotropic, arthropod-borne flavivirus with a single-stranded 
positive-sense RNA genome. It belongs to the Japanese encephalitis antigenic complex of 
the family Flaviviridae, which also includes other important human pathogens such as 
Japanese encephalitis (JEV), Dengue virus (DENV), and Tick-borne encephalitis virus 
(TBEV). WNV is maintained in an enzootic cycle between mosquitoes and birds, but can 
also infect and cause disease in mammals such as horses and humans, which serve as 
incidental dead-end hosts as viremia in these mammals is generally too low to infect 
mosquitoes [1].  
The WNV genome is approximately 11 kb in length and translates into a single 
polyprotein, which is cleaved by host and viral proteases into three structural proteins 
(Envelope E, Pre-membrane/membrane prM/M and Capsid C), and seven non-structural 
proteins (NS1, NS2a, NS2B, NS3, NS4A, NS4B and NS5) (Figure 1). The E protein binds 
to the host cell surface receptor mediating viral entry and fusion, C encapsulates the viral 
RNA, and prM acts as a chaperone for E during intracellular virion assembly by masking 
and inactivating E to prevent fusion of premature virions. Non-structural proteins are 
implicated in viral transcription, translation, replication, maturation, and immune evasion 
[2].  
 
 
    
Figure 1. Structure and genome of West Nile virus  
(credited to: http://www.expasy.ch/viralzone/all_by_species/24.html, and Valiakos et al., 2013) 
 
Epidemiological studies indicate that frequency and severity of clinical illness 
increases with age [3, 4]. Infection with WNV remains asymptomatic in the majority of 
cases while it results in West Nile fever (a mild flu-like illness) in approximately 20 to 30% 
of infected individuals [3, 5, 6]. Symptoms are of sudden onset and may include malaise, 
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eye pain, headache, myalgia, gastro-intestinal discomfort and rash [5, 7-10]. In a small 
percentage (~1%) of cases, WNV-infected patients develop meningitis and/or encephalitis, 
which may result in acute flaccid paralysis (AFP) [3, 4], and long-term neurological 
sequelae are common in more than 50% of patients who develop encephalitis [11-15]. This 
disease manifestation is explained by neuronal damage in several regions of the brain. The 
fatality rate for hospitalized encephalitic cases is approximately 10%, with increased risk 
for patients with a compromised immune system, of young and old age, and with 
underlying conditions such as diabetes mellitus [16].  
WNV was first identified in 1937 in a febrile patient in northern Uganda [17] and is 
currently one of the most geographically spread arboviruses in the world as it can be found 
on every continent except Antarctica [18]. WNV is endemic in parts of Africa, Europe, the 
Middle East, Asia [1], and since the turn of the century also in North America. In fact, it is 
only following its emergence in New York City in the United States in 1999 that WNV 
gained significant attention in the Americas. In late August of that year, an unusual cluster 
of encephalitis cases was reported to and investigated by the New York City Department of 
Health. At the same time, an epizootic among birds associated with a high fatality rate had 
been noted in and around New York City [19]. Sequencing of the virus isolated from brain 
tissue of some of these birds, as well as from three human encephalitis cases, all identified 
the same lineage 1 strain of WNV [20]. In total, 62 human cases were identified during this 
outbreak, including seven deaths [21], while retrospective extrapolation from a household 
based study estimated a total of 8200 subclinical infections and 1700 symptomatic 
infections. This was the first evidence of WNV activity in the Americas, and since the 1999 
outbreak WNV spread across the country from east to west within 5 years, and is now 
reported from all over the Americas [22-24]. 
WNV can be divided into seven distinct genetic lineages [25], of which lineages 1 and 
2 are the most frequently recognized. Lineage 1 can be divided into three subclades: WNV-
1a harbors strains from all over the world, including North America and North Africa; the 
Australian Kunjin virus is part of subclade 1b, and a few Indian strains constitute subclade 
1c. The majority of viruses belonging to lineage 1 are grouped into a cluster called the 
“European Mediterranean/Kenyan cluster”, while those responsible for outbreaks in Israel 
and in the New World can be grouped into the “Israeli/American cluster.” The former 
cluster is made up of two subclusters, of which one subcluster includes strains isolated in 
the western Mediterranean basin (WMed; France, Italy, Morocco), while the other includes 
strains isolated in the eastern Mediterranean basin (EMed; Israel) and southeastern Europe 
(Romania, Volgograd) [26]. Lineage 2, on the other hand, was mainly present in sub-
Saharan Africa and Madagascar, where it was considered to be non-pathogenic for humans 
and horses [27, 28]. More recently, however, more virulent lineage 2 strains have also been 
observed in South Africa and some European countries, such as Hungary, Austria, Greece, 
Romania, Italy, and Serbia, where it has demonstrated its capacity to cause severe clinical 
symptoms in humans, equines and wild birds [29-31].  
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West Nile virus can be considered an ecological generalist [32] with an exceptionally 
complex eco-epidemiology, as in North America it has been found to be transmitted by 
numerous species of mosquitoes and is able to infect a highly diverse vertebrate host range 
that includes mammals, amphibians, and reptiles [33], while a wide array of bird species act 
as primary hosts. Despite this wide host range, not all infected hosts can transmit the virus, 
and only those in which the virus replicates efficiently to reach sufficiently high titers in the 
blood are able to infect mosquitoes through blood feeding. This is called “host competence” 
and is a characteristic of each host species that is part of a specific host-virus-vector system 
[34]. In fact, competent hosts for WNV transmission are found almost exclusively among 
avian species [35], and a viremia level of >105 PFU/mL has been determined as the lower 
limit for efficient infection of feeding Culex (Diptera: Culicidae) mosquitoes found in the 
United States [36, 37]. As a result, avian hosts that are competent to transmit the virus to 
feeding mosquitoes are also often referred to as “amplifying hosts”. However, this 
threshold appears to vary per mosquito species or geographical region, as for example, the 
threshold titer for Cx. univittatus in South Africa was reported to be <104.0 50% suckling 
mice lethal doses (SMLD50)/mL of blood, and 104.6 SMLD50/mL of blood for infection of 
C. perexiguus in Egypt [38], while some California populations of C. tarsalis, C. pipiens, 
and C. erythrothorax can be infected at titers of <105.0 PFU/mL [39]. Even though it is 
possible that titers below 105.0 PFU/mL result in fewer infections, it stresses that for a better 
insight in the role of different species in transmission, reservoir competence studies should 
be conducted for a large range of mosquito and bird species from different geographical 
locations. 
Bird mortalities among free ranging birds have been the hallmark of WN disease 
emergence in North America. Birds of at least 326 different species are known to have died 
from WNV disease [40], of which bird species belonging to the order Passeriformes have 
been found to be the most susceptible, with the family Corvidae being most affected. In 
fact, deaths among American crows (Corvus brachyrynchos) have been used to track the 
spread of the virus across many parts of North America [41-43]. In contrast, wild bird 
mortality events are very infrequent in the Old World, with small, sporadic episodes 
affecting few individual birds, and are often detected in wildlife rehabilitation centers [44]. 
Despite the proposition of several hypotheses, an explanation for the differences in wild 
bird mortality in Europe as compared to North America is still pending.  
Among arthropods, WNV replicates in a wide range of mosquitoes, also called 
“vectors”, which are considered to serve as a source of (re-)infection of humans, and are 
able to sustain a pathogen when it is not infecting humans. WNV has been found to infect 
up to 59 different species of mosquitoes in the US [45]. Similar to vertebrate hosts, not all 
infected mosquito vectors are able to transmit the virus efficiently, as the ability of 
transmission to occur after biting a host is dependent on whether the virus is able to 
replicate systematically and reach a high enough viral titer in the salivary glands. This so-
called “vector competence” applies to each vector species in a particular virus-vector 
system [34]. Culex mosquitoes, and especially the ornithophilic ones (e.g. Cx. pipiens), play 
 14 
an important vector role. However, some non-Culex (non-ornithophilic) species, such as 
Aedes albopictus, have been found positive for WNV antigen in a field light trap [46], and 
were also identified as competent vectors in the lab [47], but their role in transmission is 
still unclear. More importantly, however, at least 12 mosquito species have been implicated 
as potential ‘bridge’ vectors or epidemic vectors, which are considered responsible for 
transmission to humans [48, 49]. Indirect evidence based on blood-meal analysis and theory 
suggest that Cx. pipiens may serve as both an enzootic and an epidemic ‘bridge’ vector [50, 
51]. However, most mosquito studies have so far been conducted using North American 
mosquitoes, and it is likely that even within the United States vectors that are most 
important for transmitting WNV to humans differ per region. As a result, especially for 
European mosquitoes, research efforts should continue to focus on studying vector 
competence, as well as feeding preferences and behavior. 
Interestingly, other arthropods such as ticks have also been found to be susceptible to 
WNV infection, as the virus has been isolated from both soft and hard ticks [52-57] and 
Ornithodoros moubata ticks became infected and were able to transmit the virus to rodent 
hosts in the lab [58]. Even though ticks are unlikely to play a major role as vectors in the 
transmission of WNV, these findings suggest that some species still have the potential to 
act as a source of infection (“reservoir host”) [58]. As a result, it is likely that this complex 
eco-epidemiology, which involves hundreds of different vectors and hosts per location, has 
contributed to the broad geographical range of WNV. 
 
2. West Nile virus in Europe 
The first indication of the presence of WNV in Europe was in 1958, when specific WNV 
antibodies were detected in two Albanians [59]. The first isolations of the virus in Europe 
were then recorded in 1963 from patients and mosquitoes in the Rhône Delta [60] and from 
patients and Hyalomma marginatum ticks in the Volga Delta [61, 62]. Cases of WN fever 
were observed in the 1960s in southern France [63], southern Russia [64] and Spain [65], 
southwestern Romania [66], as well as in the 1970s, 1980s and 1990s in Belarus [67], 
western Ukraine [68], southeastern Romania [4, 69] and Czech Republic [70]. Despite this, 
however, before the mid-1990s, WNV was only sporadically detected in humans.  
The first major outbreak of WNV, which consisted of a high case fatality rate in 
humans (~10%), occurred in Romania in 1996 [4, 71]. Since then, the virus has been 
isolated from horses, humans and mosquitoes, in several Eastern and Western European 
countries [72, 73]. However, with the exception of an outbreak among horses in Camargue, 
Southern France in 2000 [74], and a few cases that occurred in Spain [75], significant WNV 
activity in Europe has mostly been concentrated in Italy and in southeastern and eastern 
Europe rather than in Western Europe. 
Detailed phylogenetic analysis of the lineage 1 viruses that had caused the later 
outbreaks indicated that those which had been isolated around the western Mediterranean 
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were caused by a single strain, referred to as the WMed subtype, and that this virus was a 
single introduction that had overwintered for a number of years [76]. It was speculated that 
this sub-lineage was transferred between Mediterranean countries by viremic birds, 
resulting in the initiation of new outbreaks. A second closely related sub-lineage included 
viruses isolated from Romania and Russia, while a more divergent sub-lineage was 
responsible for outbreaks in Israel (and North America). It is likely that each sub-lineage 
represents a separate introduction of WNV into Europe from Africa [31]. 
WNV lineage 2 was first detected in Europe in 2004 and was isolated from the brain 
of a goshawk (Accipiter gentiles) in Hungary [28]. Retrospectively, a human case of WNV 
lineage 2 infection was confirmed to have occurred in Russia in the same year [77]. 
Following surveillance of dead birds of prey, especially goshawks, between 2004 and 2009, 
led to repeated isolations of the virus across Hungary [30]. Outbreaks of WNV lineage 2 
subsequently occurred in a number of other European countries, including Austria, Greece, 
Romania, Serbia and Italy, of which the outbreak in Greece was particularly severe. The 
virus was first detected there in 2010 [78] in northern Greece, which, in contrast to the 
emergence in Hungary, developed into a significant human epidemic. The majority of cases 
were reported west of the city Thessaloniki, between the rivers Axios and Aliakmonas. In 
total, 262 patients were recorded, with 65 classified as West Nile fever and 197 as 
neurological cases, of which 33 died [79]. Subsequent surveillance resulted in the isolation 
of WNV lineage 2 from mosquitoes, giving rise to the Nea Santa-Greece 2010 strain [80], 
and from wild resident birds [81]. Retrospective serology in humans suggests that this 
virus, or at least a closely related one, had been circulating in Greece for several years prior 
to the first human cases of WN fever [78]. This seropositivity was at a low level of <1%, 
however, and was not accompanied by reports of disease. Following the 2010 outbreak, 
further epidemics of WNV lineage 2 infections in Greece occurred during the late summer 
of both 2011 and 2012 [82, 83]. Sequencing of viruses detected in humans has confirmed 
that the same virus strain was present in both humans and wildlife in each subsequent year, 
suggesting endemic persistence of WNV lineage 2 in Greece. So far, this strain appears to 
cause disease in humans, and infects wild avian species as determined by serological and 
molecular surveillance [81], but with relatively few confirmed reports of disease in equine 
species [31] and few confirmed deaths among birds. 
WNV lineage 1 has been present in Italy since at least 1998, when the virus was first 
detected during an outbreak in horses, in which 14 animals had tested positive for WNV, 
with 6 fatal cases [84]. Subsequent evidence of seroconversions in sentinel horses and 
chickens was found in different risk areas under serosurveillance in the following years, but 
no infections in humans were recorded. The first human cases of neuroinvasive disease 
appeared a decade later affecting eight provinces in three Northern regions of Italy (Emilia 
Romagna, Veneto, Lombardy) in September-October 2008 [85, 86], where a total of 794 
cases of WNV infection in 251 equine stables were detected on the basis of clinical signs 
and as a result of serological screening [87]. In addition, wild birds captured or found dead, 
including European magpies (Pica pica), carrion crows (Corvus corone), rock pigeons 
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(Columba livia) and Eurasian jays (Garrulus glandarius) were found positive by RT-PCR 
[87-89], and nine human cases of WNV, which included four characterized by 
neuroinvasive disease, were detected in 2008 [90-92]. In 2009, a new epidemic emerged in 
the same area as that of the 2008 outbreak, but with new foci of infection in Central Italy. 
Since then, WNV lineage 1 has become endemic in Italy, and is often detected in humans, 
horses, wild birds, mosquitoes and sentinel chickens, with most WNV epidemic activity 
localized in the northeastern part of Italy [86]. 
Interestingly, the first case of a WNV lineage 2 infection in Italy, in the coastal town 
of Ancona on the Adriatic Sea, was reported in 2011 [93], a year after the first detection in 
Greece. Shortly after this, six cases of neurological disease resulting from a WNV lineage 2 
infection were reported in Sardinia between September and October, 2011 [94], and 
mosquito surveillance also detected a lineage 2 WNV strain in Cx. pipiens mosquito pools 
and in a collared dove (Streptopelia decaocto) in northern Italy [95], where lineage 1 has 
been circulating since 2008 [86]. WNV lineage 2 in Italy continued to be detected in 
subsequent years, including in more human cases [86, 95]. The presence of a lineage 2 
strain in the same area where a lineage 1 strain is still circulating could potentially create a 
new scenario with unpredictable consequences [95]. 
 
3. Virulence 
The virulence of WNV is mostly associated with its capacity to invade the nervous system 
(neuroinvasiveness), its ability to infect neurons and spread within the CNS (neurotropism), 
and its tendency to cause disease through infection of the nervous system (neurovirulence). 
Even though a neurovirulent virus is usually neuroinvasive, it does not always indicate that 
the virus is neurotropic [96] as it may cause disease by triggering immunopathologic 
responses. Furthermore, neuroinvasiveness does not always lead to neurovirulence [96] as a 
virus may infect the brain without causing disease. As a result, the virulence of WNV 
appears to be quite complex and WNV strains may therefore possess varying degrees of 
virulence, which may be caused by different underlying mechanisms.  
3.1. Molecular basis of virulence 
The ability of WNV to persist and cause disease within the host largely depends on its 
ability to infect target cells and evade recognition by the immune system. Particular 
biological aspects of WNV facilitate its capacity to cause severe disease. Firstly, WNV is 
able to productively infect diverse cell populations from many animal species, which 
suggests the use of multiple and/or well-conserved receptors [97-103]. Secondly, in vitro, 
WNV is cytolytic and induces apoptosis in a variety of cell types, most importantly neurons 
[104, 105]. There are several cases in which WNV has been found to cause neuronal 
necrosis in vivo, in for example, wolves [106], large falcons [107], raptors [108], squirrels 
[109], dogs [110], horses [111] and humans [112]. Studies have indicated that individual 
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WNV proteins may contribute to virus-mediated cytotoxicity and may therefore function as 
virulence factors. For example, in vitro expression of NS3 or capsid protein induced rapid, 
caspase-dependent apoptosis, and in vivo capsid protein expression led to cell death [113, 
114]. Further details on mechanisms of cell death will be discussed below, in the section 
Pathogenesis. 
Genetic variation also influences WNV virulence. Several mutations have been found 
to increase or reduce virus pathogenicity via various mechanisms. Of these, some appear to 
have a major impact on the replication mechanisms of WNV. Beasley et al. found that 
mutations in the envelope protein at residues 154 to 156, which abolished the N-linked 
glycosylation motif (N-Y-S/T), attenuated virus pathogenicity for mice. In fact, it was 
hypothesized that the enhanced virulence of North American strains of WNV compared to 
Old World lineage 1 strains was at least partly related to this envelope protein glycosylation 
[115]. They in particular appear to alter the protein such that it cannot be recognized by 
oligosaccharyl-transferase, resulting in a loss of glycan [116]. This glycosylation motif is 
common to various flaviviruses and spatially it is located close to the center of the fusion 
peptide of domain (D) II (which is one of the three structural domains (DI-III) of the E 
protein [117, 118]), and has therefore been proposed to increase the stability of the protein 
[119, 120], including at high temperatures [121]. Beasley et al. therefore hypothesized that 
the decreased neuroinvasive potential of non-glycosylated variants of WNV is due to their 
lower stability, which results in less infectious virus in the periphery. This dose of 
“infectious virus” additionally contains a larger proportion of noninfectious virus, which 
acts as an inactivated antigen that can significantly stimulate innate and adaptive immune 
responses. Nonetheless, it is also possible that E glycosylation may have an effect on other 
aspects of the WNV replication cycle, such as target cell tropism, virion assembly and 
release, and efficient fusion of E protein with target cell membranes [115]. 
Glycosylation was also found to be important for virus replication in a bird model as E 
glycosylated WNV variants inoculated into young chicks were more virulent and replicated 
to higher viremia titers than non-glycosylated variants. Furthermore, glycosylated variants 
also showed more heat-stable propagation in mammalian (BHK) and avian (QT6) cells. 
Interestingly this phenomenon was not seen in mosquito (C6/36) cells [121]. E-protein 
glycosylation may therefore also be a requirement for efficient transmission of WNV from 
avian hosts to mosquito vectors. 
Contrastingly, however, when Moudy et al. mutated the E protein glycosylation site 
from NYS to IYS in a full-length clone of the NY99 genotype, which resulted in a virus 
lacking the glycan at aa154 (WNV-N154I), they found that this mutant replicated less 
efficiently than WNV-WT in Culex mosquito tissues, although the decrease was more 
profound in Cx. pipiens than in Cx. tarsalis. Furthermore, following peroral infection, 
mosquitoes infected with WNV-N154I were less likely to transmit the virus than those 
infected with the WT [122]. The contradicting results between the studies by Murata et al. 
and Moudy et al. may be due to the fact that the former generated non-glycosylated variants 
by specifically mutating aa156 to NYP for one variant, and to NYE for another variant, 
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while the latter mutated the site from NYS to IYS. It is therefore possible that very specific 
differences in amino acid sequence have an effect on viral propagation and dissemination in 
vector mosquitoes.  
Interestingly, multiple amino acid changes at the first glycosylation motif in the NS1 
protein also attenuated mouse neuroinvasiveness. Specifically, mutants lacking 
glycosylation at either two or three of the three NS1 glycosylation sites (residues 130, 175, 
and 203) induced lower viremia and decreased lethality in mice [123]. Additionally 
mutating all three amino acids of the NS1130-132 glycosylation motif (NTT-QQA) gave the 
most attenuated strain out of several mutants harboring different mutations in the NS1 
glycosylation motif [124]. It therefore appears that substituting amino acids in WNV E as 
well as in NS1 glycosylation sites can result in a virus with a highly attenuated phenotype. 
A follow-up study using confocal and transmission electron microcroscopy (TEM) found 
that the lack of attenuation is due to a lack of NS1 glycosylation that blocks efficient 
replication, maturation, and NS1 secretion from the ER, resulting in changes to the virus-
induced ultrastructure [125].  
Most of the virulent lineage 1 strains, as well as the recent virulent lineage 2 strains 
associated with the Greek outbreak possess the N-glycosylation site, which could implicate 
it as a prerequisite for the efficient circulation and amplification of the virus in a mosquito-
avian transmission cycle [81, 126]. However, the role of the NS3 protein in the propagation 
of virus between birds and mosquitoes can also not be excluded. The NS3 protein contains 
a serine protease at the N-terminal and the RNA helicase, an NTPase and an RTPase at the 
C-terminal. Mutations in this protein have so far been found to have the most profound 
effect on the virulence of WNV in birds. Specifically, the introduction of a T249P in an 
attenuated Kenyan strain was found to be sufficient to generate a phenotype highly virulent 
to American crows, while a P249T introduction in the virulent NY99 strain resulted in an 
attenuated phenotype [127]. The H249P mutation in the Greek strain that caused the major 
WNV disease outbreak in 2010-2011 in Greece, where it was detected in mosquito pools, 
corvids and chickens, is considered a contributor to the observed increase in virulence of 
this lineage 2 strain, as all other lineage 2 strains contain a histidine at this position [126, 
128]. It is therefore possible that both the N-glycosylation site and the presence of a proline 
at NS3-249 play a (simultaneous) role in the emergence of virulent strains of WNV. 
The exact mechanism through which the NS3-249P mutation would increase the 
pathogenicity of WNV is unknown. It is possible that the proline mutation enhances RNA 
helicase function, resulting in an increased replication rate, leading to high viremia titers 
that may help surpass the bird viremia threshold required for infection of many mosquito 
species vectors (> 105 PFU/mL) [129]. Brault et al. did observe that the helicase activity on 
the uwinding of short dsRNA by alternative WNV NS3-249 helicase proteins differed 
between amino acid substitutions (249A, 249D, 249H, 249P, 249T); however, they found 
that the proline and threonine point mutations separated >80% of the dsRNA strands, while 
the NS3-249 proteins containing the alanine and histidine residues unwound more of the 
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dsRNA strands (>95%). As a result, these differences did not correlate well with the in vivo 
effects observed in American crows, where the 249P mutant replicates to higher viremia 
titers [130]. However, further helicase analysis under more biologically relevant 
temperatures (< 43ºC) [131] may provide more insight in this matter. 
WNV has also evolved certain strategies to avoid and/or attenuate innate and adaptive 
immune responses. The whole family of Flaviviridae is largely resistant to the antiviral 
effects of IFN as soon as cellular infection is established. In particular the flavivirus 
nonstructural proteins NS2A, NS2B, NS3, NS4A, NS4B and NS5 have been found to 
disable IFN-induced responses at multiple stages within the cell by delayed IRF-3 
activation and IFN-β gene transcription, as well as by impairing JAK1 and Tyk2 
phosphorylation [132-138]. In particular for WNV, the ability to control the host IFN 
response has been linked to the replication fitness and virulence of lineage 1 and 2 strains, 
as a pathogenic lineage 1 Texas isolate actively antagonized IFN signaling, whereas an 
attenuated lineage 2 strain from Madagascar did not have this ability [139]. However, the 
reduced replication and virulence of the lineage 2 isolate was restored in cells and mice 
lacking the IFN-α/βR. It therefore appears that inhibition of type I IFN responses are a key 
feature in the evolution of pathogenic WNV strains. Consistent with this, a mutation 
(A30P) in the NS2A of the Kunjin subtype WNV strain was found to reduce the ability of 
the virus to inhibit the IFN response, leading to increased levels of IFN synthesis in 
weanling mice, as well as attenuated neurovirulence [140]. Interestingly, introducing this 
mutation into a North American (lineage 1) strain did not lead to significant changes in 
phenotype, indicating that in many cases the effect of particular mutations can be virus 
strain-specific [141]. 
Several other non-structural proteins have been implicated in virulence. For example, 
a study has shown that substitution of cysteine with serine at position 102 of NS4B 
(Cys102Ser) leads to a high temperature-sensitive phenotype as well as attenuation of the 
neuroinvasive and neurovirulent phenotypes in mice [142]. The first 125 amino acids of the 
N-terminal of the NS4B protein of flaviviruses appear to be sufficient for the inhibition of 
IFN-α/β signaling [138], and a mutation located in this region of WNV may therefore 
interfere with the ability of the virus to inhibit IFN signaling. 
Another mutation in NS4B, E249G, also attenuated viral pathogenicity, as 
recombinant E249G virus exhibited smaller plaques, slower growth kinetics, and lower 
RNA synthesis than the WT in vitro, with the greatest difference in rodent cells (C3H/He 
and BHK-21) and the least difference in mosquito cells (C6/36). In addition, mice 
experienced no lethality upon inoculation with this virus [143]. A study examining an 
NS4B-P38G mutation also observed no lethality in a mouse model, as well as a lower level 
of viremia. Furthermore, mutant NS4B-P38G infected in cultured bone marrow-derived 
dendritic cells (DCs) exhibited a reduced replication rate but a higher level of innate 
cytokine production than WT WNV. This was shown to be related to the induction of 
higher innate and adaptive immune responses in mice, with specifically higher type I IFNs 
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and IL-1β levels and stronger memory and effector T cell responses. It therefore appears 
that the NS4B-P38G mutant strain induces faster and higher protective innate and adaptive 
immune responses in mice, which results in a lower viremia and no lethality [144]. 
Theoretically, amino acid changes that are considered to have a potential effect on the 
secondary structure of the proteins include substitutions of hydrophilic to hydrophobic 
amino acids or vice versa, and also substitutions of cysteine, glycine, and proline residues 
[145]. A study examining complete genome sequences of lineage 2 WNV strains isolated 
from patients in South Africa that had suffered mild or severe disease recognized that these 
kind of substitutions at NS3 (S160A and R298G), NS4A (A79T) and NS5 protein (T614P, 
M625R, M626R) were present in strains of high virulence [146]. They therefore concluded 
that mutations in the NS proteins encoding viral replication and protein cleavage 
mechanisms are the most likely determinants of differences in virulence.  
Flaviviruses have a low-fidelity RNA-dependent RNA polymerase that leads to the 
generation of quasispecies. This is because viral RNA polymerases exhibit 
characteristically low fidelity mutation rates of approximately 10-4 mutations per nucleotide 
copied, which is much greater than those of nearly all DNA-based viruses and organisms 
[147-149]. Given the large population sizes observed in both experimental and natural 
infections, it has been estimated that every possible point mutation and many double 
mutations are generated during each viral replication cycle and may therefore be present 
within the population at any given time [150]. Even a defined molecular clone will rapidly 
transform into a collection of related sequences when introduced into cells. This collection 
is termed the quasispecies and is organized around a master sequence [151]. 
 WNV has also been demonstrated to exist as quasispecies in nature. WNV was 
sampled from ten infected birds and ten infected mosquito pools during the peak of the 
2003 transmission season in New York State. Analysis of the E and NS1 revealed that 
WNV infections are derived from a genetically diverse population of genomes, with WNV 
sequences in mosquitoes being significantly more diverse compared to those in birds. Non-
consensus clones obtained from two avian specimens were genetically highly similar, 
which suggests that WNV genetic diversity may be maintained throughout the enzootic 
transmission cycle, rather than arising independently during each infection [152]. 
In a follow-up study, the mutant spectra that arose as a result of 20 serial in vivo passages in 
Cx. pipiens and young chickens was examined in order to determine the impact of 
mosquitoes and birds on intra-host WNV population dynamics. Genetic diversity was found 
to be greater in mosquito-passaged WNV compared to chicken-passaged WNV. 
Furthermore, mortality in mice was significantly negatively correlated with the size of the 
WNV mutant spectrum, in the sense that the more variable mosquito-passed strains were 
less pathogenic to mice while the genetically more homogenous chicken-passed strains 
were as virulent as the parental unpassed WNV. Together these studies suggest that 
mosquitoes serve as sources for WNV genetic diversity, that birds are selective sieves, and 
that both the consensus sequence and the mutant spectrum contribute to the WNV 
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phenotype [153]. It is also tempting to speculate that the antigenic variation exerted by 
quasispecies allows escape from antibody-mediated neutralization [154], as it is possible 
for strains with mutations at the dominant neutralizing epitope in DIII to emerge [155]. 
3.2. Host genetic determinants of WNV susceptibility 
A small number of genetic risk factors have been linked to increased susceptibility to 
WNV, and may explain why a certain number of individuals may progress to paralysis, 
meningitis, and/or encephalitis after WNV infection. In inbred mouse strains, a truncated 
form of the gene for OAS1b has been mapped to susceptibility to infection by flaviviruses 
[156, 157]. For humans, a recent study with 33 WNV-infected patients showed an increased 
frequency of an OAS splice-enhancer site that could give a dominant-negative protein 
[158]. Furthermore, a study by Lim et al. suggests that a hypomorphic allele of the OAS1 
human ortholog is associated with both symptomatic and asymptomatic WNV infection 
[159]. However, an actual analogous deletion in humans linked to severe WNV infection 
has not been identified yet. 
Experiments in animals have established that chemokines direct leukocytes to the 
brain to clear WNV from infected neurons and promote survival, as a genetic deficiency of 
the chemokine receptor CCR5 or the chemokine CXCL10 in mice was associated with 
depressed leukocyte trafficking, increased viral burden, and enhanced mortality [160, 161]. 
Interestingly, a study examining CCR5Δ32 (a relatively common mutant allele of the 
chemokine receptor CCR5) in WNV-infected cohorts found a greater incidence of 
CCR5Δ32 homozygosity in symptomatic and lethal WNV cases. In fact, even though only 
about 1% of the general United States population is homozygous for the CCR5Δ32 allele, 
4%-8% of individuals with laboratory-confirmed symptomatic WNV infection were 
homozygous for the mutant allele. These studies therefore suggest that CCR5 may function 
as an essential host factor for the resistance of neuroinvasive WNV infection [162]. 
Ultimately this may also have implications for the use of CCR5 antagonists in HIV therapy, 
as it could imply that HIV patients are more susceptible to WNV. 
 
4. Pathogenesis 
Despite the significance of central nervous system (CNS) pathology in severe disease, the 
mechanisms by which WNV and other encephalitic flaviviruses cause neurological signs 
and symptoms in vivo have not been completely elucidated. The increased risk for 
immunosuppressed patients seems to suggest that an intact immune system is essential for 
the control of WNV infection. Even though peripheral immune responses to WNV can 
prevent encephalitis, up to 40% of immunocompetent animals infected with a virulent strain 
of WNV develop lethal neuroinvasive disease [163, 164]. As a result, the involvement of 
the immune system in the pathogenesis of such cases cannot be excluded.  
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Most of the knowledge regarding the mechanisms of WNV dissemination and 
pathogenesis is derived from studies using rodent models. It is believed that after a 
mosquito bite WNV infects keratinocytes [165] and Langerhans cells (LC), of which the 
latter migrate to regional lymph nodes where initial replication occurs [166-170]. WNV 
then spreads systemically to visceral organs, such as the kidney and spleen, where a second 
round of replication takes place, presumably in epithelial cells and macrophages 
respectively [171]. WNV can then enter the brain, probably via the blood-brain barrier 
(BBB) or another unconfirmed mechanism (as discussed below), and cause meningo-
encephalitis. The envelope glycoprotein of WNV has been implicated in neuroinvasiveness, 
particularly DIII of the protein, which constitutes the receptor binding domain [172-174].  
It is interesting to note that several other flaviviruses are known to cause neuroinvasive 
disease, but little is known about the pathogenic mechanisms. Studies of flaviviruses that 
rarely cause neuroinvasive disease may contribute to a better understanding of the 
mechanisms involved in viral entry of the brain. For instance, infection with DENV, one of 
the most important arboviruses of humans, may result in severe systemic disease, 
manifested as haemorrhagic or shock syndrome [175], but this virus is generally considered 
non-neurotropic. Recent observations, however, indicate that the clinical profile of DENV 
infection may be changing, as neurological manifestations are becoming more frequent 
[176, 177].  
4.1. Crossing the Blood-brain-barrier (BBB) 
The BBB is a diffusion barrier that impedes the influx of compounds from blood to brain. It 
is made up of three cellular elements, namely endothelial cells on the capillary basement 
membrane (BM), astrocyte end-feet that ensheath the vessels, and pericytes (PCs) that are 
embedded in the BM. Tight junctions (TJs) are present between the cerebral endothelial 
cells and form the diffusion barrier, which selectively prevents most blood-borne 
substances from entering the brain. Lastly, the CNS is populated by three different glial cell 
populations: (1) astrocytes, (2) microglia, and (3) oligodendrocytes, which form the 
immune system in the brain.  
In mice, WNV crosses the BBB and infects the CNS after peak viremia (around day 3) 
[178]. How WNV is able to enter the CNS is not completely understood, but several 
mechanisms have been proposed: (i) infection or passive transport through the endothelium 
or choroid plexus epithelial cells (Wang, 2004, hypothesized only), (ii) infection of 
olfactory neurons and spread to the olfactory bulb [179-181], (iii) a “Trojan horse” 
mechanism in which the virus is transported by infected immune cells trafficking to the 
CNS [99], and (iv) direct axonal retrograde transport from infected peripheral neurons [182, 
183]. Even though the cited studies provide indications that such mechanisms may indeed 
be employed by the virus to enter the brain, the majority of the studies do not provide actual 
clear evidence in support of these hypotheses, as the majority of the conclusions are based 
on an over-represented amount of in vitro experiments that lack adequate in vivo validations 
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as support. As a result, several gaps remain in the hypothesized routes of WNV 
neuroinvasion and need to be investigated further; in addition to the investigation of 
alternative routes of neuroinvasion that have thus far received little attention, such as the 
role of the arachnoid (meningeal barrier) [184]. 
In fatal human cases, WNV is most often detected in neurons in the cerebral cortex, 
thalamus, brainstem, basal ganglia, cerebellum, and spinal cord (mainly anterior horn), and 
in some cases, infection has been detected in the olfactory bulb and hippocampus [185] 
(Figure 2). WNV has been detected in the same regions of the brain of experimentally 
infected mice as in humans, indicating a similar tropism of WNV in humans and mice 
[184]. Histological analysis of samples from fatal human cases also provided evidence of 
gliosis, indicating involvement of microglial cells and astrocytes during WNV infection. 
Overall, in vitro experiments have shown that WNV can infect primary neurons, human and 
mouse neuroblastoma cells [104, 105, 186], human brain cortical astrocytes (HBCA), 
human brain microvascular endothelial cells (HBMVE) [187, 188], and oligodendrocytes 
[189], while infection of microglia resulted in low viral yield [187]. So far, animal 
experiments have only shown infection of neurons by WNV [103, 112, 190, 191] and have 
provided limited evidence of in vivo glial cell infection. 
A study performed by Verma et al. using HBMVE cells and HBCA, showed that 
several matrix metalloproteinases (MMPs), which are produced by monocytes and glia cells 
and appear to be involved in the migration of leukocytes to the perivascular space as well as 
migration through the glia limitans [192], were significantly induced in WNV-infected 
HBCA cells [188]. Incubation of naïve HBMVE cells with the supernatant from WNV-
infected HBCA cells resulted in loss of tight junctions. These data provided evidence that 
astrocytes represent a source of MMP in the brain, which may lead to disruption of the 
BBB. Degradation of components of the glia limitans is another mechanism facilitating 
migration of leukocytes into the brain parenchyma. Collagen (a component of glia limitans) 
could be degraded by extracellular proteases such as the cysteine protease cathepsins K, S, 
and L [193, 194], whereas conversion of plasminogen into plasmin may lead to degradation 
of laminin or fibronectin, other important components of the glia limitans [193, 195]. When 
the integrity of the BBB is compromised, immune cells may enter the brain, thereby 
contributing to WNV viral clearance and immune mediated damage.  
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Figure 2. Frequency of infection of several regions of the human brain by West Nile virus  
(Lim al., 2011) 
 
4.2. Mechanisms of Cell Death upon Infection 
Programmed cell death can be considered a defense mechanism of the host in response to 
pathogenic insults. Pathogens may induce cell death to the host either by direct infection of 
host cells (e.g. cytolytic viruses) or by releasing toxic products (e.g. bacterial toxins). Cell 
death has been generally divided into necrosis, which is accidental, uncontrolled cell death 
resulting in an inflammatory response, and programmed cell death, a regulated and 
controlled process that has traditionally been considered to be non-inflammatory. Even 
though programmed cell death is often used as a synonym for apoptosis, it is more 
accurately described as cell death that is dependent on genetically encoded signals or 
activities within the dying cell [196, 197]. No cellular activity is required as acute cell 
breakdown occurs as a result of the direct action of a damaging stimulus, and programmed 
cell death is therefore only prevented by the absence of this stimulus [196].  
Recent studies have revealed several pathways that lead to programmed cell death: 
apoptosis, pyroptosis, autophagy and oncosis [198]. Apoptosis is mediated by a subset of 
cysteine-dependent aspartate specific proteases, or caspases, which can be divided into two 
functional subgroups: initiator caspases (caspase-2, -8, -9, and -10) are mainly involved in 
activation of the effector caspases-3, -6, and -7, which cleave a variety of cellular 
substrates. Apoptosis involves nuclear and cytoplasmic condensation and formation of 
membrane-bound cellular fragments or apoptotic bodies. During viral infection, 
programmed cell death has an antiviral effect by inducing the death of infected cells. 
However, cell death can also have pathological effects if it occurs in non-renewing cell 
populations, such as neurons, or late in the process.  
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Many studies have shown that WNV induces replication-dependent apoptosis in vitro, 
and it has been hypothesized that virus-induced apoptosis contributes to neuronal death and 
the pathogenesis of encephalic flaviviruses [104, 114, 199, 200]. Experiments in mice have 
been performed to analyze the occurrence of apoptosis in vivo. Most studies used the 
terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) 
staining, which detects DNA fragmentation, to confirm that apoptosis occurred in the CNS 
of WNV-infected mice.  
Recently, evidence has been provided that the cell death of WNV-infected neurons is 
caspase-3 dependent [201]. It was shown that WNV infection induced caspase-3 activation 
and apoptosis in the brains of wild-type mice, while congenic caspase-3-/- mice were more 
resistant to lethal WNV infection. It is interesting to note that no significant differences in 
the tissue viral burdens or the kinetics of viral spread were found, but decreased neuronal 
death was observed in the cerebral cortices, brain stems, and cerebella of caspase-3-/- mice. 
Consistently, primary neurons derived from the CNS of wild-type mice showed caspase-3 
activation and induction of apoptosis after WNV infection, and treatment with caspase 
inhibitors resulted in a significant decrease in virus-induced cell death. Nonetheless, a 
deficiency in caspase-3 did not completely protect neurons from WNV-mediated death in 
vitro or in vivo, indicating that caspase-3-independent pathways also contribute to WNV 
pathogenesis. For example, it is possible that the activation of non-caspase proteases, such 
as calphain and cathepsin family proteins, is also triggered during WNV infection [202, 
203].  
Yang et al. (2002) showed that direct expression of the WNV capsid protein in the 
striatum of mouse brain or interskeletal muscle caused cell death and inflammation [114]. 
Similar effects were observed in cultured, SH-SY5Y neuroblastoma cells, which could 
eventually be attributed to capsid-induced apoptosis occurring via the mitochondrial 
pathway, involving caspase-9 and caspase-3 activation. These studies suggest a role for the 
capsid protein of WNV in viral pathogenesis through the induction of the apoptotic 
cascade. No role for alternative cell death pathways, such as pyroptosis, parthanatos or 
necroptosis, has yet been described in the pathogenesis of WNV. However, WNV has been 
shown to induce necrosis in vitro in cells exposed to very high viral inocula [204]. More 
effort should be deployed to define the different cell death pathways involved in the 
pathogenesis of severe WNV neuroinvasive disease.  
The function of caspase-12 in viral immunity has not received much attention. 
Previously, it was shown that caspase-12 plays a role in endoplasmic reticulum stress-
induced apoptosis in response to amyloid toxicity [205]. Wang et al. found that caspase-12-
deficient mice had greater mortality, higher viral burden in peripheral (serum, lung, spleen) 
and neural (brain, cerebellum, spinal cord) tissues, and a defective type I interferon 
response after WNV challenge compared to wild-type mice [206]. In vitro studies of 
primary neurons and mouse embryonic fibroblasts further demonstrated that caspase-12 
positively modulated the production of type I interferon by regulating E3 ubiquitin ligase 
TRIM25-mediated ubiquitination of RIG-1, which is a critical signaling event for the type I 
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interferon response to WNV and other viral pathogens. Alternatively, high levels of WNV 
non-structural (e.g. WNV-NS2A, 2B, 4A, 4B) or glycoprotein (WNV-E) may result in 
endoplasmic reticulum (ER) stress and unfolded protein response induction, resulting in 
apoptosis [207]. 
4.3. Immunopathology  
How much cell injury can be attributed to viral cytopathology and how much to the 
inflammatory response is not known. Infection of neurons with WNV leads to the induction 
of several cytokines and chemokines, which promote leukocyte invasion into the CNS and 
neuroinflammation [161, 208]. However, the extent to which this inflammation contributes 
to disease pathology remains unclear. In particular, the relative contribution of neurons to 
inflammation is subject of intensive research.  
Recently, it has been shown that WNV induced the expression of IL-1β, -6, -8, and 
tumor necrosis factor (TNF)-α in human neuroblastoma SK-N-SH cells in a dose- and time-
dependent manner, which coincided with increase in virus-induced cell death [209]. 
Treating cells with anti-IL-1β or anti-TNF-α resulted in a significant reduction of the 
neurotoxic effects of WNV. When naïve astrocytes were treated with UV-inactivated 
supernatant from WNV-infected SK-N-SH cells, expression of glial fibrillary acidic protein 
(GFAP) and key inflammatory cytokines were increased. These results suggest that neurons 
are a source of pro-inflammatory cytokines in WNV-infected brain, and that pro-
inflammatory mediators are one of the main factors driving WNV-induced neurotoxicity. 
Recent studies with Japanese encephalitis virus (JEV; a closely related neurotropic 
flavivirus) also support a role of TNF-α in cell death, as increased expression of TNF-α 
receptors in neurons directly resulted in the initiation of death cascade via tumor necrosis 
factor receptor type 1-associated DEATH domain protein [210]. 
In animal models of JEV there is some evidence that activation of microglial cells 
plays a role in the pathogenesis of encephalitis through the action of pro-inflammatory 
mediators, which induce neuronal cell death [211]. Although reactive gliosis (activation of 
astrocytes and microglia) has been reported in WNV neuroinvasive disease and is 
considered a key pathogenic feature [212-214], the extent to which infection of glial cells 
contributes to WNV-induced neurological disease has never been fully investigated. It is 
believed that collateral damage is mediated by inflammatory factors that are either 
neurotoxic or attract leukocytes into the affected area, which results in a detrimental 
inflammatory milieu.  
Murine infection models have provided substantial evidence that Toll-like receptor 3 
(TLR3) is involved in WNV immunopathogenesis. Firstly, Wang and colleagues 
demonstrated that mice deficient in TLR3 experienced a reduced viral load and a reduced 
production of antiviral and pro-inflammatory cytokines, as well as reduced mortality rate 
upon intraperitoneal WNV challenge [215]. Specifically, the reduced production of the pro-
inflammatory cytokines TNF-α and IL-6 by microglia was associated with their inability to 
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promote injury of neuron-like cells and primary mouse neurons, whereas wild-type 
microglia released inflammatory cytokines and induced neurotoxicity. The authors 
hypothesized that the reduced peripheral inflammatory responses, with in particular TNF-α, 
which has a detrimental effect on the permeability of the BBB, is in particular responsible 
for the enhanced survival shown by TLR3-deficient mice. These results suggest that the 
presence of TLR3 plays an important role in neuroinvasion. A later study, on the other 
hand, showed the opposite, namely that a lack of TLR3 enhanced viral replication in 
neurons, both in vitro and in vivo. As a result, TLR3 may limit WNV infection in a cell-
type restricted manner [216]. This is supported by another in vitro study, which 
demonstrated that TLR3 may be dispensable for WNV recognition in certain cell types 
[217].  
Interestingly, observational studies suggest that macrophages from young individuals 
can down regulate TLR3 following infection with WNV, whereas macrophages of the 
elderly cannot [218]. Therefore, it has been hypothesized that failure to down regulate 
TLR3 in infected cells results in production of high levels of pro-inflammatory and 
vasculogenic cytokines, which may lead to increased BBB permeability. This could 
partially explain the increased severity of WNV infection observed in older individuals. 
Nonetheless, the role of TLR in immunopathogenesis remains controversial. 
A study conducted by van Marle et al. using fatal cases of human WNV encephalitis 
suggested that WNV infects both neurons and glia cells, and that infection of these cells, in 
particular astrocytes, contributed to neuronal death by releasing neurotoxic mediators [208]. 
This study also showed induction of neuroinflammatory genes, where a subset of these 
genes was specifically induced by the capsid protein of WNV. Particularly CXCL10, IL-1β 
and indolamine-2’,3’-deoxygenase (IDO) were shown to be over-expressed in astrocytes ex 
vivo and in vivo. Interestingly, production of CXCL10 by astrocytes has also been 
implicated in the neuropathogenesis of other viral infections, such as human 
immunodeficiency virus [218-222]. Nonetheless, further studies are needed to define the 
genetic programs associated with neuroprotection or the neurotoxic action of glial cells 
during WNV infection. 
Recently, a paradoxical role for neutrophils in WNV pathogenesis has been described. 
When Bai et al. investigated the role of chemokines in WNV pathogenesis by infecting 
macrophages from mice with WNV, they found that expression of CXCL1 and CXCL2, 
which are two CXC-type chemokines that induce the migration of neutrophils, was 
dramatically up-regulated [223]. In addition, neutrophils were found to be the most 
abundant cell type in the peritoneal cavity as early as 12 hours after WNV inoculation. 
These results suggest that neutrophils are the predominant immune cells that are initially 
and rapidly recruited to sites of infection with WNV. Contrastingly, however, mice 
depleted of neutrophils had significantly lower WNV in their blood on day 2 or 3 after 
infection, and increased survival rates were seen. In contrast, when mice were infected with 
WNV before the depletion of neutrophils on days 1 and 2 after infection, they showed 
higher levels of viral load as well as reduced survival rates. The authors concluded that 
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WNV may replicate in neutrophils and increase WNV load in blood early in infection, but 
that in the later course of infection these cells contribute to the control of infection. 
Although these results should be confirmed, it is tempting to speculate that neutrophils play 
a critical role in WNV replication and dissemination in vivo, especially in humans that have 
neutrophils as the predominant cell type in blood.  
 
5. Adaptive immune responses against severe WNV infection 
Most of the neutralizing antibodies against flaviviruses recognize the structural E protein, 
even though a subset binds to the prM/M [224-227]. Interestingly, antibodies to the NS1 
protein, which is not part of the virion, are also protective against WNV in vivo [228, 229]. 
Also antibody responses to the intracellular proteins NS3 and NS5 have been observed 
during WNV infection [230], but their significance remains uncertain. Most of the potent 
neutralizing antibodies against WNV recognize the upper lateral surface of DIII that is 
protruding off the surface of the virion [172, 231, 232]. Even though humans can produce 
antibodies of this specificity in response to natural infection [233], studies have indicated 
that the human humoral immune response to WNV infection is actually narrower than 
anticipated, with the specificity of the antibody focused on determinants around the fusion 
loop at the tip of DII. In fact, B-cell repertoire analysis of three WNV-infected humans 
showed that only 8% of WNV-specific B-cell clones produced antibodies to DIII, while 
almost half produced antibody that bound to determinants in DII, particular the fusion loop 
[234]. Moreover, functional studies of the polyclonal response of WNV-infected horses and 
humans revealed that the neutralization activity of sera is actually not dependent upon 
antibodies directed against the DIII-lateral ridge (lr) epitope [233, 235]. 
It has been recognized that the elderly and immunocompromised are especially at risk 
for disseminated WNV infection and for developing fatal encephalitis. Even though there 
have been several indications, as mentioned earlier, the exact basis for the increased 
susceptibility in the elderly remains unclear.  Nonetheless, experiments with mice have also 
begun to elucidate the role of the different components of the innate and adaptive immune 
response in controlling infection, in particular the role of immunoglobulin M (IgM), CD4+ 
and CD8+ T cells. It is believed that changes in both innate and adaptive immune function 
converge in the reduced response to vaccination and protection against infection in the 
elderly [236]. For instance, the decline in thymic output of naïve T cells diminishes 
responses to novel antigens, such as WNV, while clonal expansions leading to defects in 
the T cell repertoire are associated with blunted responses of memory T cells to conserved 
epitopes of the influenza virus [236]. 
Use of a well-characterized mouse model of WNV infection, which in many respects 
mimics human disease, showed that mice deficient in the production of secreted IgM 
(sIgM), but still capable of expressing surface IgM were vulnerable to lethal infection, even 
after inoculation with low doses of WNV [237]. sIgM-/- mice developed higher levels of 
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infectious virus in sera compared to wild-type animals. This enhanced viremia correlated 
with higher WNV burden in the CNS. Consistently, passive transfer of polyclonal anti-
WNV IgM or IgG protected sIgM-/- mice against mortality, while administration of 
comparable amounts of a non-neutralizing monoclonal anti-WNV IgM did not provide any 
protection. Overall, these results indicate that the induction of a specific, neutralizing IgM 
response early in the course of WNV infection limits viremia and dissemination of virus 
into the CNS, resulting in protection against lethal infection. Whether the kinetics of the 
IgM response to WNV differs between young and the elderly and how it might affect 
susceptibility to severe WNV infection in humans is not clear. 
Furthermore, it has also been demonstrated that mice with a genetic or acquired 
deficiency in CD4+ T lymphocytes display protracted WNV infection in the CNS, leading 
to uniform lethality by 50 days after infection [238]. Mice that survived past day 10 had 
high-level persistent infection in the CNS compared to wild-type mice, even up to 45 days 
after infection. WNV-specific IgM levels decreased about 20-fold at day 15 post-infection 
in CD4-deficient mice and IgG levels were about 100 to 1,000-fold lower throughout the 
course of infection compared to wild-type mice. Furthermore, WNV-specific CD8+ T-cell 
activation and trafficking to the CNS were markedly compromised at day 15. These results 
suggest that the main protective role of CD4+ T cells during primary infection of WNV is 
to assist in antibody responses and to sustain WNV-specific CD8+ T cell responses in the 
CNS that enable viral clearance.   
CD8+ T cells have been shown to directly play a role in controlling WNV infection 
and preventing severe disease. When mice lacking CD8+ T cells or classical Ia major 
histocompatibility complex (MHC) antigens were infected with a virulent WNV isolate, 
higher viral titers were recovered from the CNS and increased mortality rates were recorded 
[239]. In contrast, absence of CD8+ T cells did not affect the quantitative antibody response 
and did not alter the kinetics or magnitude of viremia during primary infection. 
Interestingly, infectious virus could still be recovered from the CNS of CD8+ T cell-
deficient mice that survived initial WNV challenge for several weeks. However, in spite of 
the normal quantitative antibody response, WNV was still able to enter the brain, even 
though it has been shown that IgM and IgG are important in preventing dissemination of 
WNV into the CNS [237]. These experiments collectively suggest that WNV-specific 
antibodies are responsible for reducing viremia and preventing development of severe 
disease, while CD8+ T cells play an important role in clearing infection from tissues and 
preventing viral persistence. Whether antibodies can prevent neuroinvasion remains to be 
determined. 
 
6. Diagnosis of WNV 
Even though the majority of people infected with WNV do not suffer from serious disease, 
the outcome can be quite severe for the young, elderly and immunocompromised. However, 
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if treated quickly, the outlook for West Nile virus recovery can be quite good. As a result, it 
is important to diagnose West Nile neuroinvasive disease (WNND) accurately and quickly. 
In addition, identifying any case of WNV is important for surveillance, as circulation of the 
virus needs to be identified so that important measures can be taken accordingly. Several 
diagnostic tools are currently available for the laboratory diagnosis of WNV infections 
[240], including many nucleic acid based assays (Table 1). When WNND is suspected, the 
diagnosis is generally made by the detection of viral RNA in serum or cerebrospinal fluid 
(CSF) samples with real time RT-PCR assays. Detection of the WNV genome in the CSF 
or serum during the acute stage of neurological involvement is generally considered to be a 
confirmatory diagnostic parameter [241]. When viral RNA is undetectable, identification of 
a specific IgM response in either the CSF or serum is accepted as a reliable diagnostic 
indicator, and the detection of IgG (a four-fold or greater increase in the serum) during the 
convalescent phase of the infection can subsequently confirm this.  
WNV-specific antibodies can be detected by immunofluorescence assay and enzyme 
immunoassay (incl. indirect IgG, IgM antibody-capture and blocking) [240]; however, an 
important practical weakness of these techniques is the limited specificity due to the wide-
spread immunological cross-reactions among flaviviruses [242]. As a result, a confirmatory 
plaque reduction neutralization test (PRNT) is generally advisable. Unfortunately, due to 
the requirement of BSL3 safety conditions [243], only a few laboratories in Europe are able 
to routinely perform this confirmatory test. The detection of a specific IgG response, 
usually by enzyme immunoassay, can be valuable in the context of epidemiological studies 
as the potential evolving circulation of WNV among humans in Europe can be monitored.  
As a response to the emergence of WNV, many countries adopted regulations 
regarding blood safety in blood products for direct transfusion. For example, in the USA, 
screening for WNV RNA was introduced in 2003 [244]. In Europe, on the other hand, the 
Commission Directive 2004/33/EC introduced a temporary 28 days deferral of donors after 
leaving an area with ongoing transmission of WNV to humans. Alternatively, blood 
donations can be screened using Nucleic Acid Testing (NAT) for WNV [245, 246]. Two 
commercially licensed tests are available for the screening of WNV RNAs in both blood 
and organ donors [247, 248], of which the first uses real-time RT-PCR, while the second is 
based on transcription-mediated amplification technology. A potential concern regarding 
the sensitivity of these tests in the detection of WNV in Europe, is the well-documented 
genetic variability of the European strains and the recent emergence of human infections 
caused by WNV lineage 2 in Europe, which contrasts the more straight-forward North 
American situation [93, 249-251].  
Fortunately, diagnostic tests are continuously advancing towards improved specificity 
and sensitivity. For example, in an effort to improve the detection of lineage 2 viruses, 
Linke et al. developed a real-time PCR targeting a conserved region of the 5’-untranslated 
region (5’-UTR) and part of the capsid gene of lineage 1 and 2 WNV [252], while Eiden et 
al. developed two quantitative RT-PCRs for the detection of lineage 1 and 2 strains using 
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primers and probes located in either the 5’-UTR or in NS2a [253]. All assays were able to 
detect both lineages with high sensitivity. 
 
Technique Reference 
SYBR Green RT-PCR Papin, 2004; Johnson, 2010 
TaqMan RT-PCR Lanciotti, 2000 
TaqMan-MGB RT-PCR Chao, 2007 
Multiplex RT-PCR Dyer, 2007; Naze, 2009 
Molecular beacon RT-PCR Jimenez-Clavero, 2006 
RT-PCR/ESI-MS Lee, 2005 
RT-PCR/LDR Grant-Klein, 2010 
RT-PCR/FRET Rondini, 2008 
RT-LAMP Parida, 2004 
NASBA Notomi, 2000 
Digital PCR Invitrogen 
Table 1 Overview of nucleic acid based assays for WNV detection. 
 
7. Prevention 
Within Europe, the quality of data concerning the circulation of WNV among vectors, birds 
and humans varies between countries. Currently, there are no implemented surveillance 
methods or health policies for the application of control measures in the event of disease 
outbreaks [254]. However, as precise identification of viral circulation in vectors and 
vertebrate hosts within defined geographical areas is essential to defining the risk of WNV 
transmission via mosquitoes, blood transfusions and organ donations, ECDC recently 
introduced a web-based publication of WNV-affected areas (available at:  
http://ecdc.europa.eu/en/healthtopics/west_nile_fever/west-nile-fever-maps/pages/index). On the 
basis of these risk maps and the local surveillance data, each European country should be 
able to define the areas and seasons for the implementation of vector control measures, as 
well as the laboratory screening of blood and organ donations, in order to reduce the risk of 
WNV transmission to humans. 
 Currently, three licensed equine vaccines against WNV exist for commercial use, 
namely a formalin-inactivated, whole West Nile virus, (West Nile Innovator®), another 
killed virus vaccine (Vetera® WNV vaccine), and a chimeric recombinant canarypoxvirus 
vaccine (Recombitek® Equine West Nile Virus Vaccine) [241]. In contrast, no licensed 
vaccination options or other immune prophylaxis for human WNV disease are currently 
available. A vaccine preparation developed in the USA (a chimeric vaccine based on the 
backbone of Yellow-Fever 17D human vaccine expressing the prM and E genes of the 
NY99 strain (ChimeriVax-WN01)) went successfully through a phase II trial a few years 
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ago; however, the manufacturer decided to stop the development process due to market 
uncertainty regarding the potential target population that should receive the vaccine [255].  
Nonetheless, many vaccines for WNV that employ different kinds of platforms or 
antigens are at early stages of development. The best-known strategy for vaccination uses 
purified viral proteins. For example, Martina et al. produced a recombinant domain III 
(rDIII) of the E protein to vaccinate mice, and compared it to a β-propiolactone (BPL) 
inactivated WNV vaccine [256]. Neutralizing antibodies against WNV were detected in all 
mice and cross-neutralizing IgG against JEV was also produced. However, survival rates 
were lower (80% for WNV and 60% for JEV) in comparison to mice vaccinated with the 
BPL inactivated WNV (100% for WNV and 80% for JEV). In fact, even though purified 
viral protein vaccines often provide protection against disease in animal models, multiple 
injections and/or strong adjuvants are usually required to reach acceptable efficacy. As a 
result, many other vaccination platforms are often used for the development of vaccines, 
including for WNV. 
One common strategy used in WNV vaccination is the recombinant vector vaccine. 
For example, Martina et al. evaluated a recombinant influenza virus expressing DIII as a 
WNV vaccine candidate in a mouse model. Specifically, the WNV DIII was cloned in the 
N-terminal region of the influenza virus neuraminidase (FLU-NA-DIII), which destroys the 
functional activity of the influenza protein [257]. Subcutaneous immunization of mice with 
the vaccine resulted in high virus-neutralizing and WNV-specific IgG ELISA titers and a 
100% survival rate. Another study created an adenoviral vaccine vector (CAdVax-WNVII) 
that expressed WNV proteins C, prM, E and NS1. Despite the proteins being derived from 
a lineage 2 virus strain, neutralizing antibodies were produced against both lineage 1 and 2 
viruses [258]. In fact, with the emergence of pathogenic lineage 2 strains in Europe, it was 
questioned whether the existing WNV vaccines, which are mainly based on lineage 1 
strains, would be able to protect against the new circulating lineage 2 strains of WNV. 
However, Minke et al. demonstrated that Recombitek® Equine West Nile, a vaccine that 
expresses the prM/E genes of lineage 1 in a recombinant canarypox virus, was able to 
protect horses against a neurovirulent lineage 2 WNV isolate [259]. Even though the 
poxvirus vector Modified Vaccinia Ankara virus (MVA) is a commonly used vaccination 
platform, it has not yet been utilized in WNV vaccination studies. This platform will be 
discussed in depth in the Discussion section of this thesis. 
Another strategy for WNV vaccination is DNA vaccination [260-264]. Davis et al. 
were the first to demonstrate that plasmid DNA encoding the WNV membrane and 
envelope proteins injected intramuscularly into mice and horses was able to provide 
protection against challenge with WNV, resulting in both a humoral response as well as a 
strong Th1 response [260]. In fact, this study paved the way for the licensing of the first 
DNA vaccine for animal use, namely West Nile Innovator® DNA. After this, other 
administration routes and carriers for the delivery of WNV DNA vaccines were also 
exploited. For example, Dunn et al. evaluated DNA vaccines with derivatives of the WNV 
E gene (full length, truncated E or DIII region) that were conjugated to the P28 region of 
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the complement protein C3d, vaccinated either intramuscularly or by the gene gun route 
[263], while Chang et al. developed a plasmid DNA (pDNA) that after transfection gave 
rise to single-round infectious particles (SRIPs) based on WNV [264]. 
Despite the use of different platforms, a commonly used antigen across platforms is 
DIII. DIII contains predominantly sub-complex- and type-specific epitopes, of which many 
induce neutralizing antibodies [118, 265-270]. Many vaccines for WNV based on DIII have 
demonstrated immunogenicity and efficacy among different platforms [256, 257, 263, 271-
275]. For example, Spohn et al. chemically coupled recombinantly expressed DIII protein 
to VLP derived from bacteriophage AP205 and this conjugate vaccine was found to be 
more immunogenic in mice than a mixture of corresponding amounts of free DIII and its 
carrier AP205. Moreover, after three injections mice were also fully protected against a 
lethal challenge with WNV [273]. 
 Lastly, other vaccination strategies employed for WNV include the use of an 
attenuated non-epidemic WNV strain of lineage 2, which was found to be effective against 
a virulent epidemic strain of lineage 1 in mice [276]. Another strategy followed by Mason 
et al., used a live-attenuated virus, single-cycle WNV (RepliVAX WN) in which the gene 
encoding the capsid protein was deleted from the WNV genome. This vaccine induced 
protective immunity in mice [277], hamsters [278] and non-human primates [279]. In 
addition to the existence of many different types of vaccines in the pre-clinical stages, there 
are currently no specific therapeutic treatments for WNV infections. Ribavirin [280], 
interferon-α [281, 282] and WNV-specific immunoglobulin [283, 284] have all been 
considered as specific treatments for WNV, yet no rigorously conducted clinical trials have 
been completed. As a result, only preventive or supportive care can currently be 
administered for WNV disease. 
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Aims and scope of this thesis 
The once limited geographic and host ranges of many vector-borne diseases are rapidly 
expanding. WNV is currently expanding into Southern and Eastern Europe. As a result, it is 
necessary to address Europe’s need to prepare for vector-borne diseases such as WNV. This 
includes the pursuit of improved ways to monitor the spread of WNV, to diagnose, treat and 
also to prevent infections caused by this virus.  
The first part of this thesis looks at the virulence and pathogenesis of WNV, which 
addresses the question whether the strains circulating in Europe differ in virulence. This 
may help to improve Europe’s ability to monitor the spread of WNV infections and provide 
a basis for diagnostic and prognostic tools and novel intervention strategies. Chapter 2 
compares the neuroinvasive capacity of a selection of WNV strains currently circulating in 
Europe. Chapter 3 describes the development and application of a qRT-PCR assay that 
more accurately quantifies replicating WNV and therefore aids in the assessment of 
virulence as well as the determination of WNV tropism. Chapter 4 aims to identify 
markers of virulence in WNV lineage 2 strains, based on virulence markers known for 
lineage 1 strains.  
The second part of this thesis focuses on the vertebrate host as part of the enzootic 
cycle of WNV, which is aimed at generating knowledge on avian susceptibility that may 
lead to important insights necessary for determining the type of surveillance system that 
may be appropriate for European countries in order to detect and predict emerging WNV 
outbreaks. In Chapter 5, the susceptibility of the European jackdaw is addressed, and in 
Chapter 6 the susceptibility of the closely-related Carrion crow.  
The third part of this thesis investigates a potential prevention technique that may 
eventually be useful as part of an intervention strategy in the preparation of Europe against 
WNV. The severity of WNV neuroinvasive disease, the long-term sequelae reported from a 
number of cases of infected individuals, as well as the potential negative impact of these 
infections on the blood transfusion system may collectively justify the development of a 
safe and effective vaccine against WNV. Chapter 7 evaluates the effectiveness of a 
vaccine for lineage 1 and 2 WNV based on the MVA vaccination platform. Chapter 8 
summarizes and discusses the results of this thesis in the context of the rapidly progressing 
field of WNV research. 
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ABSTRACT 
West Nile virus (WNV) has caused outbreaks and sporadic infections in Central, Eastern 
and Mediterranean Europe for over 45 years. Most strains responsible for the European and 
Mediterranean basin outbreaks are classified as lineage 1. In recent years, WNV strains 
belonging to lineage 1 and 2 have been causing outbreaks of neuroinvasive disease in 
humans in countries such as Italy, Hungary and Greece, while mass mortality among birds 
was not reported. This study characterizes three European strains of WNV isolated in Italy 
(FIN and Ita09) and Hungary (578/10) in terms of in vitro replication kinetics on 
neuroblastoma cells, LD50 values in C57BL/6 mice, median day mortality, cumulative 
mortality, concentration of virus in the brain and spinal cord, and the response to infection 
in the brain. Overall, the results indicate that strains circulating in Europe belonging to both 
lineage 1 and 2 are highly virulent and that Ita09 and 578/10 are more neurovirulent 
compared to the FIN strain.  
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INTRODUCTION 
West Nile virus (WNV) is a positive-sense single-stranded RNA virus, which belongs to 
the genus Flavivirus. WNV is transmitted by infected mosquitoes and is maintained in an 
enzootic cycle between mosquitoes and birds, but can also infect and cause disease in 
horses and humans, which serve as incidental dead-end hosts. Previously, WNV was 
considered an Old World virus being endemic in parts of Africa, Europe, the Middle East, 
and Asia [1]. However, in 1999, WNV emerged in New York City in the United States and 
has since rapidly spread across North America, Mexico, South America, and the Caribbean 
[2-4]. No vaccines or specific therapy are currently registered for use in humans. 
WNV has caused sporadic outbreaks in Central, Eastern and Mediterranean Europe 
for over 45 years. Phylogenetically WNV strains are classified into two major lineages. 
Lineage 1 constitutes strains from North America, Africa, the Middle East, Asia, Australia 
(Kunjin virus) and Europe. Lineage 2 strains were restricted to sub-Saharan Africa. This 
genetic classification has been used frequently to classify WNV obtained during outbreaks. 
In this respect, many strains isolated from patients with neuroinvasive disease have been 
classified as lineage 1. In 2008, an outbreak affected small numbers of wild birds, horses 
and humans in eight provinces in three regions of Italy [5,6]. Subsequently, in 2009, a new 
epidemic was reported in the same region, as well as in other neighboring regions in Italy, 
with up to 17 confirmed cases of WNV neuroinvasive disease [7]. Several strains of WNV 
were isolated from human specimens and sequenced. Phylogenetic analyses on the basis of 
the E and NS3/NS5 revealed that these strains belong to lineage 1, clade 1a, and constitute 
a distinct group within the western Mediterranean cluster [8]. In 2004, a lineage 2 strain 
was isolated from birds of prey in Hungary [9], which established itself in the region and 
largely spread throughout the country and into eastern Austria by 2008 [10]. During this 
outbreak, cases of human neuroinvasive disease were comparatively rare and rather mild 
with no deaths reported [10]. Recently, Greece became the focus of a large outbreak in 
summer-autumn 2010 [11]. Up to October 4th, 2010, 192 cases of neuroinvasive disease in 
humans, including 32 deaths, had been laboratory diagnosed, all in the elderly. Culex 
pipiens mosquitoes trapped in Nea Santa were found to be positive for WNV RNA, and 
sequencing of the NS5 gene gave the first indication that this virus belongs to lineage 2, and 
that it is highly similar to the strain that emerged in Hungary in 2004 [10]. As of November 
2012, 237 confirmed human cases have been reported in the European Union (EU), of 
which 161 cases were in Greece, 50 in Italy, 14 in Romania and 12 in Hungary 
(http://www.ecdc.europa.eu/en/healthtopics/west_nile_ 
fever/West-Nile-fever-maps/Pages/index.aspx). These outbreaks were caused by both lineage 
1 and 2 strains of WNV.  
It is remarkable that many of the outbreaks in humans caused by lineage 1 and 2 were 
not preceded by massive bird mortality. WNV-induced wild bird mortality has been 
described in Europe but much less intensively compared to the US. The outbreak in 1998 in 
Israel and 1999 in New York were the first ones where mortality among birds was reported. 
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Because of the higher incidence of WNV neuroinvasive disease seen during the US 
outbreak, it was hypothesized that the introduced strain was more virulent. The complete 
genomic sequencing of the bird and human virulent IS-98 and NY99 strains of WNV 
revealed that both isolates belong to the same phylogenetic clade, sharing more than 99.8% 
nucleotide similarity [12]. We wished to characterize and determine the virulence profile of 
the European-derived WNV strains.  
Virulence for WNV has often been associated with envelope (E) protein glycosylation 
[13] and glycosylation of the NS1 protein [14]. Other virulence factors described for WNV 
include tropism, induction of rapid cell death, resistance to interferon, quasispecies 
generation and up-regulation of MHC class I expression [15]. It is therefore clear that 
virulence is a multi-factorial process and that many aspects need to be studied in order to 
elucidate the pathogenic force of viruses. Several parameters can be used to describe 
virulence. In vivo surrogate markers of virulence include immune-interfering properties, 
lethal dose 50 (LD50), median survival time (ST50), tropism for particular cells or tissues, as 
well as the viral burden present in infected tissues. In the present study we characterized the 
virulence of three selected European strains of WNV in vitro and also in vivo by infection 
of C57BL/6 mice with different doses of these virus strains. We compared their LD50, ST50, 
cell tropism and pathology in the brain, as well as the response to infection in the brain.  
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MATERIALS AND METHODS 
Ethics statement  
All animal experiments described in this paper have been conducted according to Dutch 
guidelines for animal experimentation and approved by the Animal Welfare Committee of 
the Erasmus Medical Centre, Rotterdam, The Netherlands. All efforts were made to 
minimize animal suffering. The Dutch Animal Experimentation Act (1977) demands that 
research establishments request a licence from the Ministry of Welfare, Public Health and 
Cultural Affairs before carrying out any experiment. Research plans must be approved by 
local ethical review committees that consider the benefit of an experiment and whether this 
justifies the distress caused to the animals used in the procedure. The pain assessment is 
prospective and a system of research plan review based on the cost-benefit principle is also 
in place. A statistical reporting system of all animal experimentation provides the 
opportunity to count the number of experiments involving pain or distress to the animals 
with or without pain relief drugs. 
 
Cells and viruses 
Vero E6 cells were cultured in DMEM with 10% heat-inactivated fetal bovine serum (HI-
FBS), supplemented with 0.75% sodium bicarbonate and 10 mM hepes buffer. C6/36 insect 
cells were cultured in Leibovitz-15 medium supplemented with 5% HI-FBS, 10% tryptose 
phosphate broth, 0.75% sodium bicarbonate and 10 mM hepes buffer. All media were 
supplemented with antibiotics (100 U penicillin, 100 µg/ml streptomycin) and 2 mM L-
glutamine. Cell culture reagents were obtained from LONZA (Lonza Benelux BV, Breda, 
the Netherlands). All cell lines tested negative for mycoplasma using a PCR assay as 
described [16]. Viruses used in this study and passage history were as follows: two lineage 
1 Italian strains, FIN (a kind gift from Dr. Vittorio Sambri, University of Bologna, Italy; P2 
on Vero E6) and Ita09 (accession GU011992.2, kindly provided by Dr. Louisa Barzon, 
University of Padova, Italy; P1 on Vero E6) and the Hungarian lineage 2 strain 578/10 
(accession KC496015, a kind gift from Dr. Tamás Bakonyi, Szent István University, 
Hungary; P2 on Vero E6) isolated from the brain of a horse that died of WNV-
neuroinvasive disease. Virus stocks used for this study were prepared by growing the 
viruses once on C6/36 insect cells and viral titers were determined on Vero E6 cells using 
the Spearman & Kärber method [17,18] after determining cytopathic effects five days post 
inoculation.   
 
Sequencing of the envelope gene of WNV strains 
Viral RNA was isolated from C6/36 derived viral stocks using the MagnaPure LC robot 
system and the Total Nucleic acid isolation kit according to the manufacturer’s instructions 
(Roche, Almere, The Netherlands). Primers specific for the E protein were designed using 
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the Primer Select module of DNASTAR software (DNASTAR, Madison WI, USA) and 
adjusted manually to obtain highest similarity with NY99 (Table S1). cDNA was 
synthesized using specific primers and Superscript III RT enzyme (Invitrogen, Breda, The 
Netherlands) and subsequently PCR-amplified using Taq DNA polymerase (Invitrogen) 
according to the instructions of the manufacturer. DNA fragments were gel-purified and 
cloned into the pCR4-TOPO vector (Invitrogen). The cloning reaction products were 
transformed into E. coli (One-Shot Top 10 competent cells; Invitrogen). Positive 
transformed bacteria were identified by PCR using M13 primers and sequenced using 
specific primers (Table S1). Five bacterial clones were selected to determine the consensus 
sequence of the virus stocks. Sequencing was performed in an ABI3130XL sequencer using 
ABI PRISM Big Dye® Terminator (Applied Biosystems, Bleiswijk, The Netherlands). 
Sequences were analyzed using the SeqMan module of DNASTAR software and aligned to 
a reference strain (original sequence of isolate deposited in GenBank) so that the E protein 
of the different strains was obtained from the consensus sequence of five bacterial colonies. 
The GenBank sequence for the original FIN isolate had not yet been deposited; therefore a 
closely related Italian (JF719067) sequence that gave at least 99% identity in BLAST was 
used as a reference instead.  
 
Sequencing the complete genome of WNV-FIN 
RNA was isolated from the WNV-FIN strain (P2 on Vero E6) with the High Pure RNA 
isolation kit (Roche) according to the instructions of the manufacturer. cDNA was 
synthesized using random hexamer primers (Invitrogen) or a reverse primer spanning the 
last 24 nucleotides of the 3’UTR of published WNV sequences, as well as Superscript III 
RT enzyme (Invitrogen). Fifteen sets of primers spanning the complete genome sequence of 
WNV were designed in conserved areas. Primers were designed using the PrimerSelect 
module of DNASTAR software (DNASTAR, Madison WI, USA). Primer sequences are 
available from the authors upon request. cDNA was amplified using PfuUltra II Fusion HS 
DNA Polymerase (Stratagene) and DNA fragments were purified from gel and sequenced 
directly in an ABI3130XL sequencer using the same primers as used for PCR 
amplification. Sequences were analysed using the SeqMan module of DNASTAR software. 
 
Next generation sequencing (NGS) 
Primers were designed for the E gene that allowed five fragments of sizes between 200-400 
nucleotides with about 50 nucleotides of overlap to be generated (Table S1). RT-PCR was 
conducted using random primers (Invitrogen) and Superscript III (Invitrogen), and DNA 
amplification was performed using the specific primers and PFU polymerase (Invitrogen). 
Fragments were gel-purified using QIAquick gel extraction kit (Qiagen, Venlo, The 
Netherlands) and were organized in libraries of equal concentration. Libraries were created 
for each virus without DNA fragmentation (GS FLX Titanium Rapid Library Preparation, 
Roche), emPCR (Amplification Method Lib-L) and GS junior sequencing runs were 
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performed according to instructions of the manufacturer (Roche). Amplicons were 
sequenced in a blinded fashion using 454 technology. Reads from the GS-FLX sequencing 
data were sorted by barcode and aligned to reference sequences using CLC Genomics 
software 4.6.1. Using the alignment, a SNP table was made with a minimum coverage of 10 
reads and a minimum variant frequency of 1.0%. Raw nucleotide sequences were filtered, 
aligned, trimmed and translated using pre-specified criteria applied uniformly so that all the 
protein E sequences used in the analyses spanned the exo-domain and the transmembrane 
region. 
 
Replication kinetics of WNV-FIN, Ita09 and 578/10 viruses 
The replication kinetics of WNV-FIN, Ita09 and 578/10 were studied in vitro by means of a 
one-step growth experiment using a multiplicity of infection (MOI) of 5. N2a cells were 
cultured overnight in 96-well flat bottom culture plates (105 cells/well) and virus was 
added. Viruses were allowed to adsorb for one hour at 37 oC. Cells were subsequently 
washed three times with serum-free medium to remove virus inoculums, replenished with 
fresh medium and cultured at 37 oC for 24 hours. Culture supernatants were collected in 
triplicate at time points 0 and 6 followed by sampling every 2 hours up to 24 hours, and 
were subsequently stored in -80 ºC until virus titer determination. Studies of replication 
kinetics were conducted in parallel to eliminate any confounding effects of host cell culture.  
Several parameters were determined using the results of the one-step growth 
experiment. The approximate eclipse period was defined as the time point before infectious 
virus was detected in the supernatant. The latent period (LT50) was defined as the time point 
at which half the number of virus progeny has been released into the environment and was 
determined by use of curve fitting to the data points by least squares (ordinary) fit. 
Replication rate (RR) is the slope obtained by the linear regression of the natural logarithm 
(ln) of the titer against time during the period of exponential growth. 
 
Mouse infection and survival studies 
Six-week old (age-matched) female C57BL/6 mice (Harlan Laboratories B.V., Venray, The 
Netherlands) were inoculated intraperitoneally (i.p.) with several doses of each three virus 
strains (n=8 for each dose). Mice were euthanized by cervical dislocation under isoflurane 
anaesthesia when they reached humane end-points (immobility and paralysis), after which 
the brain was immediately collected for further processing. At 14 days after infection, the 
end-point for the survival experiment was reached and the survival rate was analyzed, and 
LD50 was calculated according to the Reed & Muench [19] and the Probit method [20]. 
Mice were maintained in specific pathogen-free conditions, had a 12-hour day-night cycle 
and were fed ad libitum. Serology studies were conducted using enzyme-linked 
immunosorbent assay (ELISA). 
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Quantitation of virus in the brain 
RNA copy numbers were quantified using a standard curve of in vitro transcribed RNA of 
known quantities. Run-off transcripts were generated from a plasmid containing the 
sequence of the 3’ UTR of WNV-NY99. Plasmid was linearized and run-off transcripts 
were generated using the Ambion® MaxiScript T7/T3 kit (Invitrogen). The product was 
digested with DNase to remove residual DNA and the reaction was cleaned up using the 
Qiagen RNeasy Minikit (Qiagen). In vitro transcribed RNA was diluted to a concentration 
at which DNA was no longer detected. In order to quantify viral burden in the brain, half 
the brain was weighed and homogenized using a metal bead in 1 mL of DMEM containing 
antibiotics (100 U penicillin, 100 µg/mL streptomycin). RNA copy numbers in the brain 
homogenates were determined using qRT-PCR with the Taqman® EZ RT-PCR kit 
(Applied Biosystems) and primers and probe located on the 3’ UTR of WNV (Table S1). 
Infectious titers in the brain were determined by titration of the brain homogenates on Vero 
E6 cells and calculation of the TCID50. 
 
Immunohistology 
Sagittal brain and transverse spinal cord 4-µm thick paraffin sections were processed for 
streptavidin-biotin-peroxidase immunohistochemistry and immunofluorescence of virus 
nonstructural protein and cell-type markers. Sections were deparaffinized in xylene, 
rehydrated in descending concentrations of ethanol and incubated for 10 min in 3% H2O2 
diluted in PBS to block endogenous peroxidase activity. Antigen exposure was performed 
by incubation for 15 min at 121 ºC in citrate buffer (0.01 M, pH 6.0). Sections were 
incubated overnight at 4 ºC with one of the following primary antibodies: goat anti-WNV 
NS3 (1:100; R&D Systems, Abingdon, UK), rabbit anti-human CD3 (T cell marker; 1:100; 
Dako, Eindhoven, Netherlands), rabbit anti-GFAP (astrocyte marker, 1:500; ZYMED, 
Breda, The Netherlands), and rabbit anti-Iba1 (microglial marker, 1:500; WAKO, Ochten, 
The Netherlands). For immunohistochemistry, primary antibodies were detected with 
secondary goat anti-rabbit IgG-PO, rabbit anti-goat IgG-PO (Dako) or biotinylated goat 
anti-polyvalent/streptavidin peroxidase (Thermo Scientific, Etten-Leur, The Netherlands) 
antibodies. Sections were counterstained with Mayer’s hematoxylin and mounted with 
Kaiser’s glycerin-gelatin and analyzed using a light microscope.  
For double staining, immunofluorescence sections were incubated with goat anti-
WNV NS3, and either rabbit anti-Iba1, rabbit anti-GFAP or rabbit anti-NeuN (neuronal 
marker, 1:500; Millipore, Amsterdam, The Netherlands) was used. Secondary antibodies 
directly conjugated to Alexa Fluor 488 (donkey anti-goat) and 555 (donkey anti-rabbit) 
(Invitrogen) were used. Nuclei were stained with DAPI. Fluorescence staining was 
analyzed using a Zeiss LSM 700 confocal microscope. 
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Determination of inflammatory and cell death markers by qRT-PCR 
RNA was isolated from brain homogenates of infected mice using the MagnaPure LC 
system according to the manufacturer’s instructions. cDNA was synthesized using oligo dT 
primer (Invitrogen) and Superscript III enzyme (Invitrogen) according to the instructions of 
the manufacturer. Primers specific for matrix metalloprotease (MMP)-3, MMP-9, tumour 
necrosis factor (TNF)-α, neuronal pentraxin (Nptx)-1,-2 and pentraxin-related protein (Ptx)-
3 (Applied Biosystems) were used in PCR amplification, and mRNA copy numbers were 
quantified relative to β-actin using the following formula: (2-quantity)*100000. Quantity was 
determined by subtracting the Ct value of β-actin from the Ct value of the specific marker. 
 
Statistical analysis  
P-values equal to or less than 0.05 were considered to be statistically significant. Survival 
curves were analyzed with the Log-rank Test, differences between viral loads and 
differences in expression of inflammatory and apoptotic markers were assessed using the 
Mann-Whitney U test.  
 
RESULTS 
The E protein of different WNV strains is not significantly affected by in vitro culture  
To determine whether generation of virus stocks, through one extra passage on insect cells, 
resulted in changes in the consensus sequence of the respective viruses, the E protein of the 
different virus stocks was sequenced using the Sanger method and sequences were 
compared to those deposited in GenBank. All virus stocks were 99% identical to the 
sequences of the low passage isolates deposited in GenBank (Figure S1). There were no 
amino acid changes found in Ita09 and 578/10 compared to the sequences deposited in 
Genbank. The FIN isolate, was compared to the highly similar sequence in Genbank 
because FIN was not sequenced before. A conservative amino acid substitution (histidine to 
tyrosine) was found at position 371. The lineage 2 strain from Hungary (578/10) differed by 
20 amino acid substitutions from the lineage 1 strains. We have determined the complete 
sequence of the FIN isolate used in this study and the sequence was deposited in GenBank 
(accession: KF234080). 
 
Differences in amino acid sequence of closely related strains WNV-FIN and Ita09  
As the lineage 1 strains FIN and Ita09 are very closely related and completely identical on a 
nucleotide level in terms of the envelope, the complete genome of FIN was compared with 
Ita09. The complete genome of the WNV-FIN strain (KF234080) was 99.7% identical to 
the nucleotide sequence of Ita09 (GU011992.2). Specifically, nine conservative nucleotide 
substitutions were observed throughout the genome compared to Ita09. In addition, three 
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non-conservative amino acid differences were observed in NS3, including the proline 
(Ita09) to threonine (FIN) at position 249, a threonine (Ita09) to isoleucine (FIN) change at 
position 267 and a histidine (Ita09) to glutamine (FIN) change at position 488. 
 
Dominant virus variants were recovered from viral stocks and the brain of infected 
mice 
Measuring the virulence of individual variants within a virus stock may misrepresent the 
virulence of a quasispecies. Since the virus population diversity is an important component 
of virulence, we next characterized the population diversity in our stocks using NGS (deep 
sequencing). Between 30-47 × 103 reads were obtained per sample from the virus stocks. 
Given the sequence heterogeneity within protein E, the use of strain-specific primer sets 
with degeneracy or located in conserved regions resulted in efficient amplification. The 
reads generated during sequencing were aligned using the reference sequences deposited in 
GenBank. The viral RNA sequences recovered from the brains yielded an average of 23-38 
× 103 reads per sample. Coverage of the amplicons was heterogenous and ranged from 
2,950 to 30,675 reads for RNA sequences recovered from the viral stocks, and 1,079 to 
28,362 reads for viral RNA sequences recovered from the brain. After the filtering steps, 
>99.7% of the original sequences were retained.  
In FIN virus stock, 52.4% of the baseline viral population consisted of the T form and 
47.6% of the C form at reference position 1176 (Figure 1), leading to a conservative amino 
acid substitution (H371Y). Furthermore, at position 2118, 92.9% of the variants contained 
the C form and 7.1% of the minor mutations were of the T form. Several other low-
frequency mutations were found in the viral stock, ranging from 1% to 6%. In the brain of 
FIN-infected animals, all the variants were in similar ratios, while the frequency of the 
minor variant at position 2118 increased significantly by 26.1%. This variant, C2118T, also 
resulted in a conservative amino acid substitution (H685Y).  
The baseline viral stock of Ita09 consisted of the 62.5% T form and 37.5% of the C 
form at reference position 2058 (Figure 1). Several other minor variants were found, 
ranging from 1.1% to 4.8%. For all the variants found in the viral stock, only the 
predominant variants were detected in the brain of infected animals, with the exception of 
the 2058 variant where both mutations were found. The viral stock of 578/10 consisted of 
only one variant at position 2270 with 96% of the T form and 4% of the C form (Figure 1). 
This variant was found at a similar ratio in the brain. The results indicate that the 
predominant variants in all the viral stocks were replicating in the brain of infected animals 
and that minor variants were not preferentially selected. The results from the NGS 
sequencing also confirmed the consensus sequence that we acquired using the Sanger 
method. 
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Figure 1. Virus variants recovered from the different WNV stocks and from the brains of 
infected mice. Sequences of glycoprotein E were obtained using Next Generation Sequencing 
(NGS) and aligned with reference sequences deposited in GenBank. Variant frequencies are 
indicated by nucleotide substitution at a particular reference position. 
 
WNV-FIN, Ita09 and 578/10 have similar replication kinetics in vitro  
As the replicative capacity of a virus is considered a surrogate marker for virulence, we 
decided to compare the replication kinetics of the different WNV strains using a one-step 
growth experiment. This approach assumes that virulent strains produce more progeny 
within the host than the avirulent ones, which in turn leads to higher viral densities and 
consequently greater virulence levels. The one-step growth curves of the different WNV 
strains are summarized in Figure 2A and Table 1. Infectious virus production by the three 
virus strains began at approximately 14 hours post-infection. However, in order to obtain a 
more accurate estimate of the latent period and facilitate comparisons between the strains, 
 60 
we calculated the LT50, which is a mathematically more robust determination of the latent 
period. As shown in Table 1, the RR was found to be 1.69, 1.75 and 1.71 for FIN, Ita09 and 
578/10, respectively, indicating similar replication rates for the different virus strains. The 
LT50 was calculated as 16.06, 13.44 and 16.09 hours for FIN, Ita09 and 578/10, 
respectively. This indicates that Ita09 is released the earliest from the cell, followed by FIN 
and 578/10. Furthermore, the burst size of Ita09 was ten-fold higher compared to the two 
other strains.  
 
 
Figure 2. Infectious virus titers recovered from supernatant over 24 hours after infection 
of N2a cells with different WNV strains at a high (5) MOI. N2a cells were inoculated with 
WNV-FIN, Ita09 and 578/10 at an MOI of 5 TCID50/cell. Experiments were performed in 
triplicate and data represent mean ± standard deviation. 
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Virus Eclipse  period (h) 
Latent 
period (h) LT50 (h) 
Burst size 
(TCID50) RR 
FIN 12 14 16,06 ± 0,02 101.1 1.69 ± 0.04 
Ita09 12 14 13,44 ± 0,72 102.1 1.75 ± 0.05 
578/10 12 14 16,09 ± 1,11 101.2 1.71 ± 0.02 
     LT: latent time, RR: replication rate. 
Table 1. Analysis of the replication kinetics of WNV-FIN, Ita09 and 578/10 on N2a cells at 
high (5) MOI over 24 hours. Experiments were carried out in triplicate and values for LT50 and 
RR are indicated as mean ± standard deviation. The LT50 was determined using curve fitting by 
least squares (ordinary) fit and the replication rate (RR) is the slope obtained by the linear 
regression of the natural logarithm (ln) of the titer against time during the period of exponential 
growth. 
 
Neuroinvasive properties of WNV-Ita09, FIN and 578/10 strains  
As factors such as mortality rate, in vivo tropism, and immune response to infection 
constitute important components of virulence in the dynamic host environment, we first 
determined the outcome of infection in 6-week old female C57BL/6 mice following i.p. 
infection. Mice were infected with three different doses of virus (104, 102 and 101 TCID50) 
and differences in mortality rates were observed between the respective WNV strains 
(Table 2). The cumulative mortality by 14 days after challenge was higher for 578/10 
(91%) than FIN (78%) and Ita09 (74%). However, comparison of the cumulative survival 
curves of the mice infected with all doses of the various strains revealed no statistically 
significant differences (Figure 3B; P = 0.70). By contrast, significantly more mortality was 
observed for Ita09 compared to FIN (P <0.001) and 578/10 (P = 0.001) for the 104 TCID50 
dose of virus (Figure 3A). In addition, the ST50 for Ita09 was shorter (8.5 days) followed by 
578/10 (11 days) and FIN (11 days).  
The LD50 calculated using the Reed & Muench method is in agreement with the probit 
method, indicating similar LD50 values for FIN and Ita09, while considerable lower values 
were found for the 578/10 strain (Table 3).  
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Table 2. Mortality of 6-week old i.p. infected C57BL/6 mice using three different doses of 
WNV-FIN (n=23), Ita09 (n=23) and 578/10 (n=23). *These groups were only used to calculate 
the LD50 and were not used for determination of median day of mortality and cumulative 
mortality percentage. 
 
 
Figure 3. Survival curves of mice inoculated intraperitoneally with different WNV strains. 
(A) Mice were inoculated i.p. with 104 TCID50 WNV-FIN (n=8), Ita09 (n=7) and 578/10 (n=7). 
Significant differences in survival were observed between FIN and Ita09 (P < 0.001), and Ita09 
and 578/10 (P = 0.001).  (B) Cumulative survival curves of mice inoculated i.p. with doses of 
101 TCID50, 102 TCID50, and 104 TCID50 of WNV-FIN (n=23), Ita09 (n=23) and 578/10 (n=23). 
WNV strain 
/ dose 
First day 
mortality 
Last day 
mortality 
Median 
day 
mortality 
Total 
mortality 
Mortality 
(%) 
Cumulative 
mortality (%) 
FIN 
101 TCID50 9 11 
11 
4/8 50 
78 102 TCID50 10 12 6/7 85.7 
104 TCID50 9 11 7/8 87.5 
Ita09 
10-1 TCID50* 12 12  1/8 12.5  
101 TCID50 8 11 
8.5 
5/8 62.5 
74 102 TCID50 7 12 6/8 75 
104 TCID50 7 9 7/7 100 
578/10 
10-1 TCID50* 8 11  3/8 37.5  
101 TCID50 9 14 
11 
6/8 75 
91 102 TCID50 9 11 8/8 100 
104 TCID50 8 12 7/7 100 
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No statistical significance was found between the cumulative survival curves (P = 0.70). Mice 
were euthanized between days 6-14 upon display of clinical signs of disease.  
 
WNV strain LD50 (Reed & Muench) LD50 (Probit) 
FIN 100.98 TCID50 100.75 TCID50 
Ita09 100.43 TCID50 100.75 TCID50 
578/10 10-0.42 TCID50 10-0.14 TCID50 
Table 3. LD50 calculated with the Reed & Muench and the Probit method of WNV-FIN (n=23), 
Ita09 (n=23) and 578/10 (n=23) i.p. infected C57BL/6 mice. 
 
High viral RNA load in brains of mice infected with Ita09 and 578/10 strains 
We further investigated the viral burden in the brain of the mice infected with the different 
strains of WNV and euthanized when the humane end points were reached, within 14 days 
post infection. RT-PCR analysis of brain homogenates revealed high titers of viral RNA 
(105 -109) for all mice. However, mean viral RNA copies were found to be significantly 
higher in brains of mice infected with Ita09 and 578/10 compared to mice infected with FIN 
(P = 0.009 and P = 0.02, respectively) (Figure 4A). However, in terms of infectious virus 
titers (TCID50), no significant differences were observed in the brains of these mice (P 
>0.05 for all) (Figure 4B). 
Mice that did not develop signs of WNV neuroinvasive disease by day 20 post 
infection (n=26) were considered survivors of the infection. Infection was confirmed by the 
fact that all these animals developed IgG antibodies to WNV (data not shown). Viral RNA 
was detected in the brain of nine survivors (Figure 4C). Specifically, four mice from the 
FIN group (one from the 104, one from 102 and two from the 101 TCID50 group), and one 
mouse infected with 102 TCID50 of Ita09. However, viral RNA titers were considerably 
lower (101-105) in these mice compared to those that died from infection. No significant 
differences were found in the number of RNA copies in the brains of these mice compared 
to each other (Figure 4C; P >0.05 for all). No viral RNA could be detected in the blood of 
any of the animals that survived WNV infection (data not shown), indicating that the 
detected RNA was not spillover from blood.        
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Figure 4. Viral burden in the brains of mice infected with WNV-FIN, Ita09 and 578/10. 
Mice were euthanized within 6 to 14 days upon reaching humane endpoints and viral burden 
was measured in terms of (A) RNA copies per gram of brain, and (B) TCID50 per gram of brain. 
(C) Viral RNA copies per gram of brain in mice infected with WNV-FIN, Ita09 and 578/10, and 
euthanized on day 20 in the absence of clinical signs of disease. * P <0.05, ** P <0.01. 
 
Histopathology and immunohistochemistry 
In order to assess if the viruses differ in their tropism for particular regions of the brain, and 
compare the relative damage caused by the different strains, we performed 
immunohistochemical staining with anti-WNV-NS3 polyclonal antibody. WNV-NS3 
positive cells occurred in brains and spinal cords of all mice that developed neurological 
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signs. Most positive cells could be identified as neurons, with the antigen being distributed 
in the cell body and proximal dendrites (Figure 5A). Some positive cells showed features of 
degenerative processes such as dystrophic neurites, small cell body and pyknotic nuclei 
(Figure 5B). In addition, labeling was associated with unidentifiable structures likely 
representing neuronal debris. In order to confirm that positive cells were neurons, we 
performed double-labeling immunofluorescence with the neuronal marker NeuN (Figure 
5C). Most positive cells were positive for NeuN, while no WNV-NS3 positive cell was 
positive for glial fibrillary acidic protein (GFAP, astrocytes) or Iba1 (microglia), although 
in many occasions WNV positive cells and debris-like structures were surrounded by Iba1 
positive processes, pointing to an intimate relationship with microglia cells (Figure 5D).  
 The extent of infection in the brain was determined in terms of infected brain areas 
(Table S2). In general, positive neurons occurred in all areas of the brain (Table S2) and the 
spinal cord, although the regional distribution and relative density of positive cells was 
highly variable between animals injected with the same virus. For instance, animals 
infected with Ita09 virus showed highly sporadic, moderate amounts, or very frequent NS3-
positive neurons in the hippocampal CA1 area (Figure 5A & B). A similar variability was 
also observed in other brain areas, including the neocortex, striatum and cerebellar cortex 
(Figure 5E & F), and there was no correlation between the amount of positive cells in 
different brain areas in the same mouse. Because of the large variability between animals 
injected with the same viruses, it was difficult to determine whether systematic differences 
occurred in the amount and distribution of positive cells between animals injected with 
different viruses. For instance, infection of Purkinje cells in the cerebellum was observed in 
sections of some mice infected with Ita09 (Figure 5H) and 578/10 but not in mice infected 
with FIN. However, in view of the potential focal distribution of infected cells, the question 
whether this difference holds true for all Purkinje cells of FIN-injected mice would require 
the systematic analysis of the entire cerebellum of all mice, which is beyond the scope of 
this study. Nevertheless, based on the analyses performed in this study, mice infected with 
Ita09 and 578/10 showed more positive cells than mice infected with FIN.  
Furthermore, antigen distribution and quantity of positive cells in the spinal cord was also 
highly variable, with WNV positive cells occurring in both dorsal and ventral horns. 
Although not systematically investigated, spinal motor neurons in the ventral horn were 
infected more often than dorsal horn cells, despite their relatively low abundance compared 
to other spinal cord cells (Figure 5G).  
 Analysis of WNV-NS3 expression in the brains of mice that did not develop clinical 
disease and that were killed at 20 days post infection revealed no positive cells, which is 
consistent with the absence or low abundance of virus antigen in the brains of these mice. 
Positive cells were also not found in the spinal cord of these animals.  
To determine whether the presence of virus-positive neurons and neuronal debris 
correlated with microglia cell activation we stained for Iba1, which is up-regulated in 
activated microglia cells [21-24]. Increased Iba1 staining, as compared to control mice, was 
observed in the nervous system of all mice with virus-positive neurons (Figure 5J). In 
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accord with the variability in distribution and quantity of WNV-NS3 positive neurons, 
changes in Iba1 staining was also variable between different mice infected with the same 
virus or different viruses. Remarkably, however, in some cases, areas with high levels of 
WNV-NS3 positive cells and debris did not show a strong increase in Iba1 positive cells, 
indicating that a high level of virus-infected cells is not necessarily paralleled by high levels 
of microglia cell activation. Astrocytosis (as demonstrated by increased GFAP-staining) 
was seen in all animals and cases ranged from mild to severe for all virus strains (Figure 
5I). Astrocytosis and microgliosis were also evident in the brains of the survivor mice.  
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Figure 5. Histopathology of 6-week old C57BL/6 mice infected with WNV-FIN, Ita09 and 
578/10 and euthanized upon reaching humane endpoints between days 6-14 p.i. 
Representative picture of (A) Neurons in the hippocampus of a mouse infected with Ita09, 
stained with anti-WNV NS3 antibody (objective 20×). Antigen is distributed in the cell body 
(red arrow) and proximal dendrite (black arrow). Some of the infected neurons appear to be in a 
healthy state with normal nuclear, perikaryal and dendritic morphologies (red/black arrow), 
while some uninfected neurons appear to be in a  moribund state (yellow arrow). (B) Neurons in 
the hippocampus of a mouse infected with Ita09, stained with anti-WNV NS3 antibody 
(objective 20×). Antigen-expressing neurons appear to be in a different state of health varying 
from healthy appearance with normal nuclear, perikaryal and dendritic morphologies (black 
arrow), to dying cells (red arrow). (C) Double staining as seen by confocal microscopy 
(objective 20×) showing neurons (stained with NeuN antibody and Alexa Fluor 555 conjugate; 
red) infected with Ita09 (stained with anti-NS3 antibody and Alexa Fluor 488 conjugate; green). 
(D) Double staining as seen by confocal microscopy (objective 40×) showing activated 
microglia (stained with anti-Iba1 antibody and Alexa Fluor 555 conjugate; red) engulfing 
neurons infected with WNV-Ita09 (stained with anti-NS3 antibody and Alexa Fluor 488 
conjugate; green). Nuclei are stained with DAPI (blue). (E) Neo-cortical neurons in the brain of 
a mouse infected with WNV-Ita09, stained with anti-WNV NS3 antibody (objective 10×). (F) 
Neo-cortical neurons in the brain of a mouse infected with WNV-FIN, stained with anti-WNV 
NS3 antibody (red arrows; objective 10×) (G) Spinal cord of a mouse infected with WNV-
578/10, stained with anti-WNV NS3 (objective 4×). Infection of motor neurons (red arrow), 
anterior horn (orange arrow) and posterior horn (yellow arrow) was observed. Insert shows 
infected motor neuron (objective 20×). (H) Purkinje cell in cerebellum of mouse infected with 
Ita09 (red arrow), stained with anti-WNV NS3 antibody (objective 20×). (I) Mild to moderate 
activation of astrocytes in the cortex of a mouse infected with WNV-578/10, stained with anti-
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GFAP (objective 20×). (J) Activation of microglia cells in the cortex of the brain of a mouse 
infected with WNV-FIN, stained with anti-Iba1 (objective 10×). 
 
Finally, we analyzed infiltration of T-cells using anti-CD3 staining (Table S3). 
Perivascular cuffing by CD3-positive cells was highly variable and was only evident in 
localized regions in a subset of sections examined, consistent with the large variability of 
infected areas. Infiltration of the neuropil by T cells (CD3-positive cells) was mainly seen 
in animals infected with Ita09 in the cerebrum and brainstem (~1 positive cell per high 
power field [HPF]; objective 40×) and in some of the animals infected with FIN or 578/10 
(<1 cell per HPF in the brainstem). Interestingly, infiltration of CD3-positive cells into the 
cerebrum and brainstem were found in all mice that survived infection with any of the 
WNV-strains. In comparison to the mice that had died from infection, all mice that survived 
appeared to have more CD3-postive cells in the brain. Taken together, the IHC studies 
provide supportive evidence that Ita09 and 578/10 are more virulent than FIN. 
 
Response to WNV infection in brains of mice 
To allow for quantitative comparison of the response to infection with different strains of 
WNV, we performed qRT-PCR using half brain homogenates (Figure 6). The survivor 
mice were split into two groups based on presence or absence of viral RNA in the brain. 
We chose for markers that have been associated with viral encephalitis and 
neurodegenerative diseases. The inflammatory marker TNF-α was increased in the brains of 
mice infected with FIN (P = 0.002; P <0.0001), Ita09 (P = 0.007; 0.007) and 578/10 (P = 
0.006; 0.003) compared to the survivors positive and negative for viral RNA in the brain, 
respectively. One of the markers involved in the breakdown of extracellular matrix, MMP-
3, was significantly up-regulated in the brains of mice infected with FIN (P = 0.004; 
0.0009), Ita09 (P = 0.0007; 0.0007) and 578/10 (P = 0.003; 0.002) compared to 
convalescent mice with and without viral RNA in the brain. In addition, MMP-3 transcript 
levels were significantly higher in Ita09 compared to those infected with FIN (P = 0.005). 
MMP-9 transcript was increased in mice infected with FIN (P = 0.02) and 578/10 (P = 
0.03) only when compared to the convalescent mice positive for viral RNA in the brain. 
Nptx-1 (a marker involved in apoptosis) was only up-regulated in the brains of the survivor 
mice group with viral RNA in the brain compared to the group without viral RNA (P = 
0.05). Nptx-2 and Ptx3, inflammatory markers involved in complement activation and 
complement-mediated clearance of apoptotic cells, were not significantly up-regulated in 
any of the experimental groups. These data identify some inflammatory markers 
significantly elevated during infection of the brain with WNV, but none of the examined 
markers correlate with virulence. 
 
 69 
 
 
 
 
 70 
 
Figure 6. Relative number of RNA transcripts of markers in the brains of mice infected 
with WNV-FIN, Ita09 and 578/10. Sick animals were euthanized within days 6-14 upon 
reaching humane endpoints or on day 20 post-infection in the absence of clinical signs. 
Transcripts were compared with animals that survived WNV infection (day 20 p.i) and that were 
either positive or negative for viral antigen in the brain. Mean is indicated by a cross and median 
by a line in the boxes. The box represents the interquartile range. * P <0.05, ** P <0.01, *** P 
<0.001. Abbreviations: TNF = tumour necrosis factor; MMP = matrix metalloproteinase; Nptx = 
neural pentraxin; Ptx = pentraxin. 
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DISCUSSION 
In this study we have characterized the European WNV strains FIN, Ita09 (both lineage 1) 
and 578/10 (lineage 2). Neurovirulence of the three WNV strains were determined by 
comparing in vitro replication kinetics, median day mortality, cumulative mortality, LD50, 
concentration and distribution of virus in the brain, and the response to infection in the 
brain. 
Despite the fact that WNV has been circulating in Europe for half a century, it is only 
in the more recent years that this virus has caused considerable outbreaks in humans, horses 
and to a much lesser extent in wild birds. This is in contrast to the emergence of WNV in 
North America during which wild birds were heavily affected and significant numbers of 
human neuroinvasive disease cases with high mortality were reported. It is possible that this 
increase in severity is a result of the movement of the virus into areas with large 
immunologically naïve populations that consist of a large proportion of elderly and 
immunocompromised individuals [25]. However, it has also been suggested that a more 
virulent strain of the virus was introduced [26]. It is also hypothesized that the viruses 
currently circulating in Europe differ in their virulence profile compared to the North 
American strains.  
There have been a number of explanations for why viruses are virulent [27,28], and it 
is clear that virulence is an adaptive process and that it is the result of the trade-offs 
between virus transmissibility, virus pathogenic force, and recovery potential of the host. In 
several models it has been shown that changes in virulence are associated with changes in 
different aspects of the biology of virus-host interaction, suggesting that virulence of a 
given virus may be affected by a potentially large number of factors (reviewed in [29-33]). 
Since no single general factor exists that can be used to predict the relative virulence of 
viruses, we investigated the virulence of European WNV strains by considering a series of 
parameters. Even though it is possible to investigate virulence by conducting a straight 
kinetic analysis and examining viral spread in the brain over time, we decided to use 
survival as an outcome of disease severity. This is because disease can be a direct 
consequence of viral burden, inflammatory response and injury and death of cells in the 
CNS, and therefore an appropriate measure of virulence. Following infection, WNV 
replicates to high levels during the acute phase, after which the virus typically enters the 
brain and causes meningo-encephalitis before the immune system is able to control the 
infection. Our aim was to define the virulence profile of European WNV strains by 
measuring different markers in vitro and in vivo.  
First we determined the population structure (quasispecies) in our virus stocks. We 
chose to characterize the stock rather than the dominant variant in the stock that was used to 
infect mice. It has been shown that viral quasispecies is more than just a collection of 
mutants, but a group of interactive variants, which together contribute to pathogenesis [34]. 
For instance, it was found that the diversity of the quasispecies of Polio virus correlated 
with enhanced pathogenesis in mice [34]. Ciota et al. [35] have shown that the quasispecies 
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in WNV populations correspond to substantial phenotypic diversity that differed in relative 
fitness in vitro. We have used NGS to determine the population phenotype of our viral 
stocks, based on the glycoprotein E gene. This gene was selected because it is the principal 
receptor that determines tropism for neurons, contains markers of virulence, and it harbors 
areas that allow monitoring of virus evolution. One advantage of the NGS is the possibility 
to detect minor variants. In this study, we found that only the dominant variants from the 
stock were selected in the brain. One important issue concerning the NGS is the ability to 
distinguish between true variants and variants detected as a result of errors introduced 
during PCR amplification and/or sequencing. Therefore, within our department, we have 
determined the error rate threshold specific for this platform. We found that a threshold of 
0.026% (manuscript in preparation) is sufficient to exclude variants detected as a result of 
errors. The technical cut-off value of 1% described in this manuscript is therefore well 
above the error margin attributed to reverse transcription, amplification and sequencing 
errors. Furthermore, emergence of new variants was also detected in the brain, which could 
have been a result of mutations arising during the replication cycle. We did not specifically 
study whether the population structure of our strains contributed to virulence.  
The infection cycle of WNV has not been studied extensively in vitro, so we first 
addressed the dynamics of WNV infection in vitro in neuronal cells. We found that only 
adherent cells could be infected and infection of N2a cells in suspension was not successful 
(data not shown). The reason for this phenomenon is unknown, but may be related to 
receptor availability on adherent cells. Currently, there is little known about the host 
receptor for flaviviruses. The replication cycle of WNV can be divided into three phases; 
(1) dispersal-diffusion-attachment phase, (2) eclipse phase (begins with infection and ends 
when the virus progeny matures inside the host), and (3) release phase (the virus offspring 
are released from the infected cell). The total number of progeny released in the supernatant 
is termed the burst size. Examination of these three stages in virus replication is useful, 
because the associated growth parameters (eclipse period, latent period, exponential growth 
rate, and burst) yield plausible hypotheses to account for differences in virulence. 
A study has shown that large clusters of matured virus of the Sarafend strain appear at 
the plasma membrane, as well as in vacuoles, at 10-12 hours post-infection [36]. This is in 
line with our results where we determined the eclipse period to be at approx. 12 hours p.i. 
The study further showed that maturation of WNV at the plasma membrane, and therefore 
budding from infected cells, is the dominant mode of maturation for this virus, but that 
during the later stage of infection (from 12 hours p.i.) the virus is also released via 
exocytosis, most likely due to advanced cytopathic effects [36]. As a result, it may be 
difficult to determine the precise time point of the burst size and we have therefore 
additionally determined the LT50. Furthermore, analyzing the RR may shed light on the 
potential of WNV strains to overwhelm the target cells. Virions that are able to overwhelm 
the system quickly will have an increased chance of colonizing the remaining uninfected 
cells, an advantage particularly important in vivo. We found that Ita09 replicates faster as 
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evidenced by the LT50 and release of up to ten-fold more virus after the first replication 
cycle.  
The increase in morbidity and case-fatality rates caused by North American lineage 1 
strains relative to lineage 2 strains led to the hypothesis that lineage 1 strains are highly 
pathogenic while lineage 2 strains that used to be endemic only to Africa are of low 
virulence [4]. Conversely, recent outbreaks in South Africa and Europe indicate that lineage 
2 strains may also cause severe disease [37]. This observation was also supported by 
experimental studies in mice showing that differences in virulent WNV strains did not 
correlate with the phylogenetic lineage, source of isolate, geographic distribution, passage 
level or year of isolation, and suggest instead that pathogenicity is not genotype specific 
and that both lineage 1 and 2 are neurovirulent [38,39]. Our results indicate that all the 
European strains studied are virulent in C57BL/6 mice and that the lineage 1 strain (Ita09) 
and lineage 2 strain (578/10), which share similar virulence profiles, are slightly more 
virulent than FIN. Two lineage 1 viruses with 99.7% identity (FIN and Ita09) were found to 
share a different virulence profile. These viruses differed in terms of three non-conservative 
amino acids. One of the substitutions present in the Ita09 strain, T249P, is a mutation in the 
helicase domain of the NS3 protein and has been associated with increased virulence in 
American crows [40]. This mutation has been found in the more recent Italian WNV 
isolates from 2008 (15803/08 and 15217/08), while the Italy 1998-equine strain still has the 
threonine at this position [41]. Interestingly, the 2010 Greek isolate also contains the 
proline, and may be responsible for the increased virulence of this strain compared to other 
strains from lineage 2 [10]. However, the virulence properties of this sole substitution in 
outbred mice remains unclear, and its role in virulence in humans on a population level is 
questionable. For instance, a WNV strain isolated in 2007 from golden eagles in Spain 
carrying a TP mutation did not have increased pathogenicity in mice compared to other 
strains [42]. Similarly, the WNV-FIN strain used in this study was isolated from a patient 
with neuroinvasive disease. It is possible that the three amino acids differences between 
Ita09 and FIN collectively reduced the virulence of FIN.   
Mice that had died as a result of infection with Ita09 and 578/10 were found to have a 
significantly higher number of RNA copies in the brain compared to those infected with 
FIN. Infectious virus titers, however, were not significantly different. This discrepancy 
might be explained by the involvement of immature virus particles, which may also play a 
role in the pathogenesis of WNV [43]. It is therefore possible that there was a higher viral 
burden in the brains of mice infected with Ita09 and 578/10 as a result of a larger amount of 
immature virus particles, which may explain the higher virulence observed for these virus 
strains. 
The histopathologic findings observed in the brain and spinal cord samples of the 
mice that succumbed to the infection were pathognomonic, with moderate to severe 
infection observed in mice infected with Ita09 and 578/10 strains. In agreement with 
previous studies, WNV antigen was found in neurons in the spinal cord, cortex, 
hippocampus and brainstem [15,44]. Interestingly, antigen of Ita09 and 578/10 was found 
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also in the Purkinje cells of the cerebellum. Infection of Purkinje cells by North American 
strains of WNV has been demonstrated in hamsters [45-47], birds [48,49], macaques [50] 
mice [51] and humans [52]. This targeting of Purkinje cells of the cerebellum has been 
shown to be a unique pathologic finding in WNV encephalitis, unlike the encephalitides 
caused by other closely related flaviviruses [48,53-57]. The higher frequency and intensity 
of antigen staining in the central nervous system and the higher mortality observed in the 
Ita09 and 578/10–infected groups compared with the FIN–infected group (lineage 1), 
suggest that these two strains are more virulent.  
Even though some of the mice that survived infection were positive for viral RNA, 
IHC staining did not demonstrate antigen in the brain. The intensity of staining found using 
IHC did roughly correlate with the amount of RNA found in the brain. As RNA titers in the 
brain of the survivor mice were significantly lower compared to mice that died from 
infection, it is possible that these low titers, in addition to unsystematic sampling, resulted 
in the absence of detection of positively stained cells using IHC in brain samples of the 
survivor mice. 
We have also measured the response to infection in the brain as a virulence factor. 
Although astrocytosis and microgliosis were observed in all mice that died from the 
infection, we did not find evidence of infection of these cells. It is believed that activated 
microglia and astrocytes contribute to an excessive inflammatory response, which triggers a 
process of secondary cell death or functional depression in structurally normal areas distant 
from, but connected to the original sites involved. We have found that MMP-3 transcript 
was significantly elevated in all animals that developed severe disease. MMPs are capable 
of degrading the tight junction proteins of human brain microvascular endothelial cells, 
thereby compromising the integrity of the blood-brain barrier. Further studies are necessary 
to address the question of whether MMP-3 is a virulence factor triggered by pathogenic 
WNV strains. 
To our knowledge, this is the first study to characterize pathogenic properties of WNV 
strains circulating in Europe. We have found that all three European strains of WNV are 
neurovirulent in C57BL/6 mice; however, the data also suggest that Ita09 and 578/10 show 
an increased virulence in comparison to FIN. Studies are ongoing to determine the 
virulence of these strains in European birds and in other outbred animal models. 
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SUPPORTING INFORMATION 
Primer  Sequence (5’to 3’) Application 
#721modified48R AGCTCTTGCCGGCTGATGTC RT-PCR 
#722modified51F AGCTTCAACTGCCTTGGAATGAG PCR/Sequencing 
#723modified57R TGTCAGCGTGCACGTTCACGGA PCR/Sequencing 
#43WNV.E04F CGCCAAATTTGCCTGCTCTAC Sequencing 
#44WNV.E05R AGTTTGAGGAACCACACGCCA Sequencing 
#732WNVII-870f* CCTCGTTGCAGCTGTCATTG Sequencing 
#733WNVII-
1630r* TCCATGGCAGGTTCAGATCC Sequencing 
WNVE-Deepseq-
F1 ATGACAAACGTGCTGACC 454 sequencing 
WNVE-Deepseq-
R2 GTTCACAGTCCACTGTCACCTCTC 454 sequencing 
WNVE-Deepseq-
F2 CGCCTTCATACACACTAAAG 454 sequencing 
WNVE-Deepseq-
R3 AGCCTTTGAACAGACGCCAT 454 sequencing 
WNVE-Deepseq-
F3 GTAGAGTGAAGATGGAAAAATTGC 454 sequencing 
WNVE-Deepseq-
R4 GCTGTGTCTCCTAGAGCGGC 454 sequencing 
WNVE-Deepseq-
F4 ACAACCACCCTCAAAGGA 454 sequencing 
WNVE-Deepseq-
F1/853-HUN AACGAGAAAAGAGCTGACCCCG 454 sequencing 
WNVE-Deepseq-
R2/854-HUN GCTCACAGTCAACCGTGACCTCAC 454 sequencing 
WNVE-Deepseq-
F4/859-HUN CCTTTACCACTACACTCAGAGGAGCT 454 sequencing 
WNVE-Deepseq-
723-HUN TGTCAGCATGGACGTTGACCGA 454 sequencing 
3’UTR F  CCACCGGAAGTTGAGTAGACG Taqman 
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3’UTR R TTTGGTCACCCAGTCCTCCT Taqman 
3’UTR probe FAM-
TAMRA TGCTGCTGCCTGCGGCTCAACCC Taqman 
Supplementary Table 1. Primers used for sequencing the envelope of WNV-NY99, FIN, Ita09 
and 578/10. Primers indicated with * were kindly provided by Dr. Tamás Bakonyi (Szent István 
University, Hungary) and were used to sequence the envelope of 578/10. 
 
WNV strain CTX CNU TH HY HPF MB MY/Pons CB 
WNV-FIN 
n=10 (died) 60% 20% 10% 40% 30% 30% 20% 40% 
n=9 (survived)          
WNV-Ita09 
n=10 (died) 90% 60% 50% 20% 30% 20% 50% 60% 
n=6 (survived)          
WNV-578/10 
n=18 (died) 78% 50% 39% 39% 33% 44% 44% 17% 
n=3 (survived) 
        
 
Abbreviations: CTX = cortex; CNU = cerebral nuclei; TH = thalamus; HY = hypothalamus; HPF = 
hippocampal formation; MB = midbrain; MY = medulla; CB = cerebellum  
Supplementary Table 2. Antigen distribution (described in terms of staining of the NS3 
protein) in the brains of mice infected with WNV-FIN, Ita09 and 578/10, and either euthanized 
upon display of clinical signs of disease (between days 6-14) or euthanized on day 20 without 
showing signs of illness. Percentage indicates the amount of infected mice that are positive for 
antigen in each particular brain region. 
 
 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3. Detection of CD3 positive cells in the brains of mice infected with WNV-FIN, Ita09 and 578/10, and either euthanized 
upon display of clinical signs of disease (between days 6-14) or euthanized on day 20 without showing signs of illness. Numbers indicate the 
number of positive cells; HPF: high power field; objective 40X.   
T cell staining (anti-CD3 antibody) 
 Cerebrum Brainstem Cerebellum 
 Infiltration Perivascular 
cuffs 
Infiltration Perivascular 
cuffs 
Infiltration Perivascular 
cuffs 
FIN <1/ HPF (in 
50% of 
mice) 
Neg <1/ HPF Neg Neg Neg  
Survived  1 layer thick 
in 10% of 
mice 
1 cell per 
HPF (10% 
of mice) 
   
Ita09 1/ HPF (in 
50% of 
mice) 
 1/HPF   <1/mouse (1 
cell layer 
thick) 
Survived Clusters of 
positive cells 
(in 33% of 
mice) 
 Clusters of 
positive cells 
(in 33% of 
mice) 
2 cell layers 
thick 
  
578/10 Neg Neg <1/HPF (in 
50% of 
mice) 
Neg Neg Neg 
 
Survived <1 cell per 
HPF (50% of 
the mice) 
 <1 cell per 
HPF (50% 
of the mice) 
   
 81 
 
Supplementary Figure S1. The sequences of glycoprotein E of the WNV stock used in this 
study were determined with the Sanger method. The deduced amino acid sequences were 
aligned. The sequence of FIN was deposited in GenBank (KC493970). The sequence of Ita09 
and 578/10 were compared to GU011992.2 (Ita09) and KC496015 (578/10) and FIN was 
compared to a highly similar sequence (accession JF719067.1; 99% similar to FIN). 
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ABSTRACT 
Studying the tropism and replication kinetics of West Nile virus (WNV) in different cell 
types in vitro and in tissues in animal models is important for understanding its 
pathogenesis. As detection of the negative strand viral RNA is a more reliable indicator of 
active replication for single-stranded positive-sense RNA viruses, the specificity of qRT-
PCR assays currently used for the detection of WNV positive and negative strand RNA was 
reassessed. It was shown that self- and falsely-primed cDNA was generated during the 
reverse transcription step in an assay employing unmodified primers and several reverse 
transcriptases. As a result, a qRT-PCR assay using the thermostable rTth in combination 
with tagged primers was developed, which greatly improved strand specificity by 
circumventing the events of self- and false-priming. The reliability of the assay was then 
addressed in vitro using BV-2 microglia cells as well as in C57/BL6 mice. It was possible 
to follow the kinetics of positive and negative-strand RNA synthesis both in vitro and in 
vivo; however, the sensitivity of the assay will need to be optimized in order to detect and 
quantify negative-strand RNA synthesis in the very early stages of infection. Overall, the 
strand-specific qRT-PCR assay developed in this study is an effective tool to quantify 
WNV RNA, reassess viral replication, and study tropism of WNV in the context of WNV 
pathogenesis. 
 
 85 
INTRODUCTION 
West Nile virus (WNV) is a neurotropic RNA virus with a positive-sense single-stranded 
genome that belongs to the genus Flavivirus in the Flaviviridae family. The replication of 
WNV proceeds through a negative strand RNA intermediate [1], synthesized by the virus-
encoded RNA-dependent RNA polymerase. The negative strand is used as a template for 
the synthesis of new single stranded positive-sense RNA molecules [2]. Therefore, 
detection of this negative strand, which is generally significantly outnumbered by the 
positive strand, signifies viral replication.  
In vitro experiments have shown that cortical astrocytes are susceptible to infection 
with WNV while replication in microglia cells was not supported [3]. In vivo, WNV infects 
mostly neuronal cells and on occasion has also been shown to infect microglia cells [4]. In 
general, however, in vivo tropism of WNV for astrocytes and microglia cells remains 
mostly speculative. In order to determine permissibility of these cells to infection by WNV, 
synthesis of the negative strand can be assessed using strand-specific quantitative RT-PCR. 
Another issue that could be addressed by determining the presence of negative strand is 
persistence of WNV, which has been described in several organs and animal species [5-9]. 
Specific strand detection can therefore be useful in the elucidation of the mechanisms of 
persistent infection and may contribute to the further understanding of WNV pathogenesis.  
Even though qRT-PCR is the method used most widely for the quantitation of viral 
RNA, its major disadvantage is that it provides limited strand specificity. As a result, 
standard qRT-PCR cannot determine the absolute quantity of viral RNA copies in a given 
sample due to the presence of both positive and negative strands of RNA. This lack of 
strand specificity has been attributed to a combination of factors, including self-priming of 
the RNA due to secondary hairpin structures [10-15], false priming of the incorrect strand 
[10, 16-18] and random priming by contaminating endogenous or exogenous nucleic acids 
[13, 16, 19]. Attempts to overcome these problems include performing RT reactions at high 
temperatures [20, 21], use of the thermostable RTth enzyme [10, 22-24], use of tagged RT 
primers [25-28] or a combination of tagged primers and RTth enzyme [29]. It was shown 
that the approach employing tagged primers in combination with high RT temperature 
greatly improved the specificity of the RT reactions. So far, quantitation of negative strand 
RNA for analysis of positive-sense RNA virus replication has been applied for a number of 
viruses, which include hepatitis A [24, 30], hepatitis C [10, 11, 18, 29, 31], hepatitis E [32], 
GB virus C [33], dengue [25], O’nyong-nyong and Chikungunya [27], murine norovirus 
[28] and foot-and-mouth disease virus [34]. Due to the problems associated with false 
detection of negative strand RNA, conclusions derived from assays not optimized for 
strand-specific detection of RNA may not be valid [35, 36]. 
In this study, it was shown that the qRT-PCR system using conventional WNV-
specific primers for the detection of positive and negative strand viral RNAs lacks strand-
specificity due to amplification of both falsely primed cDNA generated from the incorrect 
strand, as well as cDNA generated from self-primed RNA, both occurring during the RT 
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step. As a result, a qRT-PCR system that employs both tagged primers and the thermostable 
RTth enzyme was developed in order to overcome these problems, which greatly improves 
the specificity of detection of negative and positive strand viral RNAs for the study of 
WNV replication. 
 
MATERIALS AND METHODS 
Cells and viruses 
The mouse microglia cell line BV-2 (kindly provided by Dr. M Leist, University of 
Konstanz, Germany) was grown in Roswell Park Memorial Institute (RPMI) medium 1640 
supplemented with 10% heat inactivated fetal bovine serum (HI-FBS). Virus used in this 
study consisted of the NY99 strain (accession AF196835.2, obtained from the Health 
Protection Agency, Porton Down, UK; Passage (P) 4 on Vero E6 cells). Virus stock was 
prepared by growing the P4 virus stock once on C6/36 insect cells. C6/36 insect cells were 
cultured in Leibovitz-15 medium supplemented with 5% HI-FBS, 10% tryptose phosphate 
broth, 0.75% sodium bicarbonate and 10 mM hepes buffer. All media were supplemented 
with antibiotics (100 U penicillin, 100 µg/ml streptomycin) and 2 mM L-glutamine. Cell 
culture reagents were obtained from Lonza, Breda, The Netherlands. 
 
Synthesis of in vitro RNA transcripts 
In order to quantify negative and positive strands, run-off transcripts for each strand were 
generated from a plasmid (pCR®4-TOPO®; Invitrogen, Breda, The Netherlands) containing 
the sequence of the 3’UTR of WNV. In order to synthesize the positive-sense transcript, 
plasmid DNA was linearized using the NotI restriction enzyme. For synthesis of the 
negative-sense transcript, DNA was linearized with the PmeI restriction enzyme. 
Linearized plasmid DNA was cleaned up using the MinElute Reaction Cleanup kit (Qiagen, 
Venlo, The Netherlands) and run-off transcripts were generated using the Ambion® 
MaxiScript T7/T3 kit (Invitrogen). The positive sense RNA was transcribed using the T3 
polymerase and the negative sense RNA using the T7 polymerase. The product was 
subsequently incubated with 2 U of TURBO DNase (Invitrogen) at 37 ºC for 15 min to 
remove residual DNA and the reaction was cleaned up using the High Pure RNA Isolation 
kit (Roche Diagnostics, Almere, The Netherlands), which included an additional DNA 
digestion step using 100 U of DNase I (Roche). The RNA transcripts were eluted in 50 µL 
and the concentration was determined using spectrophotometer (NanoDrop) readings at 
wavelength 260 nm. The stocks of in vitro transcribed RNA were subsequently diluted to a 
concentration of 3.7  107 copies/µL for the positive sense and 4.5  107 copies for the 
negative sense RNA, a concentration at which DNA was no longer detected using qRT-
PCR. 
 
× ×
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Quantitative RT-PCR of negative and positive strand viral RNAs using unmodified 
and tagged primers 
Primer and probe sets used in this study are specific to the 3’UTR of WNV and are based 
on previously published primers and probe (Meece et al., 2003), but with an additional TgC 
triplet added to the probe (Table 1). First, detection of strand-specific RNA was performed 
using ‘unmodified primers’. For detection of positive strand RNA, RT was performed with 
the R96 primer and for detection of the negative strand RT was done with the F34 primer. 
Subsequently, PCR amplification was performed using both the F34 and R96 primers 
added to the reaction after cDNA synthesis. Alternatively, ‘tagged primers’ were used for 
the RT reaction. To this end, the R96 and F34 primers were tagged by adding a 32-mer-
long sequence of the Grapevine virus A as a tag at the 5’-end of the respective primers 
(Table 1; tag sequence indicated in bold). This procedure has been reported to prevent the 
amplification of cDNA products made by false priming of either RNA strand as well as the 
amplification of cDNA acquired as a result of self-priming [10]. Specific detection of the 
WNV-positive RNA strand was performed during cDNA synthesis using the Tag-Rev 
primer, complimentary to the positive-sense strand, and the negative strand was detected 
using the Tag-Fwd primer, which is complimentary to the negative-sense strand. 
Subsequently, the positive strand was amplified using the Tag sequence as the reverse 
primer and WNV F34 as the forward primer. In contrast, the negative strand was amplified 
using the Tag sequence as a forward primer and WNV R96 as a reverse primer. All RT 
reactions contained 30 pmol of primer and were carried out for 2 min at 50 ºC and 30 min 
at 60 ºC using the rTth RT enzyme according to the instructions provided by the TaqMan 
EZ RT-PCR kit (Applied Biosystems, Bleiswijk, The Netherlands). RT reactions using 
unmodified primers contained 5 µL of RNA while those using tagged primers contained 7 
µL of RNA. The RT function of the rTth enzyme was inactivated for 15 min at 95 ºC. In all 
cases, PCR amplification consisted of 30 pmol of primer, 15 pmol of WNV 56 probe in a 
total volume of 50 µL, and cDNA was amplified in 40 amplification cycles of 20 sec at 95 
ºC and 1 min at 60 ºC using the rTth enzyme (DNA polymerase function). All reactions 
were carried out on a 7500 Fast real time PCR System (Applied Biosystems) and analyzed 
using 7500 Software v.2.0 (Applied Biosystems).  
The effect of the transcriptase on false-priming and self-priming was also investigated. 
To this end, RT-PCRs were carried out using Superscript III (SSIII; Invitrogen), 
MultiScribe (MS; Applied Biosystems) and Avian Myeloblastosis Virus RT (AMV; 
Promega). The RT-PCRs for these enzymes were as follows: 15 min at 25 ºC, 45 min 50 
ºC, 15 min 70 ºC for SSIII, 30 min at 48 ºC for MS, and 60 min at 42 ºC for AMV. All 
reactions were succeeded by inactivation of the RT at 95 ºC for 15 min. The RT reactions 
comprised 10 µL of RNA and 20 pmol of reverse primer. Subsequently, 2.5 µL of the 
cDNA reaction was added to the TaqMan PCR using primers and probe as described above.  
 
 
 88 
In vitro infection of mouse microglia cells with WNV-NY99 
BV-2 cells were cultured overnight in 96-well flat bottom culture plates (104 cells/well) and 
virus was added at MOI 0.5. Virus was allowed to adsorb for one hour at 37 oC. Cells were 
subsequently washed three times with serum-free medium to remove virus inoculum, 
replenished with fresh medium and cultured at 37 oC for 48 hours. Cells were collected in 
triplicate at 12, 24, 36 and 48 hours. Culture supernatants were removed and cells were 
taken in 100 µL of PBS and lysed with 400 µL of lysis buffer (Roche). RNA was then 
extracted using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche) and an 
automated nucleic acid robotic workstation (Roche) according to the manufacturer’s 
instructions. RNA was eluted in 50 µL of elution buffer (Roche) and stored at -80 ºC until 
used. Synthesis of cDNA was initiated with 7 µL of total RNA using the rTth enzyme and 
tagged primers to detect the presence of both positive and negative strand viral RNA. The 
log10 titrated in vitro RNA transcript standard curve (T3: 3.7  107 copies; T7: 4.5  107 
copies) was reverse transcribed at the same time as the cell culture RNA samples. 
 
Mouse infection with WNV-NY99  
Nine-day old female C57BL/6 mice (Harlan Laboratories B.V., Venray, The Netherlands) 
were inoculated intraperitoneally (i.p.) with 105 TCID50 of WNV-NY99. Mice were 
euthanized by cervical dislocation under isoflurane anaesthesia on days 3, 4, 5 and 6 post-
inoculation, after which the brain was immediately collected for further processing. Mice 
were maintained in specific pathogen-free conditions, had a 12-hour day-night cycle and 
were fed ad libitum. Animal experiments were approved by the Animal Ethics Committee 
of Erasmus Medical Center.  
In order to quantify viral RNA copies in the brain, half the brain was weighed and 
homogenized using a metal bead in 1 mL of DMEM containing antibiotics (100 U 
penicillin, 100 µg/mL streptomycin) using a tissue homogenizer. 100 µL of brain 
homogenate was added to 400 µL of lysis buffer (Roche). RNA was then extracted as 
indicated above and stored at -80 ºC until used. Synthesis of cDNA was initiated with 7 µL 
of total RNA and brain homogenates were examined for the presence of both positive and 
negative strand. The log10 titrated in vitro RNA transcript standard curve (T3: 3.7  107 
copies; T7: 4.5  107 copies) was reverse transcribed at the same time as the tissue RNA 
samples. The total number of RNA copies was determined per gram of brain. 
 
RESULTS 
Contribution of different reverse transcriptases to self- and false-priming using 
unmodified and tagged primers 
The role of the RT enzyme in self-priming and false-priming using unmodified and tagged 
primers was investigated (Table 1). To this end, SSIII, MS, AMV, and rTth were used for 
× ×
×
×
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the RT reaction and only one concentration of in vitro RNA transcript depending on the 
input RNA for the specific assay. First, the occurrence of self-priming, measured by 
synthesis of cDNA in the absence of RT specific primers was assessed (Table 2). The RT 
reaction was followed by PCR amplification using either unmodified or tagged primers. 
When SSIII, MS, AMV and rTth were used for RT followed by PCR containing 
unmodified primers, occurrence of self-priming of both strands could be detected. The use 
of unmodified primers for specific RT could therefore not circumvent self-priming. Self-
priming of the negative strand also occurred when tagged primers were used in combination 
with AMV. However, when the other RT enzymes were used in combination with the 
tagged primers, self-priming was not observed. This suggests that the tagged primers 
largely circumvent detection of self-priming, but that this phenomenon is still RT enzyme-
dependent.  
Secondly, generation of cDNA as a result of false-priming by unmodified or tagged 
primers using both the positive and negative strand as a template was evaluated (Table 2). 
In the RT reaction, positive and negative sense RNA transcripts were used in combination 
with the non-complementary unmodified primers. Following PCR with the corresponding 
pair of unmodified primers, it was possible to detect the positive strand at a concentration 
of 3.72 × 107 copies for SSIII and AMV, 1.49 × 107 copies for MS and 1.86 × 107 copies 
for rTth. Using a positive strand specific RT-PCR, the negative strand was detected at a 
concentration of 4.54 × 107 copies for SSIII and AMV, 1.82 × 107 for MS and 2.27 × 107 
copies for rTth. When tagged primers were used, however, no WNV specific cDNA 
produced by false-priming was detectable at these concentrations of RNA.  
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* The non-WNV (tag) sequences are indicated in bold while WNV-specific sequences are in regular 
font. 
Table 1. Nucleotide sequence of primers and probe used for either reverse transcription or 
quantitative PCR. 
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SSIII 50 Reduced Yes Yes Yes Yes No No No No 
MS 48 Reduced Yes Yes Yes Yes No No No No 
AMV 42 Yes Yes Yes Yes Yes No yes No No 
rTth 60 Yes Yes Yes Yes Yes No No No No 
Table 2. The presence of self- or false-priming events during reverse transcription (RT) of 
positive and negative strand RNA transcript using four different RT enzymes in combination 
with unmodified or tagged primers. 
Name Application Nucleotide sequence (5’ to 3’)* 
WNV 
F34 
PCR 
amplification 
CCACCGGAAGTTGAGTAGACG 
WNV 
R96 
PCR 
amplification 
TTTGGTCACCCAGTCCTCCT 
WNV 
56 
PCR 
amplification 
TGCTGCTGCCTGCGGCTCAACCC (5’FAM-3’TAMRA) 
Tag-
Fwd 
RT primer 
negative-
sense 
TTTGCTAGCTTTAGGACCTACTATATCTACCTCCA
CCGGAAGTTGAGTAGACG 
Tag-
Rev 
RT primer 
positive-
sense 
TTTGCTAGCTTTAGGACCTACTATATCTACCTTTT
GGTCACCCAGTCCTCCT 
Tag PCR 
amplification 
TTTGCTAGCTTTAGGACCTACTATATCTACCT 
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Lack of strand-specificity of qRT-PCR using unmodified WNV-specific primers for 
the detection of positive or negative strand RNAs: contribution of self- and falsely-
primed cDNAs to PCR amplification 
First the sensitivity of the unmodified primers was addressed. The transcripts were diluted 
to a concentration of 2.61 × 107 of positive and 3.18 × 107 of negative-sense RNA and 
serially diluted on a 10-fold scale so that a final concentration of 2.61 and 3.18 copies was 
reached, respectively. The limit of detection with the unmodified primers was found to be 
at 26 and 32 copies (106 dilutions) of positive strand and negative strand RNA, respectively 
(Fig. 1A and B).  
 
Figure 1. The sensitivity and specificity of the strand-specific qRT-PCR for detection of 
negative- and positive-sense RNA transcripts using unmodified primers. The strand-specific 
reverse transcription was initiated with a standard curve of 2.61 x 107 copies of the positive 
strand and 3.18 x 107 of the negative strand serially diluted ten-fold up to 2.61 and 3.18 copies, 
respectively. The log of the RNA copies is plotted against the cycle threshold (CT). Only data 
points where amplification occurred are included in the graph. (A) Positive and negative strand 
RNA was detected using positive strand-specific primers. (B) Positive and negative strand RNA 
was detected using negative strand-specific primers. Graphs depict mean ± standard deviation 
(SD). 
 
Next the contribution of self- and false-priming events during the reverse transcription 
step of WNV negative and positive strand RNAs using unmodified primers in combination 
with the rTth enzyme was quantified. WNV-specific RT reactions were performed in the 
absence of the unmodified strand-specific RT primers (Table 1). cDNAs generated during 
the RT step were then amplified by PCR using both primers. In the absence of RT specific 
primer, both strands could be amplified, with a detection limit of 2.61 × 104 copies for the 
positive strand and a detection limit of 3.18 × 104 copies (103 dilutions) for the negative 
strand, indicating the presence of self-priming for both strands. 
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Strand-specificity of these primers was also assessed by performing the RT step in the 
presence of the uncomplimentary (incorrect) strand. The detection limit of the negative 
strand using the positive strand detection system was 32 copies (106 dilution), and the limit 
of detection for the positive strand was 2.61 × 104 copies (103 dilution) using the negative 
strand detection system (Fig. 1A and B). This indicates occurrence of false-priming of the 
incorrect strand during strand-specific RT-PCR with a significantly larger contribution in 
detection of the negative strand. 
The RT-PCR was also performed testing both negative and positive-stranded RNA in 
the presence of unmodified dengue virus (DENV)-specific forward or reverse primer and 
rTth enzyme. This was followed by PCR amplification using the WNV-specific unmodified 
F34 and R96 primers. For this purpose, only one concentration of in vitro RNA transcript 
(T3: 1.86  107 copies; T7: 2.27  107 copies) was used. The positive strand was detected 
at the indicated RNA concentration with a Ct value of 34 in the presence of the DENV-
specific forward primer. This result confirms the occurrence of self-priming during the RT 
step. 
 
Validation of the strand-specific tagged primer qRT-PCR for WNV using RNA 
transcripts 
The sensitivity and reproducibility of the strand-specific qRT-PCR assay using tagged 
primers was evaluated using synthetic positive- and negative-sense RNA transcripts. The 
transcripts were diluted to a concentration of 2.61 × 107 copies per reaction for the positive 
strand and 3.18 × 107 for the negative strand. The RNA transcripts were then serially 
diluted on a ten-fold scale so that an end concentration of 2.61 and 3.18 copies was reached, 
respectively. Minimum level of detection for either the positive or negative strand varied 
between 261-2610 and 318-3180 copies, respectively (Fig. 2A, B). In order to determine 
the sensitivity of the tagged primers more precisely, the RNA transcripts were subsequently 
diluted on a two-fold scale reaching an end concentration of 25.5 and 31.1 copies. Using 
this standard curve, the minimum level of detection was found to be around 815 copies for 
the positive strand and 497 copies for the negative strand. 
False priming of the uncomplimentary strand was not detected at any of the dilutions 
tested. Although detection of the positive and negative strand was fairly similar, detection 
of the negative strand was more sensitive and less variable. The standard deviation at each 
dilution was on average 2.88 CT values for the positive strand, and 0.64 CT values for the 
negative strand. The difference in variability is also reflected by the coefficient of variation 
percentages, where the values for negative strand detection are much lower compared to 
positive strand detection (Table 3). The displayed PCR efficiency was on average 102% ± 
13 for positive strand detection and 109% ± 13 for negative strand detection. The range of 
the R2 value for the standard curves constructed from the log10 serially diluted RNA was 
0.9-0.999 and 0.957-0.997, respectively. No amplification was observed in the controls 
lacking RT primer, RNA or reverse transcriptase.  
× ×
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Figure 2. The sensitivity of the strand-specific qRT-PCR for detection of negative- and 
positive-sense RNA transcripts using unmodified and tagged primers. The strand-specific 
reverse transcription was initiated with 2.61 x 107 copies of the positive strand and 3.18 x 107 of 
the negative strand serially diluted ten-fold up to 2.61 and 3.18 copies, respectively. The log of 
the RNA copies is plotted against the cycle threshold (CT). Only data points where amplification 
occurred are included in the graph. (A) Positive strand RNA was detected using positive strand-
specific unmodified (square) and tagged (closed circle) primers. (B) Negative strand RNA was 
detected using negative strand-specific unmodified (square) and tagged (closed circle) primers. 
Graphs depict mean ± SD. 
 
 Copy numbers of positive strand 
RNA transcript 
Copy numbers of negative strand 
RNA transcript 
 103 104 105 106 107 103 104 105 106 107 
Intra-assay 
variability  
(CV%) 
6,44 4,04 4,18 2,17 1,69 2,89 1,99 0,73 1,14 1,49 
Inter-assay 
variability  
(CV%) 
6,92 10,5 12,3 16,8 21,4 1,32 1,51 0,97 4,34 1,86 
Table 3. Intra- and inter-assay reproducibility of the real-time polymerase chain reaction 
(PCR) employing tagged primers at different concentrations of positive or negative RNA 
transcript. CV = coefficient of variation calculated based on the CT values obtained from seven 
independent experiments. 
 
The sensitivity of the strand-specific qRT-PCR was also evaluated by testing the 
tagged primers in the presence of excess complimentary (correct) or uncomplimentary 
(incorrect) RNA strand (Fig. 3A and B), with the addition of 200 ng of Vero E6 RNA (Fig. 
2C and D), or a combination of both. Five dilutions of the positive-sense RNA transcript 
were made, resulting in 107, 106, 105, 104 and 103 copies, which were additionally mixed 
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with 107 copies of negative-sense RNA transcript. Alternatively, 200 ng of Vero E6 RNA 
was added to the reactions. These ratios were then tested using the qRT-PCR for the 
positive strand. The reverse experiment was also performed where five dilutions of the 
negative-sense transcript were mixed with 107 copies of positive-sense transcript, with and 
without Vero E6 RNA. It was found that positive and negative strand detection was 
generally unaltered in the presence of the high numbers of uncomplimentary strand, with a 
maximum increase of 1.22 CT value, which occurred at a ratio of 1:10 positive 
strand:negative strand and a maximum increase of 0.28 CT value at a ratio of 1:10 
negative:positive (Fig. 3A and B).  
Furthermore, the addition of 200 ng of Vero E6 RNA also did not change the 
efficiency of detection of the positive or negative strand as only a maximum increase of 
0.71 and 0.07 CT value was observed, respectively (Fig. 3C and D). The addition of the 
opposite strand plus Vero E6 RNA led to a maximum increase in CT value of 1.22 for the 
positive strand at a ratio of 1:10 (positive:negative) and 0.28 for the negative strand at a 
ratio of 1:10 (negative:positive). As the described variation in CT values are within the 
normal limits of intra-assay variability, these results suggest that the presence of 
uncomplimentary RNA does not inhibit the accurate quantification of the positive or 
negative strand of WNV.  
 
Quantitation of viral positive and negative strands of WNV RNA in cell culture 
To investigate the susceptibility of the microglia cell line BV-2 to WNV infection and to 
understand the dynamics of RNA synthesis during virus replication in cell culture, the 
strand-specific qRT-PCR was used to characterize the kinetics of negative and positive 
strand synthesis during WNV replication. BV-2 cells were infected at MOI of 0.5 and cells 
were harvested for RNA extraction every 12 hours post-infection for a total of 48 hours. 
RNA extracted from the infected cells at the indicated time points were subjected to the 
strand specific qRT-PCR as described above. The number of RNA copies was determined 
with the use of a standard curve. It was found that the BV-2 cells were susceptible to 
infection by WNV as the amount of positive and negative strand RNA as determined by 
strand-specific qRT-PCR varied over time. Between 0 and 12 hours post-infection, the 
amount of positive strand increased by approx. 2 log10 RNA copies and then continued to 
increase steadily up to approx. 6 log10 RNA copies by 48 hours post infection (Fig. 4). In 
contrast, 3.5 log10 of negative strand RNA was first detected at 24 hours post infection and 
increased to approx. 4.5 log10 RNA copies within 48 hours.  
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Figure 3. Quantitation of positive and negative-sense RNA transcripts combined with the 
opposite strand at various ratios or with the addition of 200 ng of Vero E6 RNA. The qRT-
PCRs were performed using tagged primer as described in the materials and methods. The log of 
the RNA copies is plotted against the cycle threshold (CT). (A) Quantification of positive-sense 
RNA transcript starting at a concentration of 2.61 × 107 copies and diluted ten-fold to 2.61 
copies with and without the presence of 3.18 x 107 copies of negative-sense RNA transcript. (B) 
Quantification of negative-sense RNA transcript starting at a concentration of 3.18 × 107 copies 
and diluted ten-fold to 3.18 copies with and without the presence of 2.61 × 107 copies of 
positive-sense RNA transcript. (C) Quantification of positive-sense RNA transcript starting at a 
concentration of 2.61 × 107 copies and diluted ten-fold to 2.61 copies with and without the 
presence of 200 ng of Vero E6 RNA. (D) Quantification of negative-sense RNA transcript 
starting at a concentration of 3.18 × 107 copies and diluted ten-fold to 3.18 copies with and 
without the presence of 200 ng of Vero E6 RNA. 
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Quantitation of viral positive and negative strands of WNV RNA in infected mouse 
brains 
In order to understand the dynamics of WNV titers in the brain over the course of infection, 
this assay was used to characterize the kinetics during replication in brain of C57BL/6 
mice. Mice infected with 105 TCID50 of WNV were sacrificed per groups of five on day 3, 
4, 5 and 6 irrespective of clinical symptoms, but no later than when humane endpoints were 
reached. Brains were harvested for the determination of RNA copy numbers over time. The 
negative strand increased between days 3 and 4 by about 3.5 log10 RNA copies, and then 
remained constant until day 6 (Fig. 5B), whilst the positive strand steadily increased across 
days 3 to 6 from approx. 8.3 log10 to 9.7 log10 RNA copies (Fig. 5A). In general, the amount 
of positive strand RNA detected in the brain was higher than the amount of negative strand 
RNA. The ratio of negative to positive strand RNA was found to be on average 1:2.5 x 106 
on day 3, 1:2220 on day 4, 1:470 on day 5 and 1:800 on day 6. This indicates that the 
largest amount of positive strand per negative strand was generated on day 3.  
 
     
Figure 4. Quantitation of WNV positive and negative-sense RNA during replication in cell 
culture using tagged primers. BV-2 cells were infected at MOI of 0.5 and samples for RNA 
isolation were harvested in triplicate at indicated time points post-infection. The production of 
positive and negative-sense RNA was estimated by extrapolation of standard curves as 
generated in Fig. 2 and the log of RNA copies recovered from the cells was plotted against time 
points post-infection. 
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Figure 5. Quantitation of WNV positive and negative-sense RNA in brains of mice infected 
with 105 TCID50 of WNV-NY99 (n=5). Mice were euthanized on day 3, 4, 5 and 6 post-
infection and brains were collected and homogenized for RNA isolation. The amount of positive 
and negative-sense RNA was estimated by extrapolation of standard curves as generated in Fig. 
2 and calculated per gram of brain. The log of RNA copies was plotted against time points post-
infection. (A) The amount of positive-sense RNA copies present in the brains of mice between 
days 3 and 6 post-infection. (B) The amount of negative-sense RNA copies present in the brains 
of mice between days 3 and 6 post-infection. 
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DISCUSSION 
An assay that allows for the specific detection of negative strand viral RNA is a useful tool 
for studying viral replication and kinetics, in particular for single-stranded positive-sense 
RNA viruses, which use the negative strand RNAs as a template for the synthesis of 
positive stranded RNAs [1, 37]. In this study, a strand-specific qRT-PCR using tagged 
primers and a thermostable rTth has been developed for the accurate quantitation of both 
positive and negative sense RNA of WNV. It was shown that this qRT-PCR assay is 
suitable for the study of viral replication in cell culture, but also in experimentally infected 
mice. The results of both the in vitro and in vivo study clearly show an increase in both 
positive- and negative-sense RNA over time. 
Many studies have reported the synthesis of non-specific cDNA during an RT 
reaction, which interfere with strand-specific detection of RNAs [10, 16, 25, 38]. However, 
recent developments in qRT-PCR assays, such as high temperature reverse transcriptase 
enzymes and the use of tagged RT primers, have allowed for more accuracy in the detection 
of specific RNA strands. 
In the attempt to develop a strand-specific qRT-PCR for studying WNV replication, 
the accuracy of a current standard qRT-PCR system using unmodified primers and rTth for 
the detection of positive or negative strand RNAs of WNV was first investigated. Using 
synthetic positive and negative RNA transcripts, it was shown that self-primed cDNAs are 
generated during the reverse transcription step in the absence of primers and that false-
priming occurs in the presence of unmodified primers. These self- and falsely-primed 
cDNAs are subsequently amplified in PCR to amplicons that are indistinguishable from 
positive or negative-strand specific cDNAs.  
To further elucidate these observations, four different reverse transcriptases that 
function at different temperatures were compared. It was found that both self- and false-
priming occurred in the presence of SSIII, AMV, MS and rTth. When these same reactions 
were carried out in the presence of tagged primers, false-priming was no longer observed. 
Self-priming was only evident when tagged primers were used in combination with AMV. 
This suggests that the tagged primers largely circumvent self-priming, but that this 
phenomenon is also RT enzyme-dependent. This is supported by the fact that very few 
positive strand RNA was detected when unmodified uncomplimentary primer was used in 
combination with rTth, as this reaction was carried out at a temperature of 60 ºC. The 
results in this study are in agreement with published data [29] demonstrating reduced 
strand-specificity when using tagged primers in combination with AMV or untagged 
primers in combination with rTth-RT, and further highlight the importance of combining 
the thermostable rTth enzyme with tagged primers. 
As a result, a qRT-PCR assay was developed to overcome self- and false-priming in 
the detection of WNV-specific RNA that uses rTth enzyme in combination with tagged 
primers. Even though tagged primers alone have proven to be successful in some studies 
[25-28], this study shows that a combination of tagged primers with thermostable rTth is 
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necessary to circumvent these problems for the detection of WNV-specific RNA. This 
combination greatly improved the specificity of the positive and negative strand-specific 
qRT-PCR as self-primed and falsely-primed RNAs were no longer detected.  
When using tagged primers, it was found that with a log10 titration of the RNA 
transcripts the minimum level of detection for the positive strand was 2.61 × 103 RNA 
copies at 67% of the time and 3.18 × 103 copies for the negative-strand at 75% of the time. 
This assay is therefore approx. 2 log10 less sensitive than the assay using unmodified 
primers. This extra sensitivity, however, is most likely the result of self- or false-priming, 
as it was possible to detect both strands of RNA at a minimum concentration of 104 copies 
in the absence of primers, and at 104 and 101 copies of positive and negative stranded RNA, 
respectively, in the presence of uncomplimentary primer. This therefore suggests that a 
large portion of the amplification detected originates from self- and falsely-primed cDNA. 
In comparison to the tagged primers that this study has specifically investigated, some 
other studies investigating tagged primers (using a 10-fold dilution scale) have 
demonstrated a similar sensitivity in the order of 103 copies per reaction [25], or a higher 
sensitivity of 102 [11, 26, 28] or even 101 RNA copies per reaction [24]. In another study 
[34], positive and negative strand of foot-and-mouth disease virus were detected up to a 
sensitivity of 1 × 102 and 1 × 103 copies/µL, respectively. However, despite the use of 
tagged primers, the complimentary primer was still able to detect the opposite strand at 1 × 
107 copies/µL. This low rate of incorrect strand detection in the presence of high 
concentrations of target RNA despite the use of tagged primers was also demonstrated in 
other studies [11, 18, 29]. This therefore suggests that the sensitivity of some tagged 
primers occurs at the expense of specificity. In this particular assay, however, it was found 
that in the presence of high concentrations of the opposite strand or cellular RNA, the 
tagged primers only detected the complimentary strand of RNA, demonstrating the high 
specificity and effectiveness of these primers. 
The positive strand-specific assay was found to exhibit much greater variability than 
the negative strand-specific assay. This was reflected in the standard deviation of the CT 
values as well as in the coefficient of variation percentages. In addition, the displayed 
efficiency range of the positive strand-specific assay was also greater than that for the 
negative strand-specific assay. PCR efficiency can be dependent on the assay, the master 
mix performance, and sample quality. In general, an efficiency range of 90-110% is 
considered to be acceptable [39]. It is possible that the inter-assay variability for the 
positive strand was caused by the quality of the synthetic positive-sense RNA transcripts.  
The application of the strand-specific assay was tested in vitro and in vivo in order to 
study WNV replication. First the strand-specific assay as described above was used to 
characterize the in vitro replication kinetics of WNV in BV-2 microglia cells. This 
microglia cell line was found to be susceptible to infection. The amount of positive strand 
increased from 0 to 48 hours. On the other hand, the negative strand was not detectable at 0 
hours post-infection and was only detected at 24 hours post-infection. As a full replication 
cycle of West Nile virus takes approx. 12 hours (unpublished data), it seems unlikely that 
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no negative strand is yet present at this point in the cell. The largest increase in positive 
strand was measured between 0 and 12 hours post-infection, indicating that negative strand 
synthesis must have occurred. As the negative strand-specific assay was found to have a 
detection limit of 497 copies of RNA, it is possible that negative strand was present in the 
cell but in amounts that fall below the detection limit of this assay. The lack of detection of 
negative strand in the first 12 hours of the replication cycle therefore appears to be a 
limitation of this assay.  
Furthermore, the mouse experiment characterizing the positive and negative strand 
kinetics over the course of six days showed low amounts of negative strand RNA copies on 
day 3 post-infection for 2 out of 5 mice (in the order of 2 log10 RNA copies). As the ratio of 
positive to negative strand is highest on this day, it suggests that the largest amount of 
positive strand per negative strand was produced on this day. However, it is unlikely that 
the largest amount of positive per negative strand is produced in the brain as early as day 3, 
as this is usually the first time-point at which virus can be detected in the brain (Halevy et 
al., 1994; Hunsperger et al., 2006). Instead, it is more likely that most of the positive 
stranded RNA detected in the brain was the result of contamination with virus that 
replicated in the periphery instead of de novo virus production. Several studies have shown 
that by day 4-5 after infection, there is no more virus present in the blood [40, 41] 
(unpublished observation). It is therefore more likely that the largest amount of positive 
stranded RNA per negative strand is produced in the brain on day 4.  
In conclusion, despite the possible limitation of the strand-specific quantitative RT-
PCR assay developed in this study, this assay is a useful tool for the evaluation of tropism 
and replication kinetics of WNV over a longer period of time in vitro and in vivo.  
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ABSTRACT 
West Nile virus (WNV) strains may differ significantly in neuroinvasiveness in vertebrate 
hosts. In contrast to genetic lineage 1 WNVs, molecular determinants of pathogenic lineage 
2 strains have not been experimentally confirmed so far. A full-length infectious clone of a 
neurovirulent WNV lineage 2 strain (578/10; Central Europe) was generated and amino 
acid substitutions that have been shown to attenuate lineage 1 WNVs were introduced into 
the nonstructural proteins (NS1 (P250L), NS2A (A30P), NS3 (P249H) NS4B (P38G, 
C102S, E249G)). The mouse neuroinvasive phenotype of each mutant virus was examined 
following intraperitoneal inoculation of C57BL/6 mice. Only the NS1-P250L mutation was 
associated with a significant attenuation of virulence in mice compared to the wild-type. 
Multiplication kinetics in cell culture revealed significantly lower infectious virus titres for 
the NS1 mutant compared to the wild-type, as well as significantly lower amounts of 
positive and negative stranded RNA. 
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INTRODUCTION 
West Nile virus (WNV) is one of the most widely distributed members of the genus 
Flavivirus within the family Flaviviridae. The virus can cause general, febrile and severe 
encephalitic disease in humans and a number of animal species. It possesses a capped and 
non-polyadenylated positive-sense, single-stranded RNA genome, approximately 11 kb in 
length, which contains a single open reading frame (ORF) encoding a polyprotein precursor 
that is co- and post-translationally processed by viral and host cell proteases to three 
structural proteins (capsid protein C, pre-membrane protein prM/M, envelope protein E) 
and seven non-structural (NS) proteins (glycoprotein NS1, NS2A, protease cofactor NS2B, 
protease and helicase NS3, NS4A, NS4B and polymerase NS5).  
WNV strains have been divided into at least eight distinct genetic lineages [1–3]. The 
first WNV strain, isolated in Uganda in 1937 [4], belongs to lineage 2 and this lineage has 
been confined to sub-Saharan Africa and Madagascar [5]. Until the early 1990s, WNV 
infections beyond Africa were caused by lineage 1 WNV strains that caused mainly mild 
clinical symptoms with sporadic encephalitis in humans. Lineage 1 WNV as the causative 
agent of lethal encephalitis was reported in 1994, in Algeria, followed by a high number of 
neuroinvasive cases in Romania, in 1996, and more frequent encephalitis cases in several 
other Eastern and Western European countries [6]. Moreover, in 1999, WNV emerged in 
the continental United States and rapidly spread throughout North America and also into 
South America, causing increased mortality among humans and animals as well [7–9].  
Lineage 2 strains did not appear to be as pathogenic as lineage 1 isolates, as they 
generally caused no deaths, and only mild clinical signs of infection [10]. The first proven 
case of a lineage 2 virus infection with fatal outcome outside of Africa was detected in a 
goshawk (Accipiter gentilis) in Hungary, in 2004 [11,12]. This exotic WNV lineage 2 strain 
caused subsequent infections, illnesses and deaths in wild birds, horses and humans [11–
13], and rapidly spread to Austria [14–16], Greece [17,18] and Italy [19,20]. Based on 
phylogenetic reconstruction, lineage 2 viruses isolated in Russia [21,22] and Romania [23] 
cluster together, but are distinct from the Hungarian strain [16].  
Several studies have aimed at identifying the molecular markers of virulence in 
lineage 1 WNV strains [24–27]. A number of lineage 1 viruses of moderate virulence in 
mice and exhibiting inefficient growth in cell culture have been identified so far [28]. 
Reverse genetic systems were established to investigate nucleotide and amino acid 
alterations in the WNV lineage 1 genome that led to decreased neurovirulence and 
neuroinvasiveness in mice [29,30]. Mutations in the NS protein genes, such as NS1 [31], 
NS2A [24,26,32], NS3 [33], NS4B [30,34–36] and NS5 [34], were found to be associated 
with the attenuation of these viruses.  
In contrast to lineage 1 viruses, molecular determinants of pathogenic WNV lineage 2 
strains have not been confirmed experimentally. Virulence markers have only been 
identified in silico by analyzing and comparing full genome sequences of highly or less 
neuroinvasive lineage 2 strains [37], or by comparing those that have emerged and 
106 
increased in virulence over time (1937-2011) [38]. The aim of the present study was to 
investigate the in vitro (in cell culture) and in vivo (in a mouse model) effects of selected 
nucleotide substitutions of the NS protein coding genes, known to be attenuating for lineage 
1, in a neurovirulent WNV lineage 2 strain (578/10) isolated in Central Europe with the 
help of reverse genetic methods and site-specific mutagenesis. 
 
MATERIALS AND METHODS  
Cells and viruses 
Transfection was carried out on baby hamster kidney 21 (BHK-21) cells (ATCC®: CCL-
10TM) cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 5% 
foetal bovine serum (FBS). Virus stocks were propagated and titrated on Vero E6 cells 
(ATCC®: CRL-1586TM) cultured in DMEM supplemented with 0.75% sodium bicarbonate, 
10 mM hepes buffer and 10% FBS. All media was supplemented with antibiotics (100 U 
penicillin, 100 µg/mL streptomycin) and 2 mM L-glutamine. The WNV-578/10 strain 
(GenBank accession number: KC496015) was originally isolated in Hungary from a horse 
showing clinical signs of encephalitis, which had died in 2010. 
 
RNA extraction and cDNA synthesis 
Total RNA was extracted from virus pellet using the QIAamp Viral RNA Mini Kit  
(QIAGEN, Hilden, Germany) following the manufacturer’s instructions. To obtain long 
cDNA copies of the viral genome, reverse transcription was performed using the high 
fidelity SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA) and 
gene-specific reverse primers (Table 1). In the first step, 0.5 µL of each primer (10 µM) and 
1 µL RNA in 7.5 µL RNase-free water were heated to 65 °C for 5 minutes and then cooled 
down to 4 °C for 10 minutes. In the second step, 11 µL reaction mixture (2 µL reaction 
buffer, 4 µL MgCl2, 2 µL dithiothreitol (DTT), 1 µL RNase OUT inhibitor, 1 µL SSIII 
enzyme and 1 µL dNTP mixture) were added and after 30 minutes at room temperature and 
the final 20-µL reaction mixture was heated to 50 °C for 90 minutes, followed by 85 °C for 
5 minutes, and finally cooled down to 4 °C. Before amplification, cDNA was treated with 
RNase H (1 µL RNase H was added to 20 µL of the above-mentioned solution and was 
heated to 37 °C for 20 minutes). 
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Primer code Nucleotide sequence (5’→3’) Nucleotide position (5’)* 
1F† GAGCTCGTTTAGTGAACCGTAGTAGTTCGCCTGTGTGAGC 1 
1FRC† GCTCACACAGGCGAACTACTACGGTTCACTAAACGAGCTC 20 
4750F CACACACTATGGCACACCACTAAGG 4750 
5426R GACATCAGCCTGTGTGTGAGAGTGG 5426 
8190F AGACTGGCTGCACAGAGGACCTAAG 8190 
9175R GGTCTTCATTGAGGAATCCGAGAGC 9175 
3’XbaSacIIR‡ ATCCGCGGTCTAGAGATCCTGTGTTCTAGCACCACAG 11026 
† Bases in italics are part of cytomegalovirus (CMV) promoter. * Primer positions corresponding to 
the sequence of WNV-578/10 strain. ‡ Bases in italics are the extra restriction enzyme cleavage sites. 
Table 1. List of primers used to generate overlapping fragments of the West Nile virus (WNV) 
genome in order to construct the full-length clone pWNV-578/10. 
 
Sequence analysis 
The complete genome of WNV-578/10 was determined by sequencing of overlapping PCR 
fragments amplified with Phusion Hot Start High-Fidelity DNA Polymerase (Finnzymes, 
Espoo, Finland). Amplification products were directly sequenced with the ABI Prism 
BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, 
USA) and an automated ABI 377 DNA Sequencer (Applied Biosystems). Sequence 
assembly and comparison were performed with SeqMan and MegAlign programs 
(Lasergene, Madison, WI, USA), respectively. The full-length WNV clone was sequenced 
with the ABI Prism BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) 
and an ABI Prism 310 genetic analyzer (Applied Biosystems), as described in Bakonyi et 
al., 2004 [39].  
Full genome sequencing of WNV clones with the incorporated modifications was 
carried out by using semiconductor sequencing technology. Briefly, overlapping PCR 
fragments were generated as described above. Equimolar amounts of the amplicons from 
each clone were used for preparation of Ion Torrent compatible libraries. Clonal 
amplification of library DNA (with 200 bp inserts) by emulsion PCR on an Ion One Touch 
v2 (Life Technologies, Thermo Fisher Scientific, Waltham, MA, United States) equipment 
was followed by enrichment on an Ion OneTouch ES pipetting robot, and then by 
sequencing on a 316 Chip using Ion Torrent PGM (Life Technologies). Raw reads were 
curated and then consensus genomic sequences were assembled using the CLC Genomics 
Workbench version 7 (www.clcbio.com). 
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Plasmids and bacteria strains 
Plasmid pBeloBAC TGE [40] was kindly provided by L. Enjuanes (Centro Nacional de 
Biotecnologia, Department of Molecular and Cell Biology, Madrid, Spain). The plasmid 
was propagated in Max Efficiency DH10B competent Escherichia coli cells (Invitrogen) 
that were transformed by heat shock according to the manufacturer’s instructions. 
Modifications, such as deletion of the XhoI site downstream of the 3’ accessory sequences 
and insertion of a multiple cloning site containing SfiI, SfoI, BstBI, ClaI, BamHI, XhoI, 
AsiSI, AvrII and SacII, were described earlier [41]. For large-scale DNA preparation, the 
BAC vector and recombinant BACs were isolated with the QIAGEN Large Construct Kit 
(QIAGEN) according to the manufacturer’s specifications.  
 
Generation of the full-length clone of WNV-578/10  
To amplify long, overlapping PCR products, ranging between 1 and 5.5 kb covering the 
whole genome in three fragments (Fragment I, II and III), PCRs were performed using 
genome-specific primers (Figure 1). Long-range PCR assays were implemented using the 
Phusion Hot Start High-Fidelity DNA Polymerase (Finnzymes). The construction of 
Fragment I was performed in two steps. First, the CMV promoter sequence from the 
PBeloBAC (with primers 5’SfiIF and 1FRC), as well as the 5’ side of 5426 nucleotides of 
WNV-578/10 strain (with primers 1F and 5426R), were amplified. Primers 1F and 1FRC 
were reverse complements. In the second step that joined together the two amplicons, a 
fusion PCR utilizing the overlapping sequences of the above-mentioned primers was 
performed with Phusion Hot Start High-Fidelity DNA Polymerase (Finnzymes). Fragment 
II was amplified by using primers 4750F and 9175R. For amplification of Fragment III, a 
specific reverse primer containing two extra restriction sites (XbaI and SacII) in addition to 
the 3’ conservative end of WNV-578/10 strain (3’XbaSacIIR) and forward primer 8190F 
was used. Sequences of all the primers used to generate the full-length clone are listed in 
Table 1. All fragments were separated and purified from 0.8% agarose gel using the 
QIAquick Gel Extraction kit (Qiagen).  
Restriction enzyme cleavage and cloning steps were performed according to standard 
protocols [42]. Restriction endonucleases and DNA modifying enzymes were purchased 
from Fermentas (Vilnius, Lithuania) and New England Biolabs (Beverly, MA, USA). The 
cDNA fragments were ligated with T4 DNA Ligase (Invitrogen Life Technologies). After 
the digestion of pBeloBac and fragment III with AvrII and SacII restriction endonucleases, 
fragment III was cloned into the pBeloBac to obtain WNV-3. Fragment II was digested 
with BstBI and AvrII restriction endonucleases, and was cloned into WNV-3 to get WNV-
3-2. Fragment I was digested with SfiI and BstBI restriction endonucleases, and was cloned 
into WNV-3-2 to obtain the final full-length clone pWNV-578/10. All recombinant 
plasmids were stable in bacteria, and no toxicity was observed. All the sequences of 
molecular constructs were confirmed by restriction endonuclease pattern analysis and 
PCRs. 
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Figure 1. Cloning strategy for the WNV-578/10 genome and positions of the generated 
mutations. Black numbers represent nucleotide positions in WNV genome/PBeloBac plasmid 
genome. Red numbers indicate nucleotide positions of restriction enzyme cleavage sites in 
WNV genome. Green numbers in boxes represent nucleotide positions of inserted mutations. 
Names of used primers are in blue. 
Generation of mutant full-length WNV clones 
Point mutations were inserted in the genome of WNV using PCR-based mutagenesis 
utilizing specific oligonucleotides (forward and reverse, complementary oligos) containing 
the altered nucleotides (Table 2). Depending on the position of the mutation in the genome, 
new fragments I or II were synthesized using the mutated complementary oligos in fusion 
PCRs. In the next step, the original fragment I or fragment II was removed from the 
pWNV-578/10 clone and was replaced with the newly synthesized fragment I or fragment 
II, containing the respective mutations in the pWNV-578/10 clone. The generated 
mutations were as follows: C3218T in NS1 protein gene (P250L), G3613C in NS2A 
protein gene (A30P), C5357A in NS3 protein gene (P249H), and three mutations in the 
NS4B protein gene: CC7030-31GG (P38G), G7223C (C102S) and A7664G (E249G) 
(Figure 1).  
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Primer 
code  Nucleotide sequence (5’→3’) 
Nucleotide 
Position (5’)* 
NS1F CATCACCTTGGCAGGACTCAGAAGCAATCATAA
CAGGAGACC 
3201 
NS1R 
GGTCTCCTGTTATGATTGCTTCTGAGTCCTGCCA
AGGTGATG 3201 
NS2AF TTCGCAAGAGGTGGACGCCCAAGATCAGCATTCCAGCTATCA 3596 
NS2AR TGATAGCTGGAATGCTGATCTTGGGCGTCCACCTCTTGCGAA 3596 
NS3F GGTACCAAACCTCAGCAGTGCACAGAGAGCACAGTGGAAATGA 5336 
NS3R TCATTTCCACTGTGCTCTCTGTGCACTGCTGAGGTTTGGTACC 5336 
38NS4BF TTCTTGCTTGATCTGCGGGGGGCTACAGCATGGTCTCTCTAT 7012 
38NS4BR ATAGAGAGACCATGCTGTAGCCCCCCGCAGATC
AAGCAAGAA 
7012 
102NS4BF TCAGCTCTCTTGCTGGCGGCCGGGTCCTGGGGCCAAGTGACCCTG ACTGTGACT 7198 
102NS4BR AGTCACAGTCAGGGTCACTTGGCCCCAGGACCCGGCCGCCAGCAAGAGAGCTGA 7198 
249NS4BF GGACTCTCATCAAAAACATGGGGAAACCAGGCCTCAAGAG 7643 
249NS4BR CTCTTGAGGCCTGGTTTCCCCATGTTTTTGATGAGAGTCC 7643 
* Primer positions corresponding to the sequence of WNV-578/10. Triplets in italics are the loci of 
mutations, modified nucleotides are in italics and bold. 
Table 2. List of primers used to insert point mutations into the genome of WNV-578/10.  
Transfection and recovery of the recombinant viruses from the cDNA clones 
Before transcription, the CMV-WNV clone was double digested with SfiI and XbaI 
restriction endonucleases. To remove the single-stranded nucleotide overhang generated by 
the digestion, Mung Bean Nuclease (New England Biolabs) was used. In order to get the 
purified expression cassette, pieces from digestion were separated on a 0.8% agarose gel 
and the approximately 12 kb cassette was purified with QIAquick Gel Extraction Kit 
(QIAGEN). Four micrograms of double-stranded cDNA was transfected into BHK-21 cells 
using Turbofect in vitro Transfection Reagent (Thermo Scientific, Waltham, MA USA). 
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Briefly, 4 µg of plasmid DNA were transfected into an approximately 60% confluent 
monolayer of BHK-21 cells on a 6-well culture plate after a 20 minute incubation period 
with the Turbofect reagent. The plates were incubated for 4 h at 37 °C, then the supernatant 
was removed, and fresh DMEM (Sigma-Aldrich, Saint Louis, MO, USA) supplemented 
with 10% FBS was added. The cells were incubated at 37 °C for 48–96 h until a visible 
cytopathic effect (CPE) appeared. At this time point, supernatant was harvested, clarified 
by centrifugation at 1000 × g for 5 min, and stored at –80 °C. To increase infectious virus 
titres for use in in vitro and in vivo experiments, virus stocks of the recombinant wild type 
(WT) and mutant viruses were incubated on 80% monolayers of Vero E6 cells in cell 
culture flasks. At the point of maximum CPE (4–5 days after inoculation), supernatants 
were harvested, clarified by centrifugation at 1000 × g for 5 min, and stored at –80 °C. 
Infectious titres of the virus stocks were determined by log10 titration on Vero E6 cells and 
calculating the TCID50 using the Spearman–Kärber method [43,44] after determination of 
CPE 5 days p.i.  
Subsequent full genome sequencing of each stock was performed by semiconductor 
sequencing as detailed in Section 2.3. 
 
Multiplication curves in cell culture 
Growth curves of the wild-type virus and the mutated clones were generated in Vero E6 
cells at 37 °C in two independent experiments. Vero E6 cells were seeded at 104 cells/well 
in flat-bottom 96-well plates, incubated overnight at 37 °C and 80% monolayers were 
infected in triplicate with 100 µL of virus diluted in serum-free DMEM at multiplicity of 
infection (MOI) 0.1. Cells were incubated for 1 h at 37 °C and subsequently washed three 
times with serum-free medium before adding 120 µL of DMEM supplemented with 10% 
FCS. At 0, 12, 24, 36, 48, 72 and 96 h post-infection (p.i.), supernatants were removed and 
70 µL was frozen at –80 °C until used for infectious virus titre determination, while the 
remaining 50 µL was added to 350 µL of lysis buffer (Roche Diagnostics, Almere, The 
Netherlands) for RNA extraction. Cells were also collected for RNA extraction in 50 µL of 
lysis buffer at time points 0, 12, 36 and 48 h p.i. Harvested supernatant infectious virus 
titres were determined by log10 titration on Vero E6 cells as described previously. 
 
Quantitation of viral RNA titres 
In order to quantify viral RNA copies in the supernatant and cells, RNA was extracted 
using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics) and an 
automated nucleic acid robotic workstation (Roche Diagnostics) according to the 
manufacturer’s instructions. RNA was eluted in 50 µL of elution buffer and used 
immediately in quantitative real-time PCR (qRT-PCR). Within in vivo experiments, viral 
RNA copies in half-brains were quantified after weighing and homogenization using a 
metal bead in DMEM containing antibiotics (100 U penicillin, 100 µg/mL streptomycin) 
using a tissue homogenizer. One hundred microliters of tissue homogenate was added to 
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400 µL of lysis buffer (Roche Diagnostics) and RNA was extracted as indicated above. 
RNA copy numbers were determined in a strand-specific qRT-PCR assay [45] using a 
standard curve of in vitro transcribed RNA of positive and negative strand of known 
quantities, which were generated from a plasmid (pCR®4-TOPO®; Invitrogen, Breda, The 
Netherlands) containing the sequence of the 3’UTR of WNV. Plasmid was linearized and 
run-off transcripts were generated using the Ambion® MaxiScript T7/T3 kit (Invitrogen). 
The positive sense RNA was transcribed using the T3 polymerase and the negative sense 
RNA using the T7 polymerase. The product was digested with DNase to remove residual 
DNA and cleaned-up using the High Pure RNA Isolation kit (Roche Diagnostics). In vitro 
transcribed RNA was diluted to a concentration at which DNA was no longer detected. 
 
Mouse virulence studies 
Six-week-old female C57BL/6 mice (Harlan Laboratories B.V., Venray, The Netherlands) 
were inoculated intraperitoneally (i.p.) with average doses of 10 and 104 TCID50 per mouse 
of wild-type infectious clone-derived CMV-WNV as well as the mutant viruses (n = 8 per 
clone, per dose; Table 3). Mice were observed twice daily and were euthanized by cervical 
dislocation under isoflurane anesthesia when humane endpoints were reached (immobility 
and paralysis), after which brains were immediately collected for further processing. At 14 
days p.i., the end-point for the survival experiment was reached and all remaining mice 
were euthanized and brains and kidneys were collected from those that had been infected 
with the highest viral dose. Mice were maintained in specific pathogen-free conditions, had 
a 12-hour day-night cycle and were fed ad libitum. Animal experiments were approved by 
the Animal Ethics Committee of Erasmus Medical Centre and carried out under protocol 
number 122-13-19. 
 
Statistical analysis 
Data analysis was performed using GraphPad Prism v5 software statistical analysis. The 
ANOVA test was used for the comparison of more than two groups. Statistical significance 
between individual groups was determined using the Mann-Whitney U test, and statistical 
significance was accepted at p ≤ 0.05. 
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RESULTS 
Comparison of the genome sequences of WNV Lineage 1 (NY99) and lineage 2 
(578/10) strains 
The complete genome sequence of the 578/10 strain (GenBank accession number 
KC496015) exhibits 2236 nucleotide (nt) differences (21%) compared to the WNV NY99 
strain (accession number AF202541). The nucleotide substitutions are distributed fairly 
equally within the genome (5’UTR: 0 substitutions (0%), C protein gene: 59 substitutions 
(16%), preM-M protein gene: 102 substitutions (21%), E protein gene: 309 substitutions 
(21%), NS1 protein gene: 227 substitutions (22%), NS2A protein gene: 153 substitutions 
(23%), NS2B protein gene: 82 substitutions (22%), NS3 protein gene: 382 substitutions 
(21%), NS4A protein gene: 80 substitutions (22%), 2K gene: 13 substitutions (19%), NS4B 
protein gene: 184 substitutions (25%), NS5 protein gene: 560 substitutions (21%), and 
3’UTR: 90 substitutions (20%)). Within the putative polyprotein precursor, 203 amino acid 
(aa) alterations (6%) are found (C protein: 12 substitutions (10%), preM-M protein: 7 
substitutions (5%), E protein: 22 substitutions (5%), NS1 protein: 33 substitutions (10%), 
NS2A protein: 24 substitutions (11%), NS2B protein: 7 substitutions (6%), NS3 protein: 25 
substitutions (5%), NS4A protein: 7 substitutions (6%), 2K protein: 1 substitution (5%), 
NS4B protein: 19 substitutions (8%), and NS5 protein: 46 substitutions (6%)). Due to this 
high level of sequence diversity, it is not possible to test the potential effect of each 
substitution in all combinations. As a result, within this study we only tested the effect (in a 
neuroinvasive WNV lineage 2 strain) of the nucleotide substitutions that have already been 
identified as virulence markers in WNV lineage 1 strains. 
Rescue of recombinant viruses 
In order to investigate whether molecular markers of virulence identified in lineage 1 WNV 
strains attenuate the Hungarian neuroinvasive lineage 2 WNV-578/10 strain in vitro or in 
vivo, infectious cDNA clones encoding each substitution of interest were constructed and 
transfected into BHK-21 cells. After transcription by CMV promoter, CPE had reached the 
maximum level at 72–96 h after transfection. Supernatants were harvested and passed on 
Vero E6 cells, which resulted in the generation of at least 6 log10 TCID50/mL virus stocks. 
When the titre did not reach the desired level, one more passage in Vero E6 cells was 
performed. All mutations of interest were verified by Sanger sequencing of each stock 
before in vitro and in vivo characterization. The NS4B102 mutant recombinant WNV was 
unable to multiply to a sufficient titre in BHK-21 cells nor after passage in Vero E6 cells, 
and this mutant clone was therefore excluded from the functional analyses.  
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Full genome sequence analysis of recombinant virus stocks 
To determine whether passaging the virus stocks led to the introduction of additional 
mutations, the full genome of the wild type and modified clone virus stocks were 
sequenced. One nucleotide alteration was found in addition to the mutated sites for three 
mutant clones, of which two out of three nt changes were silent: G to A on locus 627 of the 
NS1 clone, and A to G on locus 6768 of the NS4B38 clone. One nt alteration in the genome 
of the NS4B249 clone resulted in a Valine to Isoleucine change in the NS4B protein at 
locus 188 (G to A on locus 7480). The in vitro and in vivo characterization was 
subsequently carried out using the generated clones. 
 
Multiplication kinetics of the recombinant wild type (WT) and mutant WNVs in cell 
culture 
The multiplication kinetics of the mutant WNVs were compared to those of the WT 
infectious clone-derived WNV-578/10 in Vero E6 cells infected in triplicate at an MOI of 
0.1 at 37 °C, sampling every 12 hours. Overall, the infectious virus titers of the clones were 
significantly different at all time points between 12 h and 96 h p.i. (one way ANOVA; p < 
0.02). More specifically, infectious virus titres for WT were significantly higher at 24 h p.i. 
compared to all the mutated viruses; NS1 (p = 0.005), NS2A, NS3, NS4B38, and NS4B249 
(p = 0.03). Moreover, NS1 infectivity titres were found to be significantly lower compared 
to NS2A (p = 0.03) and NS4B38 (p = 0.03) (Figure 2). At 36 h p.i., WT infectivity titres 
were only significantly higher compared to NS1 (p = 0.002), NS2A and NS3 (both p= 
0.02). At this time point, the difference in infectious virus titres between WT and NS1 was 
the largest, at approx. 2500-fold. In addition, NS1 titres remained significantly lower 
compared to all the other viral clones (all, p = 0.03). At 48 h p.i., WT infectious titres were 
still significantly higher compared to NS1 (p = 0.005), NS2A and NS3 (p = 0.03), while 
NS1 titres were only significantly lower compared to NS2A (p = 0.04) and NS4B249 (p = 
0.03). At 72 and 96 h p.i., WT infectious titres remained only significantly higher compared 
to NS1 (p = 0.005; 0.02, respectively), while NS1 titres were significantly lower compared 
to all the other WNV strains at 72 h p.i. (p < 0.04), and compared to NS4B38 and NS4B249 
at 96 h p.i. (p < 0.04).  
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Figure 2. Growth kinetics of infectious virus of the wild type (WT) virus and mutant viruses 
after triplicate infection of Vero E6 cells at an MOI of 0.1. The titres are given as the mean 
(log10 TCID50/mL); error bars represent standard deviation. 
Quantification of positive and negative strand RNA for WT and NS1 mutant in vitro 
In order to assess whether the in vitro replication differences between the WT and NS1 
mutant can be attributed to differences in positive and negative strand RNA synthesis, we 
determined the amount of positive and negative strand RNA copies in the supernatant and 
cells of the in vitro multiplication kinetics experiment using a strand-specific qRT-PCR 
assay [45]. The amount of positive strand present in the supernatant was more than 1 log10 
higher for NS1 compared to WT at 12 h p.i., albeit not statistically significant (p > 0.05) 
(Figure 3A). At 24 h p.i., positive strand titres were approx. 0.9 log10 RNA copies higher 
for the WT compared to NS1 (p = 0.002). This difference increased to approx. 1.4 log10 
RNA copies by 36 h p.i. (p = 0.002) and 1.3 log10 at 48 h p.i. (p = 0.002). At t = 72, titre 
differences had decreased to 0.8 log10 (p = 0.002) and at 96 h p.i. positive strand titres were 
only 0.6 log10 RNA copies higher for WT compared to NS1, although still significantly 
different (p = 0.04) (Figure 3A).  
Positive strand intracellular RNA titres were initially also higher for NS1 compared to 
WT for the first 12 h p.i. (Figure 3B). However, after 24 h p.i., WT positive strand RNA 
titres had become approx. 0.9 log10 RNA copies higher compared to NS1 (p = 0.002), with 
the most pronounced difference of approx. 1 log10 RNA copies after 36 h p.i. (p = 0.002). 
At 48 h p.i., positive strand RNA titres were still significantly higher for the WT compared 
to NS1 (p = 0.004) but the difference had decreased to approx. 0.6 log10 RNA copies 
(Figure 3B).  
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For intracellular negative strand RNA copies, titres for NS1 were already significantly 
lower compared to the WT at 12 h p.i. (p = 0.02) (Figure 3C). NS1 negative strand RNA 
copies remained significantly lower compared to the WT with a difference of approx. 1.2 
log10 RNA copies at both 24 and 36 h p.i. (p = 0.002). After 48 h p.i., titre differences 
decreased to approx. 0.4 log10 RNA copies, at which point the difference was no longer 
statistically significant (p = 0.06) (Figure 3A). 
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Figure 3. Quantification of (A) extracellular positive strand RNA (B) intracellular positive 
strand RNA, and (C) negative strand RNA for WT and NS1 mutant after triplicate infection of 
Vero E6 cells at an MOI of 0.1. Copy numbers are given as the mean of two independent 
experiments (log10 TCID50/mL); error bars represent standard deviation. 
Mouse neuroinvasiveness of the different mutant WNV strains 
The mouse neuroinvasive phenotype of each mutant WNV was examined following i.p. 
inoculation of six-week-old female C57BL/6 mice. Compared to the WT (100% and 75% 
mortality at high and low doses, respectively), only the NS1 mutant proved to be 
significantly attenuating since all mice infected with either the high or low dose of this 
virus survived the infection (0% mortality for both) (Table 3; Figure 4A and 4B). In 
contrast, mice infected with the highest dose of the other mutant strains experienced 
substantial mortality, with rates of 100% (8/8) for NS4B38, 88% (7/8) for NS2A, 75% (6/8) 
for NS3, and 63% (5/8) for NS4B249, respectively (Figure 4A). Statistical analysis 
confirmed the attenuation of the NS1 mutant, as significant differences were found between 
the survival curves of mice infected with the highest dose of NS1 as compared to the WT 
(p<0.0001), NS2A (p = 0.0004), NS3 (p = 0.003), NS4B38 (p = 0.0002) and NS4B249 (p = 
0.008). On the other hand, the high dose survival curves of the other mutant WNVs showed 
no significant differences in comparison to the WT, or compared to each other.  
Mortality rates of mice infected with the lowest viral dose of the other mutant strains 
were 75% (6/8) for NS2A, 63% (5/8) for NS4B38, 50% (4/8) for NS4B249 and 38% (3/8) 
for NS3 (Table 3; Figure 4B). The lower dose survival curves of NS1-infected mice were 
also significantly different when compared to the WT (p = 0.002), NS2A (p = 0.002), 
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NS4B38 (p = 0.009) and NS4B249 (p = 0.03). In contrast, the survival curves of the other 
mutants were not significantly different compared to the WT, or each other.  
 
  
       
  
Figure 4. Survival of six-week-old female C57/BL6 mice after i.p. inoculation, with (A) high 
dose (104 TCID50) and (B) low dose (101 TCID50) of recombinant WNVs. 
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Virus Dose (TCID50) Total mortality Mortality (%) Median day 
WT 10^5 8/8 100 10.5 
WT 10^1 6/8 75 11 
NS1 10^4 0/8 0 NA 
NS1 10^1 0/8 0 NA 
NS2a 10^5.5 7/8 88 9 
NS2a 10^1 6/8 75 11.5 
NS3 10^3 6/8 75 10.5 
NS3 10^0 3/8 38 11 
NS4B38 10^4 8/8 100 11 
NS4B38 10^0 5/8 63 11 
NS4B249 10^4 5/8 63 9 
NS4B249 10^1 4/8 50 11.5 
Table 3. Mortality data of six-week-old female C57BL/6 mice inoculated i.p. with high and low 
doses of the WT and mutant lineage 2 WNVs. 
Sequencing of recombinant WNV in organs of euthanized and survivor mice 
All mice euthanized due to illness were found to be positive for viral RNA in the brain 
(data not shown). To determine whether the mutant strains detected in the brains of mice 
euthanized due to illness after infection with the highest viral dose had retained the original 
mutation, viral RNA obtained from two mouse brains per group was sequenced. It was 
found that the consensus sequences of the virus strains present in the selected mouse brains 
still contained the original mutation and therefore had not reverted to the wild-type. 
Additionally, we also determined the presence of persisting virus in the brain and kidney of 
all mice that had survived infection (euthanized on day 14 p.i.) with the highest dose of the 
different mutant virus strains (NS1, n=8; NS2A, n=1; NS3, n=2; and NS4B249, n=3) using 
qRT-PCR. All brains positive for viral RNA were sequenced in order to check for the 
presence of the original mutation. Out of the eight mice that survived infection with NS1, 
only one mouse was found to be positive for virus in the brain, which had reverted to the 
wild-type. For NS2A, the one survivor mouse was found to be positive for viral RNA in the 
kidney, which still contained the original mutation. Out of the two mice that had survived 
infection with NS3, and out of the two mice surviving infection with NS4B249, only one 
mouse in each group was positive for viral RNA in the brain, which was also found to have 
retained the original mutation. 
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DISCUSSION 
The aim of this study was to generate a full-length infectious clone of the WNV lineage 2 
strain 578/10 that has recently been detected in central Europe, in order to improve our 
understanding on the genetic background of WNV pathogenicity. Infectious cDNA clones 
are useful tools to investigate genetic determinants of flavivirus virulence, for studying its 
replication, creating subgenomic replicons, and using gene expression or gene of interest 
insertions [46–48]. Full-length infectious WNV clones are often constructed by fusion 
(stitching) polymerase chain reactions or plasmid-based methods [49–52]. Since assembly 
of full-length flavivirus clones in plasmid vectors have proven to be toxic, or unstable and 
deleterious for bacterial hosts, on several occasions [53–56], we cloned the  
full-length genome of WNV-578/10 using a bacterial artificial chromosome (BAC) [57]. 
This system contains the cytomegalovirus (CMV) immediate-early promoter that allows 
transcription of WNV RNA in the nucleus by cellular RNA polymerase II, eliminating the 
step of in vitro transcription. 
WNVs belonging to lineage 2 were previously considered as agents of low 
pathogenicity [10]; however, numerous neuroinvasive and highly pathogenic members have 
recently been identified in horses and humans suffering from severe encephalitis in South 
Africa [58]. WNV strains belonging to lineage 2 have also been reported in Hungary and 
surrounding countries since its first proven appearance outside of Africa in 2004. During 
the last decade, several fatal cases among horses and humans were confirmed as West Nile 
encephalitis caused by these lineage 2 viruses in the Central European region [15,20]. The 
changing epidemiology and pathogenicity of WNV outbreaks in Europe highlight our need 
to further understand how Central European WNV lineage 2 strains differ in their capacity 
to cause severe disease compared to lineage 1 strains. Furthermore, this study may also 
provide invaluable information for the development of safe and efficacious vaccines.  
Several studies have identified and proven the role of genetic markers in the NS 
proteins of lineage 1 WNV strains in pathogenicity and virulence studies [24,26,30,31,33–
36]. On the other hand, virulence markers of lineage 2 WNV strains have so far only been 
identified in silico by analyzing and comparing full genome sequences [37,38]. Thus far, it 
is known that flaviviral NS proteins are essential for virus replication; NS1, NS3, NS4A 
and NS4B can reorganize cellular membranes to generate virus-induced membrane 
structures (IMS) for site of replication [59]. Furthermore, NS2A [24], NS2B, NS3, NS4A 
[60], NS4B [61,62] and NS5 [63] play a role in virion assembly and evasion of host innate 
immune responses by blocking the interferon (IFN) signal transduction pathway [64–66]. 
The flavivirus nonstructural protein NS1 is a glycoprotein with three conserved N-
linked glycosylation sites, and has an essential role in viral RNA replication. Normally, 
NS1 exists as a heat labile homodimer that associates with cellular organelle membranes 
and is transported to the cell surface [67,68]. Cell surface associated NS1 appears to have 
an immunomodulatory function via the decrease of the complement activation by different 
routes [69,70]. NS1 is also secreted by mammalian cells as a soluble hexamer [71,72].  
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Inclusion of the mutation P250L in a conserved region of the Kunjin virus NS1 gene 
has been shown to affect the structure of the polypeptide, resulting in the inhibition of 
dimer formation but still allowing its secretion in the monomeric form. The conformational 
change resulting from the P250L mutation may have led to the decreased levels of 
infectious virus titres observed in Vero cells in the early phase of replication (100-fold 
lower between 12–24 h p.i., compared to the WT); however, this difference gradually 
decreased and eventually disappeared by 48 h p.i. [73]. Similar to this study, our NS1 
mutant also showed a 100-fold decrease in infectious virus; however, this was starting from 
24 h p.i. lasting until 48 h p.i., after which the difference was approx. 10-fold until 96 h p.i. 
We investigated these observations further by quantifying the amount of positive and 
negative stranded RNA during the first 48 hours of replication in order to determine 
whether the mutation affected the replication process. We found that the NS1 mutant 
exhibited significantly slower replication as measured by an approx. 10-fold reduced 
amount of both negative and positive stranded RNA in the cells, as well as positive 
stranded RNA in the supernatant.  
A role for the importance of NS1 in the process of RNA synthesis has already been 
described in previous studies. Youn et al. found that WNV RNA lacking intact NS1 genes 
was efficiently translated but did not form canonical replication complexes early after 
infection, resulting in a failure to replicate viral RNA and consequently significantly lower 
amounts of positive and negative stranded RNA in the cells [74]. As we also found a 
reduced amount of negative and positive stranded RNA for the NS1 deletion mutant as 
compared to the WT during the first 48 hours of infection, it suggests that the P250L 
mutation potentially affects the activity or the stability of the NS1 protein for the formation 
of replication complexes during infection.  
In the study by Hall et al., 10-fold more virus of the WNV-KUN P250L mutant was 
required to produce disease in mice. Our results, however, show that this mutation 
completely abolished the neuroinvasiveness of the lineage 2 WNV-578/10 strain, since no 
mice died after challenge with either the high or low dose of the virus. This means that in 
contrast to the Kunjin virus, neuroinvasiveness had decreased at least 10,000 fold for our 
mutant virus. It is possible that the different mouse model used in the aforementioned study 
(BALB/c mice) or the different age (18–20 days of age) of the mice explains the 
discrepancy between our results. However, it can also not be excluded that the silent 
mutation on locus 627 of the NS1 clone that we identified during full genome sequencing 
influenced the attenuated phenotype of this mutant. Furthermore, the presence of certain 
loci in the genome of the lineage 2 virus may have also augmented the attenuating effect of 
the P250L mutation observed in our study as compared to those involving lineage 1. 
Studies involving the introduction of this mutation into other, virulent lineage 1 or 2 WNV 
strains may provide more insight into the importance of this mutation. 
Nonetheless, the significantly reduced replication of the NS1 mutant that we observed 
in cell culture may explain the reduced neuroinvasiveness observed in our study, as it may 
allow for early control of the immune system followed by elimination of the virus before it 
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has reached the central nervous system. Even though only one mouse out of eight infected 
with the NS1 mutant was found to have virus in the brain at day 14 p.i. (albeit lacking the 
original mutation), we cannot rule out with certainty that the virus had still entered the brain 
in the majority of the mice but had simply been cleared by day 14 p.i. due to its reduced 
neurovirulence. Future experiments involving intracranial injections of the NS1 mutant 
could confirm the reduced neurovirulent or neuroinvasive capacity of the virus. 
NS2A is a small, hydrophobic, membrane-associated protein of WNV, believed to 
anchor the RNA replication complex by intercalating into the endoplasmic reticulum (ER) 
membrane [75]. The NS2A protein plays an important role in virus assembly and in the 
inhibition of the cellular antiviral response via the inhibition of IFN-beta promoter-driven 
transcription [32,76]. In one study, a NY99 mutant virus was less virulent in four-week-old 
Swiss-Webster outbred mice when the NS2A locus was derived from the Kunjin virus and 
harbored an introduced A30P mutation [26]. In contrast, Rossi et al. found only a slight 
decrease in virulence of the NS2A A30P mutant NY99 strain compared to the WT virus in 
five-week-old Swiss-Webster mice [25]. Our results are in line with the latter study, as we 
observed no significant differences in the replication kinetics of the mutant compared to the 
wild type virus, and no significant attenuation was detected in mice after challenge.  
The full length NS3 protein is a multifunctional enzyme (the N terminal residues 
encode trypsin-like serine protease, the C terminal residues encode RNA triphosphatase, 
NTPase and helicase) that possesses various activities in both viral polyprotein processing 
and RNA replication [77,78]. NS3 is suggested to be involved in virus assembly as well, 
but in cooperation with NS2A [79]. In corvids, the lineage 1 NY99 virus containing a 
proline to threonine substitution at the NS3-249 locus was particularly attenuating (100% to 
12.5%), while the introduction of a proline at this site in a low virulent strain led to an 
increase in virulence (31% to 94%), likely related to an increased capacity of the virus to 
replicate in corvids [33]. This site therefore appears to be a key virulence determinant of the 
lineage 1 NY99 strain in corvids; however, the influence of this mutation in a mouse model 
has been minimal [80].  
Genetic comparison of the goshawk-Hungary-2004 strain with the closely related 
lineage 2 Nea Santa-Greece-2010 identified an H249P mutation, which was speculated to 
play a role in the increased virulent phenotype of this Greek strain [18]. Interestingly, like 
the Greece-10 strain, our Hungarian lineage 2 WNV-578/10 strain also contains a proline at 
this position (data not shown). As a result, we investigated whether the NS3-249P mutation 
may contribute to increased virulence by introducing an NS3-P249H substitution and 
testing its attenuation in a mouse model. Here, this substitution proved to be slightly 
attenuating, but this was not statistically significant. Interestingly, infectious virus titres 
obtained in cell culture were found to be significantly lower for NS3 compared to the wild-
type at three time-points. It should be noted, however, that this was also the case for several 
of the other mutants, such as NS2A, which had not shown any attenuation in our mouse 
model. It therefore appears that infectious virus titres in vitro do not correlate with 
attenuation in vivo. Indeed, in a study by Langevin et al., despite the NS3-P249T mutation 
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contributing to a 6 log10 PFU/mL lower titre in corvids, there were no significant 
differences observed in mean peak infectious viral titres on Vero cells at 37 °C for this 
mutant when compared to the NS3-249P virus [80]. As we were interested in examining the 
effect of the different mutations in a murine model, no thermosensitivity experiments at 
temperatures higher than 37 °C were undertaken for any of the clones; however, further 
studies testing the different mutants in cell culture at a higher temperature (41–44 °C) or in 
a corvid model might prove to be insightful as well, as in particular mutations at the NS3-
249 locus seem to play an important role in the virulence of WNV in bird species.  
Flaviviral NS4B is a predominantly helical, hydrophobic, membrane-associated NS 
protein, which plays a crucial role in blocking host cell antiviral responses. It acts as an 
interferon antagonist, since expression of NS4B, contributed by the activity of NS4A and 
NS2A, strongly inhibits the IFN-induced signal transduction cascade by blocking STAT-1 
phosphorylation [61]. Amino acid mutations in the coding region of NS4B can alter the 
inhibitory effect on interferon signaling [62].  
The P38 residue of NS4B is predicted to localize to the junction of an ER-luminal 
region and a transmembrane domain. A study by Welte et al. found that the P38G mutation 
in the NS4B protein induced a lower level of viremia and no lethality in six- to ten-week-
old C57BL/6 mice, while inducing higher type 1 IFNs and interleukin (IL)-1 as well as 
stronger effector and memory T cell responses [35]. A later study by Wicker et al. found 
the NS4B-P38G substitution to be associated with a temperature-sensitive phenotype of the 
lineage 1 NY99 strain, which involved a significant delay in multiplication in Vero cells at 
41 °C, but not at 37 °C, as well as attenuation for neuroinvasiveness with an i.p. LD50 value 
of greater than 10,000 PFU in three- to four-week-old NIH Swiss mice. Importantly, 
however, two unexpected additional mutations were found at NS4B-T116I and NS3-
N480H and actually none of the mutations alone were attenuating in mice [36]. In our 
study, the P38G mutation did not affect replication in Vero E6 cells and the virus was 
equally virulent in mice as the WT, where we used the same mouse strain and age as Welte 
et al. Furthermore, full genome sequencing revealed that the NS4B-T116I and NS3-N480H 
mutations were not present in our NS4B38 clone. Even though it is tempting to speculate 
that the P38G mutation may therefore not be so important for a lineage 2 WNV strain, we 
cannot exclude that the presence of other co-mutations, such as the silent mutation at the 
6768 locus that we identified during full genome sequencing, or other mutations 
specifically present in the lineage 1 genetic backbone, are important for the attenuating 
effect of the NS4B-P38G mutation. 
The C102S substitution of the NS4B protein in the NY99 strain has demonstrated 
thermosensitivity at 41 °C in vitro and was found to attenuate mouse neuroinvasiveness and 
neurovirulence [29]. The same substitution in the 578/10 construct dramatically reduced the 
replicative ability of the virus in vitro as such that no virus could be rescued, and therefore 
its further in vitro and in vivo effect could not be assessed. The hypothesized mechanism of 
C102S attenuation of the NY99 strain was a reduced ability in inhibiting the IFN signaling 
pathway [29]. However, the C102S mutant 578/10 clone was not able to replicate in BHK-
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21 and Vero E6 cells, even though the IFN-α and -β pathways are not functioning in these 
cell lines. Therefore, probably other factors contributed to the lethal effect of this 
substitution in the lineage 2 WNV strain.  
The NS4B-E249G mutation has been observed in several natural WNV isolates 
[81,82]. Furthermore, it was shown that a mutant lineage 1 WNV containing the E249G 
residue replicated at a lower level in C3H/He and BHK-21 cell cultures, but only slightly 
lower in Vero cell culture. In addition, the E249G mutant lineage 1 WNV was significantly 
attenuating in six-week-old C3H/HeN mice after footpad inoculation (100% mortality vs. 
50%) [30]. On the other hand, a study by Rossi et al. reported that a WNV lineage 1 virus 
harboring the NS4B-E249G mutation demonstrated a WT phenotype with foci identical in 
size to the WT, as well as a similar LD50 value in i.p. inoculated five-week-old Swiss-
Webster mice [25]. Our results are closer to those obtained by Rossi et al. [25], as the 
E249G mutant lineage 2 WNV propagated to similar titres in Vero E6 cells as the WT and 
showed reduced mortality in mice (63%) that was not significantly different. It cannot be 
excluded, however, that the non-conservative mutation found at NS4B188 played an 
important role in decreasing the attenuated phenotype exerted by the NS4B-E249G 
mutation. 
In summary, our results have shown that in mammalian in vitro and in vivo models the  
NS1-P250L mutation contributed to significant attenuation of lineage 2 WNV, while the 
NS3-H249P and NS4B-E249G mutations conferred a partial, but not statistically significant 
reduction of virulence in mice. In contrast, the NS2A-A30P and NS4B-P38G were not 
attenuating at all in vivo. Even though it might be possible to conclude that the mutation at 
the NS1 locus could be an important marker of virulence in lineage 2 WNV strains, the fact 
that lineage 1 mutation studies as cited herein often showed varying results means that such 
results should still be addressed with caution. For example, mouse genotype and age may 
have an important influence on the outcome of mutational studies in vivo. The influence of 
other mutations in the particular genetic backbone used in certain studies may also play an 
important role. To be specific, the genetic backbone of the lineage 2 virus that we used may 
play a role in decreasing the attenuation of some of the markers that we have investigated, 
as well as in increasing the attenuation of the NS1 mutation. As a result, future studies 
investigating details of the NS1-P250L substitution should be performed in another 
vertebrate model, and also studies involving the introduction of this particular NS1 
mutation into the genome of other lineage 2 viruses, or introducing the entire WNV-578 
NS1 locus harboring this particular mutation into a lineage 1 strain, may prove to be 
insightful.  
The infectious clone described in this study provides a useful tool for testing the effect 
of hypothetical virulence marker loci in in vitro and in vivo model systems. Within the last 
decade, virulent lineage 2 WNV strains have emerged in Europe. For example, a 
descendant of the strain that had emerged in 2004 in Hungary caused an epidemic with an 
unforeseen large amount of neuroinvasive cases in Greece, in 2010. Another lineage 2 
strain (Reb_VLG_07_H, GenBank accession FJ425721) emerged in the Volgograd region 
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of Russia and caused human neurological cases [21,22]. In 2010, this strain also emerged in 
south-east Romania [23] and survived for at least three years [83]. As a result, genetic 
comparisons of different emergent isolates may help to identify and predict potential 
virulence markers. In this regard, our study has provided more insight into genetic markers 
that may contribute to the virulence of lineage 2 WNV strains. 
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ABSTRACT 
Mass bird mortality has been observed in North America after the introduction of West Nile 
virus (WNV), most notably massive die-offs of American crows (Corvus brachyrhynchos). 
In contrast, WNV epidemic activity in Europe has been characterized by very low 
incidences of bird mortality. As the general susceptibility of European corvids to strains of 
WNV remains in question, European jackdaws (Corvus monedula) were inoculated with 
WNV strains currently circulating in Greece (Gr-10), Italy (FIN and Ita09) and Hungary 
(578/10), as well as a North American (NY99) genotype with a demonstrated corvid 
virulence phenotype. Infection with all strains except WNV-FIN resulted in mortality. 
Viremia was observed for birds inoculated with all strains and virus was detected in a series 
of organs upon necropsy. These results suggest that jackdaws could potentially function as 
a sentinel for following WNV transmission in Europe; however, elicited viremia levels 
might be too low to allow for efficient transmission of virus to mosquitoes.   
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INTRODUCTION 
West Nile virus (WNV) is a flavivirus (family: Flaviviridae) that is maintained in an 
enzootic cycle between mosquitoes and birds, but may also infect humans and horses, 
which serve as incidental dead-end hosts. WNV is endemic in many parts of Africa, 
Australia, the Middle East and Asia, and more recently emerged in North America in 1999, 
and has since rapidly spread across North America, Mexico, South America, and the 
Caribbean. Since 2008, WNV has emerged as a serious veterinary and public health 
problem in central and south-eastern Europe, affecting countries such as Greece [1-3], Italy 
[4-7], Hungary, Austria [8] and Romania [9]. 
 Birds were considered to be less susceptible to WN disease until high mortality rates 
were recorded in flocks of young domestic geese in Israel in 1998 [10, 11], after which 
WNV has been implicated in deaths of members of 326 species of birds in North America 
[12]. Among the passeriform birds, the family Corvidae is ranked as the most highly 
susceptible species to WNV [13], and particularly deaths among the American crow 
(Corvus brachyrhynchos) have been used to track the spread of the virus in North America 
[14, 15]. 
 In contrast to the mass bird mortality observed in North America, sporadic isolated 
death events and low mortality rates have been reported among European birds, even 
during severe human and equine WN outbreaks [16-19]. Possible explanations for the lack 
of reporting of bird mortality could be that European birds are less susceptible to WNV-
induced disease, or that the North American strain of WNV exhibits an increased capacity 
for eliciting avian virulence. Other theories include: poor detection of bird carcasses (due to 
their small size or scavenging) [20], limited monitoring of wild bird mortality, or 
development of herd immunity due to local transmission spurred by avian migration 
through WNV endemic areas of the Middle East and Africa [21].  
 To date, the susceptibility of European jackdaws to WNV isolates circulating in 
Europe has not yet been addressed. In order to examine the role of a bird that is found 
ubiquitously across Europe as a natural reservoir for the transmission of WNV disease or as 
a potential sentinel for WNV activity, European jackdaws were inoculated with four 
different WNV isolates clinically relevant to Europe, including lineage 1 isolates Ita09 and 
FIN from Italy, as well as lineage 2 isolates from Greece and Hungary. The NY99 strain 
was used to assess and compare the susceptibility of the European birds to a strain known 
to be highly virulent in North American corvids, especially in American crows. 
Susceptibility was assessed in terms of mortality, median survival time, duration and 
magnitude of viremia, and dissemination of virus to the different organs. 
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MATERIALS AND METHODS 
Source of Virus and Birds 
Five different isolates of WNV were utilized (Table 2): The NY99-4132 strain (lineage 1a) 
[22] was originally isolated from the brain of an American crow and was passed two times 
in Vero cells before being used in this study. The lineage 2 Greek strain (Nea Santa-
Greece-2010; accession HQ537483.1) was isolated from a pool of Culex pipiens 
mosquitoes [23] and passaged once on Vero cells. Two lineage 1a Italian strains, FIN 
(provided by Dr. Vittorio Sambri, University of Bologna, Italy; two Vero E6 passages; 
accession KF234080) and Ita09 (provided by Dr. Luisa Barzon, University of Padova, Italy, 
one Vero E6 passage; accession GU011992.2) were both isolated from a patient with 
neuroinvasive disease [4]. The Hungarian lineage 2 strain 578/10 (provided by Dr. Tamás 
Bakonyi, Szent István University, Hungary, two passages on Vero E6 cells; accession 
KC496015) was isolated from the brain of a horse that died of WNV-neuroinvasive disease. 
Virus stocks used in this study (not including the NY99 and Greece-10 strain), were 
prepared by growing the viruses once in C6/36 insect cells (Table 1). 
Jackdaws were captured using walk-in traps in the municipality of Rotterdam, The 
Netherlands. They were transported to indoor housing where they were kept in groups of 
seven or eight in isolators under negative pressure. Only seronegative birds were used in 
this study. All birds were cared for in animal holding facilities at the National Institute for 
Public Health and the Environment (RIVM), Bilthoven, The Netherlands.  
 
Virus Strain Source Passage historya Location 
Genetic 
lineage 
NY99 NY99-4132 American crow (brain) V2 USA 1a 
Greece-10 Nea Santa-Greece-2010 Culex pipiens V1 Greece 2 
FIN FIN Patient with neuroinvasive disease V2, C1 Italy 1a 
Ita09 Ita09 Patient with neuroinvasive disease V1, C1 Italy 1a 
Hungary 578/10 Horse (brain) V2, C1 Hungary 2 
aViruses were propagated in Vero (V) or C6/36 insect cells (C). Numbers following passage source 
represent the number of viral passages. 
Table 2. West Nile virus strains used for susceptibility studies in European jackdaws. 
 
Detection of Preexisting WNV Antibodies 
To confirm that jackdaws had not previously been exposed to WNV, the birds were bled 
before experimental infection and serum was tested for neutralizing antibodies using tissue 
culture infectious dose 50 (TCID50) neutralization assays. Serum was heat-inactivated at 56 
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ºC for 30 min, serially diluted two-fold and incubated with an equal volume of virus (strain 
NY99, originally isolated from a dead Chilean flamingo at the Bronx Zoo in New York, 
obtained from the Health Protection Agency, Porton Down, UK; P5 on Vero E6 cells; 
accession AF196835.2) to a final concentration of 100 TCID50/0.1 mL. Samples were 
incubated at 37 ºC for 1 hr and subsequently added to an 80% confluent monolayer of Vero 
E6 cells in CELLSTAR® 96-well plates (Greiner Bio-One, Alphen aan den Rijn, The 
Netherlands). Plates were incubated at 37 ºC for 5 days. Samples were read and a 100% 
reduction in cytopathic effect (CPE) as compared to the serum-negative control was used 
for the determination of neutralization. Detection of any neutralizing activity to WNV in 
the serum of any bird precluded its use for experimental inoculation. 
 
Experimental Infection and Sampling Protocol 
Jackdaws were subcutaneously inoculated in the thigh region with 2000 TCID50 of virus/0.1 
mL of Dulbecco’s Modified Eagle Medium (DMEM) containing no fetal bovine serum 
(FBS). Jackdaws were injected with NY99-1432 (n=7), Greece-10 (n=8), FIN (n=7), Ita09 
(n=7) and 578/10 (n=7). Blood was collected from all birds (~0.1 mL) at 2-day intervals for 
a period of 8 days post-infection (dpi). Coagulated blood was centrifuged at 1300 × g for 5 
min in MiniCollect® vials (Greiner Bio-One) in order to separate serum, which was 
subsequently stored at -80 ºC. All jackdaws were examined for signs of disease twice daily 
for 14 days following inoculation and euthanized under isoflurane anesthesia upon display 
of clinical symptoms. Additionally, two birds per group were euthanized at day 4 post-
infection (p.i.) for monitoring the dissemination of virus to the organs at the approximate 
time of peak viremia, as well as all surviving birds at day 14 p.i. 
Necropsies were performed on all euthanized birds and the following tissues were 
collected: heart, liver, spleen, kidney, bone marrow and brain. A small section of each 
tissue was collected and subsequently weighed and homogenized using a metal bead in 1 
mL of DMEM containing antibiotics (100 U penicillin, 100 µg/mL streptomycin). The 
remaining portion of the tissues was collected in formalin for use in immunohistochemical 
staining.   
 
Determination of Viral Loads 
To determine viral loads in the serum samples and tissue homogenates, we used 
quantitative real-time polymerase chain reaction (qRT-PCR) to measure viral RNA titers 
(serum and tissue), and TCID50 titration for the calculation of infectious virus titers (serum 
only). Briefly, RNA was isolated from 50 µL of serum or 100 µL of homogenized tissue 
using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Almere, The 
Netherlands) and an automated nucleic acid robotic workstation (Roche) according to the 
manufacturer’s instructions. RNA was eluted in 100 µL of elution buffer (Roche) and 
stored at -80 ºC until assayed. RNA copy numbers were quantified as described in Lim et 
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al. using unmodified primers [24]. The limit of detection of the assay was 0.95 log10 RNA 
copies. 
Infectious titers in the serum were determined by log10 titration of the serum samples 
on Vero E6 cells and calculating the TCID50 using the Spearman & Kärber method [25, 26] 
after the determination of CPE 5 days p.i. Initial 1:10 dilution of serum resulted in a limit of 
detection of 101.75 TCID50/mL.  
 
Immunohistochemistry 
Sagittal organ 4-µm thick paraffin sections were processed for peroxidase 
immunohistochemistry of virus nonstructural protein markers. Sections were deparaffinized 
in xylene, rehydrated in descending concentrations of ethanol and incubated for 10 min in 
3% H2O2 diluted in PBS in order to block endogenous peroxidase activity. Antigen 
exposure was performed by 15 min incubation at 121 ºC in citrate buffer (0.01 M, pH 6.0). 
Sections were incubated overnight at 4 ºC with primary goat anti-WNV NS3 (1:100; R&D 
Systems, Abingdon, UK) or goat serum (1:100; Dako, Eindhoven, The Netherlands) for 
isotype controls, and detected with secondary rabbit anti-goat IgG-PO (Dako) antibody. 
Sections were counterstained with Mayer’s hematoxylin, mounted with Kaiser’s glycerin-
gelatin and analyzed using a light microscope.  
 
Statistical Analyses 
Survival curves were analyzed using the Log-rank (Mantel-Cox) test. All other statistical 
analyses were performed by Kruskal-Wallis one-way analysis of variance (ANOVA) and 
any significant difference found was more closely analyzed between the groups using the 
Mann-Whitney U test. 
 
RESULTS 
Morbidity and Mortality 
During a 9-day period, lethargy, low activity, anorexia and ruffled feathers were observed 
among some of the jackdaws inoculated with NY99, Greece-10, Ita09 and 578/10. Birds 
died within 24-48 hours after onset of clinical symptoms. Among the five jackdaws that 
were inoculated with NY99 and Ita09 and followed for survival, three (60%) died; and of 
the five inoculated with 578/10, two (40%) died. Among the six jackdaws inoculated with 
Greece-10, three died (50%). In contrast, all five birds inoculated with FIN survived the 
infection (Table 1). Comparison of the survival curves of the birds inoculated with the 
different virus strains revealed a significant difference between the survival curves of 
jackdaws infected with FIN compared to Ita09 (Figure 1; P = 0.05). Median day of death 
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was 7 dpi for birds that succumbed due to infection with NY99, Ita09 and 578/10, and 8 dpi 
for birds that died due to infection with Greece-10 (Table 1).  
 
Virus 
group 
Mortality:  
no. died 
/N (%) 
Median 
day of 
death 
Mean 
day 
onset  
 viremia 
± SD 
Mean peak 
viremiaa  
viral 
RNA/mL ± 
SD 
Mean 
day peak 
viremia 
± SD 
Mean 
duration  
viremiab 
± SD 
NY99 3/5 (60) 7 2.0 ± 0 6.2 ± 1.9 4.0 ± 0 5.2 ± 1.0 
Greece-10 3/6 (50) 8 2.0 ± 0 5.9 ± 1.3 3.3 ± 1.0 6.0 ± 1.2 
FIN 0/5 (0) NA 3.2 ± 1.0 4.0 ± 0.7 4.0 ± 1.3 6.4 ± 0.8 
Ita09 3/5 (60) 7 2.8 ± 1.0 4.7 ± 1.5 4.0 ± 1.3 5.2 ± 1.6 
578/10 2/5 (40) 7 2.0 ± 0 5.0 ± 1.3 4.0 ± 2.2 6.4 ± 1.5 
aViral titers are expressed as log10 RNA copy numbers/mL of sera. 
bDuration is expressed in days. 
NA = not applicable.   
Table 1. Clinical profile of five or six European jackdaws infected with West Nile virus strains 
NY99, Greece-10, FIN, Ita09 and 578/10. 
 
 
 
Figure 1. Survivorship of five or six European jackdaws, each inoculated with 2,000 TCID50 of 
West Nile virus strains NY99, Greece-10, FIN, Ita09 or 578/10. Jackdaws were monitored daily 
for signs of disease up to 14 dpi. 
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Viremia Profiles 
We determined WNV viremia profiles for the jackdaws inoculated with the five different 
virus strains and found that all birds developed viremia within 96 hours p.i (Table 1; Figure 
2). For NY99-infected birds, peak viremia titers ranged from 4.1 log10 to 9.6 log10 RNA 
copies/mL of serum (mean peak viremia titer = 6.2 log10 RNA copies/mL). Birds infected 
with the Greece-10 strain had peak viremia titers ranging from 4.2 log10 to 8.4 log10 RNA 
copies/mL of serum (mean = 5.9 log10 RNA copies/mL). For FIN-infected birds, peak 
viremia titers ranged from 3.3 log10 to 5.1 log10 RNA copies/mL of serum (mean = 4.0 log10 
RNA copies/mL). Ita09-infected birds displayed peak viremia titers ranging from 3.4 log10 
to 7.5 log10 RNA copies/mL of serum (mean = 4.7 log10 RNA copies/mL). Among 
jackdaws infected with the 578/10 strain, peak viremia titers ranged from 3.1 log10 to 6.9 
log10 RNA copies/mL of serum (mean = 5.0 log10 RNA copies/mL).  
These data demonstrate that birds inoculated with NY99 and Greece-10 had the 
highest peak viremia titers, followed by 578/10 and Ita09, with the lowest viremia peaks for 
FIN-infected birds. Mean peak viremia titers were significantly different between Greece-
10 and FIN (P = 0.02) and NY99 and FIN (P = 0.03). Onset of viremia occurred 
significantly later for FIN-infected birds compared to Greece (P = 0.02), NY99 and 578/10 
(P = 0.03, for both) (Table 1). The peak of viremia was reached the earliest by birds 
inoculated with Greece-10, followed by the other viral strains (Table 1), but differences 
were not statistically significant (P = 0.8). In terms of duration, viremia lasted the longest 
for FIN and 578/10, followed by Greece-10, NY99 and Ita09 (Table 1), but these 
differences were also not statistically significant (P = 0.4).  
Determination of the viremia profiles in terms of infectious virus (TCID50) titers was 
only successful for a limited set of birds. The infectious titers successfully recorded were 
for the birds with the highest peak viremia titer (in terms of viral RNA) in each group. 
These titers were specifically 106.3 TCID50/mL (109.6 RNA copies) for the NY99-infected 
bird with the highest peak viremia, 105.3 TCID50/mL for the Greece-10- and Ita09-infected 
birds (108.4 and 107.5 RNA copies, respectively), and 102.3 for the 578/10-infected bird (106.9 
RNA copies). 
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Figure 2. Viremia profiles for West Nile virus (WNV)-infected European jackdaws after 
inoculation with 2,000 TCID50 of either WNV-NY99 (n=5), Greece-10 (n=6), FIN (n=5), 
Ita09 (n=5) or 578/10 (n=5). Viral titers were determined by RNA copy numbers and are 
represented as geometric means. A detection limit of 0.95 log10 RNA copies/mL of serum was 
determined. Bars represent standard deviations (SD) of the mean. 
 
Tissue Tropism 
Viral loads were determined in the heart, liver, spleen, kidney, bone marrow and brain for 
all birds. In order to assess the spread of virus to the different organs at the approximate 
peak of viremia, two birds per group were euthanized on day 4 p.i. Virus was detected in all 
organs of these birds (Figure 3) with on average the highest viral titers found in the spleen 
and bone marrow (7.1 and 6.9 log10 RNA copies/g of tissue, respectively), followed by the 
liver, kidney and heart (5.8, 5.7 and 5.5 log10 RNA copies/g of tissue, respectively). The 
lowest viral titers were found in the brain (3.8 log10 RNA copies/g of tissue). Between the 
different virus strains, higher viral RNA titers were found in the organs infected by Greece-
10 (7.0 log10 RNA copies/g of tissue), followed by 578/10 (6.4 log10 RNA copies/g), NY99 
and Ita09 (5.4 log10 and 5.3 log10 RNA copies/g, respectively), while FIN-infected birds had 
the lowest tissue viral RNA burden (4.8 log10 RNA copies/g). Viral titers in the organs were 
significantly different for Greece-10 compared to NY99 (P = 0.05), FIN (P = 0.004) and 
Ita09 (P = 0.02), and in the organs infected by 578/10 compared to FIN (P = 0.01).  
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Figure 3. Viral load, as determined by RNA copy numbers, in organs harvested from birds 
experimentally infected with different West Nile virus strains and euthanized on day 4 (two per 
group). Viral titers are represented as geometric means. A detection limit of 0.95 log10 RNA 
copies/g of tissue was determined. Bars represent standard deviations (SD) of the mean. 
For birds euthanized due to morbidity, virus was also found in all the organs (Figure 
4), with the tendency for the spleen, kidney and heart to contain the highest average viral 
RNA load (6.7, 6.6 and 6.2 log10 RNA copies/g of tissue, respectively), followed by the 
liver, brain and bone marrow (5.5, 5.4 and 5.2 log10 RNA copies/g of tissue, respectively). 
Viral RNA titers were highest in organs of birds infected by Greece-10 (6.2 log10 RNA 
copies/g), followed by 578/10 and NY99 (6.1 log10 RNA copies/g, for both), with the 
lowest titers exhibited by Ita09-infected birds (5.4 log10 RNA copies/g). However, these 
titers were not found to be significantly different (P = 0.4). 
 
 
Figure 4. Viral load, as determined by RNA copy numbers, in organs harvested from birds 
experimentally infected with different West Nile virus strains and euthanized due to 
morbidity. NY99 (n=3): 1 bird euthanized on day 5 p.i., 2 birds on day 7; Greece-10 (n=3): 1 
bird euthanized on day 6, 1 bird on day 8 and 1 bird on day 9; Ita09 (n=3): 3 birds euthanized on 
day 7; and 578/10 (n=2): 1 bird euthanized on day 6 and 1 bird on day 8. Viral titers are 
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represented as geometric means. A detection limit of 0.95 log10 RNA copies/g of tissue was 
determined. Bars represent standard deviations (SD) of the mean. 
All birds that had survived infection by day 14 were euthanized and necropsied to 
determine whether virus could still be found in any of the organs (Figure 5). Viral RNA 
was detected in all organs of the three Greece-10-infected survivor birds except for in the 
bone marrow of one bird, while NY99-infected birds had a minimum of three positive 
organs (out of 6), with the liver being completely negative for both birds. FIN-infected 
survivor birds had a minimum of two organs (out of 6) positive for viral RNA, while the 
bone marrow was consistently negative for all five birds. The two birds that survived 
infection with Ita09 were both positive for viral RNA in five out of six organs, with the 
liver negative in one bird and the bone marrow in the other. Viral RNA was detected in all 
organs of the two 578-10-survivor birds except for in the liver of one bird. Between the 
different virus strains, mean viral RNA titers in the organs were significantly higher in 
Greece-10-infected birds compared to birds infected with FIN (P = 0.03). 
 
 
Figure 5. Viral load, as determined by RNA copy numbers, in organs harvested from birds 
experimentally infected with different West Nile virus strains and euthanized on day 14. 
NY99: 2 birds euthanized; Greece-10: 3 birds; FIN: 5 birds; Ita09: 2 birds; and 578/10: 3 birds. 
Viral titers are represented as geometric means. A detection limit of 0.95 log10 RNA copies/g of 
tissue was determined. Bars represent standard deviations (SD) of the mean. 
Overall, average viral titers in the organs of the survivor birds were lower (2.7 log10 
RNA copies/g of tissue) compared to the birds necropsied on day 4 (5.8 log10) or after 
illness/death (5.9 log10), with most virus persisting in the kidney and spleen (4.1 and 3.7 
log10 RNA copies/g of tissue, respectively), followed by the brain and heart (3.0 and 2.3 
log10 RNA copies/g of tissue, respectively), and the liver and bone marrow (1.7 and 1.6 
log10 RNA copies/g of tissue, respectively).  
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Immunohistochemistry 
Sections of organs of birds euthanized on day 4 p.i. were stained with polyclonal anti-WNV 
NS3 to determine replication of the virus in these tissues and rule out any positive qRT-
PCR detection as a result of spillover from blood (Table 3). Tissues most consistently 
positive for WNV antigen were the kidney (100%), followed by the heart, liver, spleen 
(90%) and bone marrow (80%), with the brain only positive in 50% of the cases. Antigen 
was most abundant in the spleen, followed by the kidney, bone marrow, heart and liver 
(Figure S1). The abundance of viral antigen found in the positive brains was minimal. 
Overall, organs of birds most often positive, as well as most abundant for viral antigen, 
were those infected with Greece-10 and 578/10, followed by FIN and Ita09, with the lowest 
amount of antigen found in the organs of the two NY99-infected birds.  
 Viral antigen appeared to be slightly more abundant in birds euthanized due to 
morbidity (Table 4) as compared to the birds euthanized on day 4, with the spleen and 
kidney consistently positive for viral antigen (100%), followed by the heart and brain 
(91%), while the bone marrow (64%) and liver (45%) were the least often positive. In terms 
of antigen abundance, staining was most prominent in the heart, kidney and spleen, while 
lower amounts of antigen were present in the brain, bone marrow and liver (Figure S1). 
Between the different virus strains, the abundance of viral antigen in the organs was very 
similar in Greece-10, 578/10 and Ita09-infected birds, and was also higher than the amount 
of antigen found in the organs of NY99-infected birds. 
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Virus strain Bird no. Heart Liver Spleen Kidney Bone marrow Brain 
Total 
score per 
bird 
Average 
score per 
virus strain 
No. of 
positive 
organs/bird 
NY99 6 +/- +/- +/- +/- + +/- 7 
6.5 
6/6 
 7 + +/- - + - +/- 6 4/6 
Greece-10 1 ++ - ++ + ++ +/- 12 
12.5 
5/6 
 4 + + ++ + ++ +/- 13 6/6 
FIN 6 +/- +/- + + +/- +/- 8 
7 
6/6 
 7 - +/- + + +/- - 6 4/6 
Ita09 1 +/- + + + - - 7 
8.5 
4/6 
 2 + + + + + - 10 5/6 
578/10 6 + + ++ + + - 11 
10.5 
5/6 
 7 +/- + ++ + + - 10 5/6 
Score per organ  15 14 21 19 16 5    
No. of positive 
birds/organ  9/10 9/10 9/10 10/10 8/10 5/10  
  
Subjective determinations of the amount of antigen in each organ were made; negative (-), minimal (+/-), moderate (+) or abundant (++). Each determination 
was given a score from 0 to 3; negative (0), minimal (1), moderate (2) and abundant (3). 
Table 3. Immunohistochemical analysis of West Nile virus antigen distribution in European jackdaws euthanized on day 4 p.i. 
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Subjective determinations of the amount of antigen in each organ were made; negative (-), minimal (+/-), moderate (+) or abundant (++). Each determination 
was given a score from 0 to 3; negative (0), minimal (1), moderate (2) and abundant (3). 
Table 4. Immunohistochemical analysis of West Nile virus antigen distribution in European jackdaws euthanized due to morbidity (days 5-9 p.i.).
Virus 
strain 
Bird 
no. Heart Liver Spleen Kidney 
Bone 
marrow Brain 
Total score 
per bird 
Average 
score per 
virus strain 
No. of positive 
organs/bird 
NY99 1 - +/- + +/- + - 6 
7.7 
4/6 
 3 + - + + - + 8 4/6 
 5 ++ - + + - + 9 4/6 
Greece-10 5 + - +/- + - + 7 
10.7 
4/6 
 6 + ++ ++ ++ ++ +/- 15 6/6 
 8 ++ - + + +/- + 10 5/6 
Ita09 3 + + + ++ + ++ 14 
10 
6/6 
 4 + +/- +/- + +/- +/- 8 6/6 
 5 + - + ++ - +/- 8 4/6 
578/10 4 + +/- + + +/- ++ 11 
10.5 
6/6 
 5 ++ - + + +/- + 10 5/6 
Score per 
organ 
 13 4.5 11 13.5 6 10    
No. of 
positive 
birds/organ 
 
10/11 5/11 11/11 11/11 7/11 10/11 
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DISCUSSION 
In this study, European jackdaws appear to be susceptible to infection with European 
strains of WNV from both lineage 1 and 2, as well as the North American strain NY99. 
However, the same extent of susceptibility as shown by the American crow upon infection 
with NY99, with 100% mortality rates and production of high viremia titers reaching peaks 
over 107 PFU/mL [22, 27-30], was not observed in this study. Herein, mortality rates 
ranged between 40-60% for four out of five strains and the highest average peak viremia 
was approximately 6.2 log10 RNA copies/mL of serum, reached by birds inoculated with 
NY99.  
Viral RNA was detected in all organs on day 4 p.i. and upon the time of euthanasia 
due to morbidity. Viral RNA titers were observed to be significantly higher on day 4 p.i. in 
the organs of birds inoculated with Greece-10 compared to NY99, FIN and Ita09, and in the 
organs of birds inoculated with 578/10 compared to FIN. Even though at this time point 
spillover of virus from blood most likely resulted in higher viral RNA titers in the organs, 
immunohistochemistry confirmed that at least the relative differences were the same, as the 
amount of viral antigen staining confirmed that the two Greece-10- and 578/10-inoculated 
birds did indeed have the most viral antigen present in their organs as a whole, suggesting 
that spillover of virus from the circulation did not generally influence these results. 
Interestingly, Greece-10 and 578/10 are both lineage 2 viruses with 99% identity, possibly 
indicating a strain-related tropism. Nonetheless, by the time the birds were euthanized due 
to morbidity (between days 5 to 9), any virus-related significant differences were no longer 
observed in terms of viral RNA titers, although IHC staining suggested a tendency for viral 
antigen to be more abundant in organs of Greece-10, 578/10 and Ita09-infected birds.  
In a previous study [31], mice inoculated with WNV-FIN displayed a slightly reduced 
mortality in comparison to the other WNV strains (also used here). In this study, however, 
the virulence phenotype of FIN has become much more pronounced, as birds inoculated 
with FIN suffered no mortality and had significantly lower peak viremia titers as well as 
delayed onset of viremia compared to the other groups. Even though viral virulence 
generally correlates well with high and prolonged viremia [32], in this case, viremia was 
not significantly shorter in FIN-infected birds compared to the other virus strains, although 
onset of viremia did occur significantly later.  
Interestingly, the two birds inoculated with FIN and euthanized on day 4 were both 
positive for virus in the majority of their organs (qRT-PCR and IHC) despite the absence of 
mortality seen in this group. This, in combination with the presence of viremia observed in 
all birds of this group, suggests that even in birds that are not susceptible to lethal WNV 
infection, the virus is able to elicit viremia and disseminate to the organs, including the 
brain. A similar observation was demonstrated in chickens, which experienced no mortality 
following infection with WNV, but exhibited titers as high as 5 log10 PFU/mL and virus 
could also be isolated from several organs, including the spleen and kidney [33]. 
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The introduction of a T249P amino acid substitution (present in North American 
WNV) in the NS3 helicase of a low virulence strain of WNV has been demonstrated to 
result in increased virulence in American crows [29]. The virus strains used in this study all 
contain a proline at this site, with the exception of FIN, which contains a threonine at this 
position [31] (Table S1). Ita09, which is 99.7% identical to the nucleotide sequence of FIN, 
did not display the same attenuation in jackdaws as FIN. It is therefore very likely that the 
attenuated phenotype of FIN demonstrated in this study is likely to be the result of this 
P249T substitution. Studies are ongoing to test the relevance of the T249P substitution 
present in the Italian backbone of WNV in both European and American corvids.  
It has been shown that a blood titer of 106 PFU/mL is required for transmission to 
feeding mosquitoes [34]. Additionally, viremic titers greater than 105 PFU/mL were 
considered infectious for Culex pipiens [35] and Culex quinquefasciatus [36]. This suggests 
that only the NY99-, Greece-10- and Ita09-infected birds that reached peak viremia RNA 
titers above 107.5 RNA copies/mL (which resulted in 105.3 TCID50/mL upon virus isolation) 
would be likely to infect feeding mosquitoes, as the lowest cut-off of 105.0 PFU/mL will 
result in approx. 105.2 TCID50/mL, according to a conversion factor of 1 TCID50 to 0.7 PFU 
[37]. It is possible that the infectious viremia titers of the other samples were below the 
detection limit of the assay. As the majority of the birds did not attain viremia titers above 
107.5 RNA copies/mL, it suggests that jackdaws would most likely not serve as efficient 
amplifying hosts in the transmission cycle of WNV in Europe. However, it is also possible 
that a higher peak of viremia was missed due to sampling on intervening days. Similar 
results were observed in a study using a French strain (Fr2000) in Carrion crows [38], 
where the highest viral RNA titer recorded was equivalent to only 104 TCID50/mL, which is 
also below the infectious viral titer required for transmission to feeding mosquitoes. 
None of the isolates used in this study have either caused massive die-offs of birds in 
the field or have spread swiftly across Europe as observed during the North American 
invasion by WNV [39]. Thus far, experimental studies using European strains of WNV and 
European birds have shown fairly low mortality rates [38, 40, 41], with the highest 
mortality rate of 33% observed following inoculation of Carrion crows with the Fr2000 
strain [38]. The study presented herein suggests that the susceptibility of European birds 
could be related to the WNV strain, as much higher mortality was observed in this study 
with alternative strains compared to the French strain. At the same time, host factors 
present in the jackdaw or other European avian species could also play an important role in 
susceptibility, as the mortality induced by the North American strain NY99, known to be 
highly virulent in corvids, was similar to that exhibited by Ita09 (60%) in jackdaws. This 
mortality rate, as well as the viremia levels, were also not comparable to those usually seen 
upon infection of American crows with NY99. This therefore suggests that host factors 
present in European jackdaws could potentially reduce their susceptibility to WNV.  
However, a substantial proportion of the jackdaws did die as a result of infection, 
which therefore suggests that perhaps some birds in Europe are indeed succumbing to 
WNV infection in the field, but that the mortality rates of these birds are simply too low to 
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be detected by the current monitoring systems present in Europe. It is also possible that 
natural infection via mosquito feeding could result in higher serum viremia titers in 
jackdaws, or that other ecological factors such as infection due to carcass scavenging by 
more susceptible birds could play a more important role in the transmission and 
maintenance of WNV in Europe. Nevertheless, this study shows that jackdaw mortality 
could potentially be useful for tracking WNV transmission in Europe. 
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ABSTRACT 
West Nile virus (WNV) outbreaks in North America have been characterized by substantial 
die-offs of American crows (Corvus brachyrhynchos). In contrast, a low incidence of bird 
deaths has been observed during WNV epidemic activity in Europe. To examine the 
susceptibility of the western European counterpart of American crows, we inoculated 
carrion crows (Corvus corone) with WNV strains isolated in Greece (Gr-10), Italy (FIN and 
Ita09), and Hungary (578/10) and with the highly virulent North American genotype strain 
(NY99). We also inoculated American crows with a selection of these strains to examine 
the strains’ virulence in a highly susceptible bird species. Infection with all strains, except 
WNV FIN, resulted in high rates of death and high-level viremia in both bird species and 
virus dissemination to several organs. These results suggest that carrion crows are highly 
susceptible to WNV and may potentially be useful as part of dead bird surveillance for 
early warning of WNV activity in Europe. 
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INTRODUCTION 
West Nile virus (WNV), a flavivirus (family Flaviviridae) transmitted by mosquitoes, uses 
birds as its primary vertebrate reservoir host. WNV has an extensive geographic range that 
includes Europe, Africa, the Middle East, southern Asia, and Australia [1]. In 1999, WNV 
emerged in North America, where it was first detected in New York, New York. The virus 
subsequently spread rapidly across the continent, becoming the leading cause of arboviral 
encephalitis in humans and horses [2], and it was associated with deaths among at least 326 
bird species [3]. High death rates are most frequently observed among passeriform birds, of 
which the family Corvidae comprises the most highly susceptible species to WNV [4]. In 
particular, deaths among the American crow (Corvus brachyrhynchos) have been used to 
track the spread of the virus across many parts of North America [5-8]. 
Since 2008, WNV has been responsible for outbreaks throughout central and 
southeastern Europe, affecting countries such as Greece, Italy, Hungary, Romania, and 
Croatia and constituting a serious veterinary and public health problem. Fatalities have been 
reported among wild birds in Europe, such as eagles [9, 10], sparrow hawks, goshawks, 
geese, and falcons [11-13]. However, death rates among birds in Europe have been low, 
and no clustered death events have occurred, even when cases were associated with 
outbreaks of severe human and equine WNV infections [14-17]. Several theories have been 
proposed to explain the low death rates among birds in Europe: limited or insufficient 
monitoring of deaths among wild birds in Europe; development of immunity among birds 
from infections acquired on wintering grounds [18]; and circulation of WNV strains in 
Europe with reduced virulence for birds. 
Experimental infection of American crows with the North American genotype of 
WNV (NY99) has shown that the strain has a highly pathogenic phenotype: viremia titers 
exceeded 9 log10 PFU/mL, and all infected birds died [19-23]. However, the lack of WNV-
associated bird deaths in Europe suggests that European birds might not be susceptible to 
WNV or that WNV strains from Europe are not virulent to birds. Thus, we evaluated the 
susceptibility of the European equivalent of the American crow, carrion crows (Corvus 
corone), which are ubiquitously present across Europe, by injecting them with selected 
strains of WNV circulating in Europe and with the prototypic NY99 strain. In addition, we 
inoculated American crows with a selection of these viruses to assess and compare the 
virulence of WNV strains from Europe in a bird species known to be highly susceptible to 
WNV. Susceptibility was assessed in terms of death, survival time, magnitude and duration 
of viremia, and spread of virus to different organs. 
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MATERIALS AND METHODS 
Source of Virus and Birds 
Five different WNV strains were used in this study: lineage 1a strain NY99-4132 (NY-99) 
[20]; lineage 2 strain Nea Santa-Greece-2010 (Greece-10; GenBank accession no. 
HQ537483.1) [24]; lineage 1a strain Italy/2009/FIN (FIN; GenBank accession no. 
KF234080); lineage 1a strain Ita09 (GenBank accession no. GU011992.2) [25]; and lineage 
2 strain 578/10 (GenBank accession no. KC496015). Further details about these viruses are 
provided in Table 1. 
Carrion crows were captured by using walk-in traps in the municipality of Rotterdam, 
the Netherlands, and then transported to indoor housing at the animal holding facilities at 
the National Institute for Public Health and the Environment, Bilthoven, the Netherlands. 
After being inoculated with WNV, the crows were cared for in groups of 8 in isolators 
under negative pressure. Only seronegative birds were used in this study. Seronegativity 
was determined by using a neutralization assay (online Technical Appendix, 
http://wwwnc.cdc.gov/EID/article/21/8/14-0714-Techapp1.pdf). 
American crows were captured by using cannon net traps in Bellvue, Colorado, USA; 
the National Wildlife Diseases Program, Animal and Plant Health Inspection Service, 
United States Department of Agriculture, assisted with the captures. The crows were 
banded and transported to Fort Collins, Colorado, where they were housed in 1-m3 cages (2 
birds per cage) at the Colorado State University Animal Disease Laboratory. 
Table 1. West Nile virus strains used for susceptibility studies in carrion and American crows.
Strain Source Passage history* Location 
Genetic 
lineage 
Crow species 
inoculated 
NY99-4132 American crow (brain) V2 United 
States 
1a Carrion, 
American 
Nea Santa-
Greece-2010 
Culex pipiens 
mosquito 
V1 Greece 2 Carrion 
Italy/2009/FIN Human with 
neuroinvasive disease 
V2, C1 Italy 1a Carrion, 
American 
Ita09 Human with 
neuroinvasive disease 
V1, C1 Italy 1a Carrion, 
American 
578/10 Horse (brain) V2, C1 Hungary 2 Carrion 
*Viruses were propagated in Vero (V) or C6/36 insect cells (C). Numbers following passage source 
represent the number of virus passages. 
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Experimental Infection and Sampling Protocol 
Crows were subcutaneously inoculated in the thigh or breast region with 2,000 50% tissue 
culture infectious doses (TCID50) of virus per 0.1 mL of serum-free Dulbecco’s Modified 
Eagle Medium (DMEM) (Lonza Benelux BV, Breda, the Netherlands). Carrion crows (8 
per virus) were injected with WNV strain NY99, Greece-10, FIN, Ita09, or 578/10. 
American crows were inoculated with NY99 (n = 6), FIN (n = 5), or Ita09 (n = 5). 
Approximately 0.1 mL of blood was collected from carrion crows at 2-day intervals, up to 8 
days postinoculation (dpi), and 0.2 mL of blood was collected from American crows at the 
same time points and added to 0.9 mL of serum-free DMEM. Coagulated blood from 
carrion crows was centrifuged at 1,300 × g for 5 min in MiniCollect vials (Greiner Bio-
One, Alphen aan den Rijn, the Netherlands) to separate serum, and coagulated blood from 
American crows was centrifuged at 3,700 × g for 10 min to pellet clotted cells. Serum 
samples were stored at −80°C until further use. 
Crows were examined for clinical signs twice daily for 14 dpi and euthanized under 
isoflurane anesthesia upon display of clinical signs. In addition, 2 birds per group of the 
carrion crows were euthanized at 4 dpi. 
Necropsies were performed on all euthanized carrion crows; heart, liver, spleen, 
kidney, bone marrow, and brain samples were collected. A small section of each tissue was 
collected, weighed, and homogenized by using a metal bead in 1 mL of DMEM containing 
100 U penicillin and 100 µg/mL streptomycin. The remaining portion of the tissues was 
collected in formalin for use in immunohistochemical staining. 
 
Determination of Virus Loads 
We used quantitative real-time reverse transcription PCR (qRT-PCR) to determine virus 
titers in serum and tissue samples and TCID50 titration to calculate infectious virus titers in 
serum only. In brief, RNA was isolated from 50 µL of serum or 100 µL of homogenized 
tissue by using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Almere, the 
Netherlands) and a MagNA Pure LC automated nucleic acid robotic workstation (Roche) 
according to the manufacturer’s instructions, and subsequently stored at -80°C. RNA copy 
numbers were quantified by using unmodified primers as previously described [26]. The 
limit of detection of the assay was 9 (1.0 log10) RNA copies. 
After log10 titration of serum samples on Vero E6 cells, cytopathic effect was 
determined at 5 dpi and TCID50 infectious titers were calculated by using the Spearman–
Kärber method [27, 28]. An initial 1:10 dilution of serum resulted in a limit of detection of 
101.8 TCID50/mL. 
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Immunohistochemistry 
Paraffin sections (4-µm thick) of sagittal organ were processed for streptavidin–biotin–
peroxidase immunohistochemical detection of nonstructural protein (NS) 3 antigen. 
Sections were deparaffinized in xylene, rehydrated in descending concentrations of ethanol, 
and incubated for 10 min in 3% H2O2 diluted in PBS to block endogenous peroxidase 
activity. Antigen exposure was performed by incubation at 121°C for 15 min in citrate 
buffer (10 mmol/L, pH 6.0). Sections were subsequently incubated overnight at 4°C with 
polyclonal goat anti-WNV NS3 protease (1:100; R&D Systems, Abingdon, UK) or isotype 
control (goat serum, 1:100; Dako, Eindhoven, the Netherlands) and then detected with 
polyclonal rabbit anti-goat IgG/HRP (Dako) antibody. Sections were counterstained with 
Mayer hematoxylin, mounted with Kaiser glycerin-gelatin, and analyzed by using a light 
microscope. 
 
Statistical Analyses 
Survival curves were analyzed by using the log-rank (Mantel-Cox) test. Statistical analyses 
between >2 groups were performed by using Kruskal-Wallis 1-way analysis of variance; 
any significant differences were more closely analyzed between the groups by using the 
Mann-Whitney U test. A Bonferroni correction was applied to each p value, according to 
the number of comparisons (corrected p value of 0.05/10 = 0.005 for carrion crow peak 
viremia and organs of carrion crows euthanized on day 4; corrected p value of 
0.05/6 = 0.008 for American crow peak viremia and organs of carrion crows euthanized due 
to illness). For all comparisons, each group had 6 crows, except for American crow groups 
that received FIN or Ita09 (n = 5). 
 
RESULTS 
Illness and Death 
Signs of illness (e.g., lethargy, unresponsiveness, anorexia, and ruffled feathers) were 
observed among most crows within 9 dpi. All 6 carrion crows inoculated with Greece-10 or 
Ita09 died, and 5 (83%) of the 6 inoculated with NY99 or 578/10 died. All 6 carrion crows 
inoculated with strain FIN survived (Table 2). Survival curves of the infected birds showed 
a significant difference in survival between carrion crows infected with Ita09, Greece-10, 
NY99, or 578/10 and those infected with FIN (p = 0.005) (Figure 1). The median day of 
death was 7 dpi for carrion crows that died from infection with NY99, Greece-10, or Ita09 
and 8 dpi for birds that died from infection with 578/10. All American crows inoculated 
with NY99 (n = 6) or Ita09 (n = 5) died, and all 5 crows inoculated with FIN survived 
(Table 3). 
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Virus group No. died/no. total (%) 
Day of death, 
median dpi 
Median peak viremia, 
viral RNA/mL serum 
(range); no. birds 
Mean duration, 
d, of viremia ± 
SD; no. birds† 
Mean day of 
peak viremia ± 
SD; no. birds† 
Median peak 
viremia TCID50/mL 
(range); no. birds‡ 
NY99-4132 5/6 (83) 7 108.7 (101.0–1010.0); 6 5.2 ± 1.0; 5 4.3 ± 0.7; 5 107.4 (101.8–108.8); 6 
Nea Santa-
Greece-2010 6/6 (100) 7 10
10.3 (109.8–1011.7); 6 5.7 ± 0.7; 6 4.5 ± 0.9; 6 107.8 (107.3–109.8); 6 
Italy/2009/FIN 0/6 (0) NA 102.7 (101.0–105.9); 6 2.7 ± 0.9; 3 6.7 ± 0.9; 3 101.8 (101.8–102.5); 6 
Ita09 6/6 (100) 7 109.7 (108.0–1010.0); 6 6.0 ± 1.2; 6 4.3 ± 0.7; 6 107.6 (106.3–108.8); 6 
578/10 5/6 (83) 8 108.4 (106.0–1010.1); 6 5.7 ± 1.8; 6 3.5 ± 0.9; 6 105.1 (102.8–108.5); 6 
*dpi, days postinoculation; NA, not applicable; TCID50, 50% tissue culture infectious dose. 
†Based on viral RNA titers. 
‡Viral titers are expressed as log10 TCID50/mL of serum. 
Table 2. Clinical profile for carrion crows experimentally infected with various West Nile virus strains. 
 
Virus group No. died/no. total (%) 
Median peak viremia, 
viral RNA/mL serum 
(range); no. birds 
Median peak viremia, 
TCID50/mL serum 
(range); no. birds† 
NY99-4132 6/6 (100) 109.6 (109.1–1010.1); 6 107.2 (104.7–107.2); 6 
Italy/2009/FIN 0/5 (0) 101.0 (101.0–106.9); 5 101.8 (101.8–102.7); 5 
Ita09 5/5 (100) 108.8 (108.0–109.1); 5 106.7 (106.0–107.5); 5 
†Virus titers are expressed as log10 50% tissue culture infectious dose (TCID50)/mL of serum. 
Table 3. Clinical profile of American crows experimentally infected with West Nile virus strains NY99-4132, Italy/2009/FIN, and Ita09. 
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Figure 1. Survival rate for West Nile virus (WNV)–infected carrion crows after inoculation with 
2,000 50% tissue culture infectious doses of WNV; each group (n = 6) was inoculated with a 
different strain. Crows were monitored daily for signs of disease through postinoculation day 14. 
 
Viremia Profiles 
WNV viremia profiles were determined in terms of viral RNA (Table 2; Figure 2) and 
infectious virus titers in serum (Table 2; Figure 3) of infected carrion crows. In strain 
NY99-infected birds, the median peak viral RNA titer was 108.7 RNA copies/mL of serum 
(range 101–1010.0 [nontransformed values]), and the median peak infectious virus titer was 
107.4 TCID50/mL of serum (range 101.8–108.8); these values include 1 bird in which 
detectable viremia did not develop during the entire course of infection. The median peak 
viremia titer for Greece-10–infected birds was 1010.3 RNA copies/mL of serum (range 
109.8–1011.7) and 107.8 TCID50/mL of serum (range 107.3–109.8). FIN-infected birds had 
median peak viremia titers of 102.7 RNA copies/mL of serum (range 101–105.9) and 101.8 
TCID50/mL of serum (range 101.8–102.5); however, viremia was detectable in only 3 of 6 
birds, and infectious virus could be isolated from only 1 bird. The median peak viremia 
titers for Ita09-infected birds were 109.7 RNA copies/mL of serum (range 108.0–1010.0) and 
107.6 TCID50/mL of serum (range 106.3–108.8). Birds infected with strain 578/10 had median 
peak viremia titers of 108.4 RNA copies/mL of serum (range 106.0–1010.1) and 105.1 
TCID50/mL of serum (range 102.8–108.5). 
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Figure 2. Viral RNA copy numbers for West Nile virus (WNV)–infected carrion crows after 
inoculation with 2,000 50% tissue culture infectious doses of WNV; each group (n = 6) was 
inoculated with a different strain. RNA copy numbers are represented as log-transformed 
medians. The assay had a detection limit of 9 (1.0 log10) RNA copies/mL of serum. 
 
 
Figure 3. Infectious virus titer profiles for West Nile virus (WNV)–infected carrion crows after 
inoculation with 2,000 50% tissue culture infectious doses (TCID50) of WNV; each group (n = 
6) was inoculated with a different strain. Infectious virus titers were determined by TCID50 
titration and are represented as log-transformed medians; error bars indicate range. The assay 
had a detection limit of 1.8 TCID50/mL. 
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Strain Greece-10–infected birds had median peak viral RNA titers significantly higher 
than those for NY99-infected (p = 0.004), FIN-infected (p = 0.005), and 578/10-infected (p 
= 0.004) birds. Greece-10–infected birds also had median infectious virus titers 
significantly higher than those for FIN-infected birds (p = 0.003), but FIN-infected birds 
had RNA and infectious titers lower than those for Greece-10–infected (p = 0.005 and 
0.003, respectively), Ita09-infected (p = 0.005 and 0.002, respectively), and 578/10-infected 
(p = 0.005 and 0.002, respectively) crows. 
Viremia profiles were also determined for American crows infected with 3 of the 5 
different WNV strains (Table 3). NY99-infected birds had median peak viremia titers of 
109.6 RNA copies/mL of serum (range 109.1–1010.1) and 107.2 TCID50/mL of serum (range 
104.7–107.2). Detectable viremia developed in only 2 of the 5 FIN-infected birds, resulting in 
median peak viremia titers of 101.0 RNA copies/mL of serum (range 101–106.9) and 101.8 
TCID50/mL of serum (range 101.8–102.7). Median peak viremia titers for Ita09-infected birds 
were 108.8 RNA copies/mL of serum (range 108.0–109.1) and 106.7 TCID50/mL of serum 
(range 106.0-107.5). American crows infected with strain NY99 had the highest median peak 
viral RNA and infectious virus titers, and FIN-infected birds had the lowest median titers 
(significant only when compared with each other: p = 0.008 and 0.006, respectively). 
 
Tissue Tropism 
Virus loads were determined in the heart, liver, spleen, kidney, bone marrow, and brain of 
all birds. To assess the spread of virus to the different organs at the approximate peak of 
viremia, we euthanized 2 birds per group at 4 dpi. Virus was detected in all organs from 
these birds. On average, the highest viral RNA titers were detected in the liver, followed by 
the bone marrow, spleen, kidney, and heart; the lowest titers were found in the brain 
(Figure 4). Between the different virus strains, viral RNA titers were the highest in the 
organs of birds infected with strain Greece-10 or 578/10, followed by NY99 and Ita09; 
titers were significantly higher than those for birds infected with strain FIN (p = 0.005 for 
all). Virus distribution in FIN-infected birds was not consistent; viral RNA was 
undetectable in the bone marrow and brain of both birds tested on 4 dpi, and for 1 of these 
birds, viral RNA was also undetectable in the spleen. 
Birds euthanized because of illness had virus present in all organs; in most cases, the 
spleen, liver, and bone marrow contained the highest average viral RNA load, followed by 
kidney and heart; the lowest average viral RNA titers were in the brain. Viral RNA titers in 
organs of Greece-10–infected birds were higher than those in organs of birds infected with 
the other viruses, but this observation was not statistically significant (Figure 5). 
The 1 NY99-infected and 3 FIN-infected survivor birds that were free of viremia 
throughout the 8 days of blood sampling underwent necropsy at 14 dpi. Of interest, virus 
was present in all organs of the NY99-infected bird (median virus load of 103.1 RNA 
copies/g of tissue) and in at least 3 of the 6 organs from FIN-infected birds (median virus 
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load of 102.0 RNA copies/g of tissue), showing that these birds did undergo productive 
WNV infection. 
 
 
Figure 4. Viral RNA copy numbers in organs from 10 carrion crows (2 per group) 
euthanized 4 days after being experimentally infected with 1 of 5 different West Nile virus 
strains (n = 6, per group). Virus titers are represented as log-transformed medians; error bars 
indicate range. The assay had a detection limit of 9 (1.0 log10) RNA copies/g of tissue. H, heart; 
L, liver; S, spleen; K, kidney; Bo, bone marrow; Br, brain. 
 
Figure 5. Viral RNA copy numbers in organs from 22 carrion crows euthanized because of 
illness after being experimentally infected with 1 of 4 different West Nile virus strains (n = 
6, per group). Copy numbers are represented as log-transformed medians; error bars indicate 
range. The assay had a detection limit of 9 (1.0 log10) RNA copies/g of tissue. H, heart; L, liver; 
S, spleen; K, kidney; Bo, bone marrow; Br, brain. 
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Immunohistochemistry 
Sections of organs from 2 birds necropsied at 4 dpi were stained with polyclonal anti-WNV 
NS3 to confirm replication of virus in the tissues and to exclude positive qRT-PCR 
detection due to spillover from blood at the approximate peak of viremia. Tissues most 
consistently positive for WNV antigen were the liver (80%), kidney (80%), bone marrow 
(80%), and spleen (78%); tissues least consistently positive for WNV antigen were heart 
(50%) and brain (10%) (Table 4). However, in terms of virus load, antigen was most 
abundant in the liver, bone marrow, and spleen. Overall, at 4 dpi, organs of birds most 
positive and most abundant for viral antigen were those infected by strains 578/10 and 
Greece-10, followed by NY99 and Ita09. The organs of FIN-infected birds were all 
negative for virus antigen at this time point. 
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Virus strain, bird no. Heart Liver Spleen Kidney Bone marrow Brain 
Total score 
per bird 
Average 
score per 
virus strain 
No. positive 
organs/total 
no. organs 
NY99-4132        9.0  
 1 − ++ ++ + ++ − 11.0  4/6 
 7 − + + +/− + − 7.0  4/6 
Nea Santa-Greece-2010        12.5  
 1 +/− ++ ++ + ++ +/− 13.0  6/6 
 7 +/− ++ ++ + ++ − 12.0  5/6 
Italy/2009/FIN        0  
 1 − − − − − − 0  0/6 
 7 − − − − − − 0  0/6 
Ita09        8.0  
 1 +/− ++ ++ +/− + − 10.0  5/6 
 7 − ++ ND +/− + − 6.0  3/5 
578/10        12.5  
 1 ++ ++ ++ +/− ++ − 13.0  5/6 
 7 +/− ++ ++ + ++ − 12.0  5/6 
Score per organ 7.0 23.0 20.0 12.0 21.0 1.0    
No. positive birds/total 
no. birds 
5/10 8/10 7/9 8/10 8/10 1/10    
*Subjective determinations of the amount of antigen in each organ were made: negative (−), minimal (+/−), moderate (+), or abundant (++). 
Each determination was given a score from 0 to 3: negative (0), minimal (1), moderate (2), and abundant (3). ND = not determined. dpi, days 
postinoculation; ND, not determined. 
Table 4. Immunohistochemical analysis of West Nile virus antigen distribution in experimentally infected carrion crows euthanized at 4 dpi*. 
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DISCUSSION 
In this study, we assessed the susceptibility of carrion crows to different strains of WNV. 
First we demonstrated that carrion crows are susceptible to WNV infection by using the 
North American strain NY99, which has previously been shown to be highly virulent in 
American crows [19-23]. In agreement with the findings in those studies, our results 
showed that infection of carrion crows with NY99 resulted in high viremia titers and death. 
In addition, virus had disseminated to the organs of infected birds by 4 dpi, further 
demonstrating the susceptibility of carrion crows to WNV infection, which appears to be 
very similar to that of American crows. 
Next we studied the susceptibility of carrion crows to selected strains of WNV from 
Europe. We found that carrion crows are highly susceptible to infection with both lineage 1 
and 2 WNV strains from Europe. In addition, we showed that susceptibility is strain-
dependent. Of the 5 WNV strains tested, 4 led to death for 83%–100% of infected birds and 
to high viremia titers and abundant antigen in the organs of euthanized birds; however, 
birds inoculated with FIN did not die from infection, and they had relatively low virus titers 
in the blood and no viral antigen in the organs at 4 dpi. A previous study describing the 
inoculation of carrion crows with WNV strains from France (Fr2000) and Israel (Is98) also 
suggested that carrion crows are susceptible to infection with WNV in a strain-dependent 
manner [29]. The study showed death rates of 33% (Fr2000) and 100% (Is98) from the 2 
strains, and viral RNA loads in serum, oral swab samples, and feathers of Is98-infected 
birds were higher than those of Fr2000-infected birds [29]. Thus, WNV strains FIN and 
Fr2000 show a similar attenuation in carrion crows. 
To more accurately assess the virulence of WNV strains from Europe, we inoculated 
American crows, a bird species known to be highly susceptible to WNV, with 2 of the 4 
strains from Europe (Ita09 and FIN) and with strain NY99 from North America. Similar to 
what was seen with carrion crows, American crows infected with Ita09 had high peak 
viremia titers, and all succumbed to the infection, whereas those infected with FIN had low 
viremia titers, and all survived infection. Furthermore, it was demonstrated that the Greece-
10 strain used in this study was also 100% lethal in American crows (A.C. Brault et al., 
unpub. data). In fact, American crows infected with Greece-10 (vs. the other strains used in 
this study) had the highest median peak viremia titers in terms of RNA and infectious virus 
(data not shown). These results show that in American crows, WNV strains (apart from 
FIN) from Europe are as virulent as the prototypic NY99 strain from North America. 
The fact that susceptibility of birds to WNV can be strain-dependent was clearly 
demonstrated by the attenuated virulence phenotype of WNV strain FIN in carrion and 
American crows (this study) and in European jackdaws [30]; FIN-infected crows 
consistently exhibited an absence of death, lower peak viremia titers, and less dissemination 
of virus to the organs at the approximate peak of viremia. A previous study showed that the 
introduction of a P249T amino acid substitution in the NS3 helicase of North American 
strain NY99 led to a highly attenuated phenotype, whereas a T249P substitution introduced 
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in a low-virulence WNV strain resulted in a phenotype highly virulent to American crows 
[22]. Four virus strains used in this study contain a proline at NS3-249, whereas FIN 
contains a threonine at this position [31]. It is therefore likely that the attenuated phenotype 
of FIN is a result of this threonine amino acid at NS3-249, a mutation that could be relevant 
for at least 3 different species of birds in the family Corvidae. Studies in North American 
and European corvids are ongoing in order to test the relevance of the T249P substitution 
and several other mutations when introduced into the genome of WNV-FIN. 
We have shown that bird susceptibility to WNV can be strain-dependent. However, 
susceptibility is also clearly related to host factors. As a whole, jackdaws were less 
susceptible than the carrion crows to the same selection of otherwise highly virulent WNV 
strains, and they had lower death rates and virus loads in blood and organs [30]. Species 
susceptibility has been shown to differ within various avian families [7], including birds in 
the family Corvidae, of which, for example, the fish crow (Corvus ossifragus) was less 
susceptible to lethal WNV infection [23]. Although the reasons for this varied susceptibility 
are not well understood, potential contributing factors may include host traits, such as 
genetic composition, immune response, and physiologic mechanisms [23]. 
A measure of the potential for transmission of virus to feeding mosquitoes is the level 
of infectious virus titers produced during viremia. The median peak serum titer of 
infectious virus was highest in Greece-10–infected carrion crows and lowest in FIN-
infected carrion crows. Studies have shown that WNV titers of >105 PFU/mL were 
considered infectious for Culex pipiens [32] and Cx. quinquefasciatus [33] mosquitoes. 
Considering this cutoff of 105 PFU/mL or of 105.2 TCID50/mL, according to a conversion 
factor of 1 TCID50 to 0.7 PFU [34], infectious titers obtained for carrion crows infected 
with Greece-10, Ita09, or NY99 would be sufficient for efficient transmission of virus to 
feeding mosquitoes. Carrion crows infected with strain 578/10 had median peak viremia 
titers slightly below this threshold (105.1 TCID50/mL; Table 2), suggesting that the carrion 
crow may not be an efficient amplifier for this WNV strain. However, a possible 
explanation for the apparent low viremia titers in 578/10-infected birds could be that blood 
sampling was conducted on alternate days, possibly missing higher peak viremia titers of 
infectious virus. For the American crows, median peak viremia titers for Ita09 (Table 3) 
were slightly lower than those for carrion crows (Table 2). However, serum samples from 
American crows underwent 2 repeated freeze–thaw cycles, which could have resulted in the 
detection of lower infectious virus titers. Nonetheless, these results show that WNV strains 
from Europe can produce viremia titers in American crows that could be sufficient for 
efficient transmission to feeding mosquitoes. Nevertheless, reservoir competence studies 
involving the feeding of European mosquitoes on viremic WNV-infected carrion crows are 
needed to determine whether the carrion crow could indeed be a potential reservoir host and 
contributor to the WNV transmission cycle.  
We have shown that carrion crows, a species of bird ubiquitously found across 
Europe, are highly susceptible to WNV strains currently circulating in Europe. These birds 
could therefore potentially be useful as part of dead bird surveillance in the early detection 
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of WNV in Europe. Future studies assessing the susceptibility of the closely related hooded 
crow (Corvus cornix) to WNV may also prove to be insightful, as this is the more 
predominant corvid species in eastern and southeastern Europe, where WNV is more 
common. The susceptibility of European birds to WNV has been demonstrated in multiple 
studies [9, 10, 12, 13, 29, 30, 35–38], however, it is peculiar that the number of WNV-
associated deaths among birds in Europe is not as extensive as that among birds in North 
America. Possible explanations may be a lower reporting of bird deaths in Europe as 
compared with that in the United States or that other ecologic factors, such as mosquito 
competence, abundance, distribution or behavior, exert a limiting effect on the transmission 
of WNV in Europe. 
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TECHNICAL APPENDIX 
Detection of Preexisting West Nile Virus Antibodies 
To confirm that Carrion crows had not previously been exposed to WNV, the birds were 
bled before experimental infection and serum was tested for neutralizing antibodies by 
using tissue culture infectious dose 50 (TCID50) neutralization assays. Serum was heat-
inactivated at 56°C for 30 min, serially diluted 2-fold and incubated with an equal volume 
of virus (strain NY99, originally isolated from a dead Chilean flamingo at the Bronx Zoo in 
New York, obtained from the Health Protection Agency, Porton Down, UK; P5 on Vero E6 
cells; accession AF196835.2) to a final concentration of 100 TCID50/0.1 mL. Samples were 
incubated at 37°C for 1 h and subsequently added to an 80% confluent monolayer of Vero 
E6 cells in CELLSTAR 96-well plates (Greiner Bio-One, Alphen aan den Rijn, The 
Netherlands). Plates were incubated at 37°C for 5 days. Samples were read, and a 100% 
reduction in cytopathic effect, as compared with the serum-negative control, was used for 
the determination of neutralization. Detection of any neutralizing activity to WNV in the 
serum of any bird precluded its use for experimental inoculation. 
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ABSTRACT 
West Nile Virus (WNV) cycles between insects and wild birds, and is transmitted via 
mosquito vectors to horses and humans, potentially causing severe neuroinvasive disease. 
Modified Vaccinia virus Ankara (MVA) is an advanced viral vector for developing new 
recombinant vaccines against infectious diseases and cancer. Here, we generated and 
evaluated recombinant MVA candidate vaccines that deliver WNV envelope (E) antigens 
and fulfil all the requirements to proceed to clinical testing in humans. Infections of human 
and equine cell cultures with recombinant MVA demonstrated efficient synthesis and 
secretion of WNV envelope proteins in mammalian cells non-permissive for MVA 
replication. Prime-boost immunizations in BALB/c mice readily induced circulating serum 
antibodies binding to recombinant WNV E protein and neutralizing WNV in tissue culture 
infections. Vaccinations in HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout 
mice elicited WNV E-specific CD8+ T cell responses. Moreover, the MVA-WNV 
candidate vaccines protected C57BL/6 mice against lineage 1 and lineage 2 WNV infection 
and induced heterologous neutralizing antibodies. Thus, further studies are warranted to 
evaluate these recombinant MVA-WNV vaccines in other preclinical models and use them 
as candidate vaccine in humans.  
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INTRODUCTION 
West Nile virus (WNV) is an arbovirus that continuously circulates between different 
mosquito species and wild birds, most commonly passerines (particularly crows), as the 
natural virus reservoir, but it can also infect vertebrate animals, including horses and 
humans through the bite of a mosquito. The virus is widely distributed in Africa, Europe, 
the Middle East, Asia and America and can cause neuroinvasive disease with the potential 
for severe outcomes especially in elderly and immunocompromised humans. 
Although not a new disease (Alexander the Great is thought to have died from West 
Nile fever 2000 years ago), the virus was first isolated in 1937 from a febrile woman in the 
West Nile district in Uganda [1]. Since then, sporadic WNV outbreaks have periodically 
occurred in Africa, Asia and Europe [2, 3]. In 1999, the virus suddenly emerged in the 
United States in the New York City District of Queens, probably introduced by an infected 
mosquito or bird [4-6]. Subsequently, WNV spread across the North American continent 
leading to a total of about 41762 human infections and 1765 deaths 
(http://www.cdc.gov/westnile/statsmaps/). During the last 15 years the virus has increasingly 
emerged in European countries, resulting in severe disease outbreaks in horses and humans 
(http://ecdc.europa.eu/en/healthtopics/west_nile_fever/pages/index.aspx).   
As a member of the genus Flavivirus in the family of Flaviviridae, WNV is 
characterized by a single-stranded positively-sensed RNA genome of about 11 kb that is 
processed as a single polyprotein. The polyprotein encodes seven non-structural proteins 
essential for virus replication and three structural proteins at the amino terminus of the 
precursor polypeptide, which comprise the capsid protein (C), the membrane protein (M), 
which is initially expressed as the precursor to M (prM) and the envelope protein (E), 
which is responsible for the formation of virus particles. The formation and maturation of 
new WNV virions takes place in the endoplasmic reticulum (ER) and the trans-Golgi-
network. The virus life cycle starts in the ER with the synthesis of immature virus particles 
comprising the prM and E protein. In the trans-Golgi network the prM is proteolytically 
cleaved into the mature form [4, 7, 8].  
Phylogenetic analyses of WNV have identified five different but antigenically related 
lineages [9-11]. Strains of WNV lineage 1 are mostly associated with severe neuroinvasive 
disease in humans and animals, while lineage 2 strains have often been associated with 
relatively mild disease and no deaths in humans. However, very recently a new 
neuroinvasive strain of lineage 2 arose in Europe [12, 13].  
So far there is no effective treatment available for WNV disease, and besides the use 
of insect repellents, the most effective approach to protect animals against WNV infection 
is vaccination. Veterinary vaccines already exist for use in horses [14, 15]; however, no 
WNV vaccine has currently been approved for human use. Preclinical and early-phase 
clinical trials in humans have been performed with recombinant protein, plasmid DNA, and 
live-attenuated strain vaccine candidates [16-18].  
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Given the continuing outbreaks of severe WNV disease in the United States and 
southeastern Europe, there is a need for a safe and effective human WNV vaccine, 
especially one that protects at-risk elderly and immunocompromised populations. Another 
requirement for an effective WNV vaccine includes the induction of cross-protection 
against different lineages of WNV.  
Modified Vaccinia virus Ankara (MVA), a safety-tested and replication-deficient 
vaccinia virus, is an advanced, well-developed viral vector for constructing new vaccines 
against infectious diseases and cancer. The WNV E protein has already been shown to be 
the major target of neutralizing antibodies against flaviviruses due to its essential role in 
attachment to cell receptors and cell entry. Analysis of the WNV E structure by 
crystallography has shown three distinct subunits of the protein, ectodamain I, ectodomain 
II and ectodomain III [19], which are very reminiscent of the structure already identified for 
dengue virus (DENV) and tick-borne encephalitis virus (TBEV). In WNV, the ectodomain 
III has been shown to serve as the receptor-binding domain [20]. In this context, 
ectodomain III-specific antibodies have been demonstrated to neutralize WNV in vitro and 
in vivo after passive immunization [21-23]. 
Here, we constructed recombinant MVA viruses stably expressing the full-length 
WNV envelope (E) protein. We generated four different versions of the WNV E protein to 
mimic different forms that are present during the MVA life cycle, and assessed the 
expression, cellular location, immunogenicity, neutralising antibody response and 
protective capacity of these MVA-WNV candidate vaccines in different mouse model 
strains.  
 
MATERIALS AND METHODS 
Plasmid constructions 
The cDNA sequences encoding the WNV (strain NY99, Genbank accession number 
AF196835, [4]) envelope target antigens (prM/ME, Esol, ETMV, ETMC) were modified by 
introducing silent codon alterations to remove G/C runs as well as three termination signals 
(TTTTTNT) for vaccinia virus early transcription. The altered WNV cDNA sequences 
were generated by DNA synthesis (Invitrogen Life Technology, Regensburg, Germany). 
The cDNA prM/ME encodes the WNV NY99 amino acids (aa 128-589). The cDNA Esol 
represents a truncated version of the WNV NY99 E protein sequence lacking the E 
transmembrane domain (TM, aa 291-541). The cDNAs ETMV and ETMC contain the WNV–
Esol gene sequence fused to the sequence encoding two heterologous transmembrane 
domains targeting expression of the synthetic fusion protein to the cell surface. ETMV 
encodes the transmembrane domain of the MVA A56 protein (GenBank No AY603355.1, 
aa 35-103, TMV= transmembrane domain Vaccinia Virus) whereas ETMC includes the 
coding sequence for the transmembrane domain of the envelope protein E2 of an 
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alphavirus: the chikungunya virus (CHIKV; GenBank No AF369024, aa 686-744, TMC= 
transmembrane domain chikungunya virus). The cDNAs WNV-prM/ME, WNV-Esol, 
WNV-ETMV and WNV-ETMC were cloned into the MVA vector plasmid pIIIH5red [24] and 
placed under the transcriptional control of the synthetic vaccinia virus early/late promoter 
PmH5 [25]. 
 
Generation of recombinant MVA viruses 
MVA (clonal isolate F6; [26]) virus was propagated on chicken embryo fibroblasts (CEF) 
prepared from 10-day old chicken embryos (SPF eggs, VALO, Cuxhaven) and served as a 
backbone virus to construct recombinant MVA expressing the WNV target gene sequences 
(MVA-WNV) using standard methodology as described previously [24]. Briefly, MVA-
WNVs were obtained following transfection of MVA-infected CEF with pIIIH5red-WNV 
plasmid DNA, clonally isolated in plaque passages on CEF and monitored for the transient 
co-expression of the red fluorescent marker protein mCherry. MVA-WNV primary stock 
viruses were grown in CEF and stored at -80°C until further analysis. Quality control 
experiments were essentially performed as described previously [24]. Genetic identity and 
genetic stability of the vector viruses were assessed by PCR analysis of genomic viral 
DNA. Replicative capacities of MVA-WNV were tested in one-step and multiple-step 
growth experiments in CEF, human HaCat cells [27], and in cultures of equine dermal 
fibroblasts (generated from primary cultures of horse skin biopsies and generously provided 
by Cornelia Deeg, Institute of Animal Physiology, LMU, Munich). Viral titres were 
determined by plaque assays using MVA-specific immunostaining and titrated in plaque 
forming units (PFU). To generate vaccine preparations, recombinant MVA-WNVs were 
amplified in CEF, purified by ultracentrifugation through sucrose cushions and 
reconstituted to vaccine stocks in Tris buffered saline pH 7.4. 
 
Immunostaining of MVA-WNV infected cells 
At 48 h, MVA-WNV infected CEF cultures (multiplicity of infection (MOI) 0.01) were 
fixed at room temperature with 4% paraformaldehyde for 30 min and washed two times 
with phosphate-buffered saline (PBS). Selected cultures were permeabilized using 0.2% 
Triton X-100 solution in PBS. Mouse monoclonal antibody against WNV-E (Fa. 
BioReliance (Rockville, USA) and fluorescent (Alexa) polyclonal rabbit/goat anti-mouse 
antibodies (Fa. Life Technologies (Darmstadt) were used to stain the cells. Nuclear DNA 
was stained using 1 μg/ml DAPI (4′,6-diamidino-2-phenylindole) solution (Sigma). A 
Keyence BZ-X700 fluorescence microscope with a ×20 objective was used for analysis of 
stained culture. 
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Western blot analysis of recombinant proteins 
Confluent monolayers of different cell lines (CEF, equine fibroblast, HaCaT) were infected 
at an MOI of 5 with the different recombinant MVA-WNVs (prM/ME, Esol, ETMV, ETMC). 
Cell lysates or supernatants were prepared at different time points after infection (8, 24, 48 
hours post-infection (hpi). Lysates from uninfected cells or wild-type MVA-infected cells 
served as controls. Polypeptides were separated by SDS-PAGE and electroblotted onto a 
PVDF membrane. After blocking, membranes were incubated with primary antibodies 
(anti-WNV E protein, mouse monoclonal, BioReliance, Rockville USA) at 4 °C overnight. 
After washing, the blots were incubated with secondary antibodies for one hour at room 
temperature.  
 
WNV challenge viruses 
Two isolates of WNV were used for mouse infection studies: one lineage 1a strain, Ita09 
(kindly provided by Dr. Luisa Barzon, University of Padova, Italy; one VeroE6 passage; 
GenBank accession number GU011992.2) isolated from a patient with neuroinvasive 
disease, and the Hungarian lineage 2 strain, 578/10 (kindly provided by Dr. Tamás 
Bakonyi, Szent István University, Hungary, two passages on Vero E6 cells, GenBank 
accession number KC496015), which was isolated from the brain of a horse that died from 
WNV neuroinvasive disease. The virus stocks were prepared by growing Ita09 once (P1) 
and 578/10 twice (P2) on Aedes albopictus C6/36 cells (ATCC CRL1660). 
 
Immunizations and infection experiments in mice 
Female BALB/c mice (6-10 weeks old) were purchased from Charles River Laboratories 
(Sulzfeld, Germany). Three-week old female C57BL/6 mice were purchased from Harlan 
Laboratories B.V. (Venray, The Netherlands). 
HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice (6–8 weeks old) 
[28] were obtained from Institut Pasteur /Charles River Laboratories (France) and used for 
immunizations to monitor for HLA-A*0201-restricted CD8+ T cell responses. All 
vaccinations were performed by intramuscular (i.m.) injection of vaccine suspensions 
containing 108 plaque-forming units (PFU) of recombinant or non-recombinant (WT) MVA 
vaccine or PBS (mock vaccine) into the quadriceps muscles of the left leg of each animal 
(BALB/c and C57BL/6 mice). Blood was collected on day 0, 14 and 56. Coagulated blood 
was centrifuged at 1300 × g for 5 min in MiniCollect vials (Greiner Bio-One, Alphen aan 
den Rijn, The Netherlands) in order to separate serum, which was subsequently stored at -
20 °C until further use. Six weeks after the last immunization (day 56), all animals were 
challenged by intraperitoneal inoculation (i.p.) of 104 TCID50 of WNV-Ita09 (n=40) or 
WNV-578/10 (n=40) in a total volume of 100 µl. Animals were monitored daily for signs 
of disease and mice were euthanized by cervical dislocation under isoflurane anaesthesia 
when humane end-points were reached (immobility and paralysis). Additionally, on day 8 
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after challenge, five mice per group were sacrificed and brains were collected for further 
processing. At day 14, the end-point of the experiment was reached and all remaining mice 
were euthanized, and the survival rate was analyzed and compared between the groups. 
All mice were maintained under specified pathogen-free conditions, had free access to 
food and water, and were allowed to adjust to the facilities for one week before vaccination 
experiments were performed. All animal experiments were handled in compliance with the 
European and national regulations for animal experimentation (European Directive 
2010/63/EU; Animal Welfare Acts in Germany and in the Netherlands). 
 
Serology  
To characterize the antibody responses induced by immunization with the different 
recombinant MVA vaccines, WNV binding antibodies were analyzed by enzyme-linked-
immunosorbent assay (ELISA) using recombinant WNV E protein. WNV E protein was 
expressed in Sf21 insect cells using recombinant baculovirus, as previously described [29]. 
The sequence encoding the ectodomain of WNV E (NY99 strain) was preceded by a signal 
sequence derived from the end of WNV M, and the C-terminal transmembrane domain was 
replaced by a 6xhis purification tag. 
96-well ELISA plates (Nunc Maxisorp, Platten, Thermo Scientific) were coated with 
0.5 µg recombinant WNV E protein per well. Wells were blocked with PBS containing 1% 
BSA, 5% sucrose for 1 hour at 37°C. After blocking, 100 µl/well of diluted serum samples 
were added to top wells, titrated down, and incubated for 1 hour at 37°C. After washing, 
100 µl/well of goat anti- mouse linked to horseradish peroxidase (Sigma) was added and 
plates were incubated for 1 hour at 37°C. Plates were washed and 100 µl/well of TMB 
substrate solution (3,3,5,5 tetramethylbenzidine, Sigma) was added. The reaction was 
stopped with 1.8M H2SO (Sigma) and the plates were read in an ELISA reader using an 
absorbance at 450 nm. The inflection point of the titration curve was taken as titer value 
(logarithmic reciprocal titer).  
For detection of WNV neutralizing antibodies, virus neutralization assays were 
performed by using tissue culture infectious dose 50 (TCID50). To this end, sera of 
immunized mice was heat-inactivated at 56 ºC for 30 min, serially diluted two-fold (1:10 to 
1:80) and incubated with an equal volume of virus (WNV-Ita09 or WNV-578/10) to a final 
concentration of 100 TCID50/0.1 ml, giving a serum dilution of 1:20 to 1:160. After one 
hour of incubation at 37 ºC, samples were added to an 80% confluent monolayer of Vero 
E6 cells in CELLSTAR® 96-well plates (Greiner Bio-One) and subsequently incubated for 
five days. Neutralizing titres were determined microscopically and a 100% reduction in the 
cytopathic effect (CPE) as compared to the serum-negative control was used to determine 
neutralization. Titres were defined as the highest serum dilution still giving 100% inhibition 
of CPE. 
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Analysis of T cell responses 
Mice were sacrificed eight or 56 days post prime or prime-boost immunizations. A cell 
suspension was prepared by homogenizing the spleens through 200 µm mesh sieves and red 
blood cells were removed by adding Red Cell lysis buffer (Sigma). After centrifugation the 
cell pellet was resolved in RPMI medium supplemented with 10% foetal calf serum, 2 mM 
L-glutamine and 100 IU/ml penicillin/streptomycin. For detection of WNV specific CD4+ 
T cell responsess, splenocytes were further processed by using the QuadroMACS Kit 
(Milteny Biotec GmbH, Bergisch Gladbach, Germany) to deplete CD8+ cells from 
splenocytes with MACS Micro Beads (Milteny Biotec GmbH, Bergisch Gladbach, 
Germany). As confirmed by flow cytometry CD8+ T cell depletions resulted in splenocyte 
suspensions containing CD4+ T cells at 80–95% purity with 0.5% CD8+cells present in the 
isolate of total CD3+ cells (data not shown). Interferon-γ secreting CD8+ T cells or CD4+ 
T cells were analyzed by ELISPOT assay (ELISPOTPLUS Kit for mouse IFN-γ, 
MABTECH, Germany) following the manufacturer’s instructions. ELISPOT plates were 
pre-incubated overnight with the antibody solution and then incubated with the cell 
suspension that had been stimulated with the WNV-specific peptide SVG9 (SVGGVFTSV; 
[30]) for detection of WNV CD8+ T cells. Stimulation of the spleen cell suspension with 1 
µg/ml recombinant WNV E protein (as used in ELISA) served for analysis of WNV 
specific CD4+ T cells after depletion of CD8+ T cells. The spots were counted and 
analyzed by using an automated ELISPOT plate reader and software following the 
manufacturer’s instructions (A.EL.VIS Eli.Scan, A.EL.VIS ELISPOT Analysis Software, 
Hannover, Germany). 
 
Analysis of WNV loads 
To quantify WNV in the brains of mice euthanized on day 8, half the brain was weighed 
and homogenized using a metal bead in 1 ml of DMEM containing antibiotics (100 U 
penicillin, 100 µg/ml streptomycin). RNA was isolated from 100 µl of brain homogenate 
using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Almere, The 
Netherlands) and an automatic nucleic acid robotic workstation (Roche). RNA was eluted 
in 50 µl elution buffer (Roche) and RNA copy numbers were determined using a standard 
curve of in vitro transcribed RNA of known quantities (as described previously, Lim et al., 
2013 (PMID: 23965252)) and qRT-PCR was performed using the Taqman® EZ RT-PCR 
kit (Applied Biosystems, Bleiswijk, The Netherlands), an ABI PRISM® 7500 detection 
instrument (Applied Biosystems) and primers and probe located on the 3’ UTR of WNV. 
 
Statistical analysis 
Differences in Kaplan-Meier survival curves between the different groups were assessed 
using the Log-rank test. Differences in neutralizing antibody titres were assessed using the 
Mann-Whitney U test and P-values equal to or less than 0.05 were considered to be 
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statistically significant. All statistical analyses were performed using GraphPad Prism 
version 5 software (GraphPad software, San Diego, USA). 
 
RESULTS 
Construction and isolation of recombinant MVA expressing WNV-E and M genes 
To construct recombinant MVA viruses we used the MVA transfer plasmid pIIIH5red, 
which introduces foreign gene sequences into deletion site III of the MVA genome. The 
strong synthetic early/late VACV specific promoter PmH5 controls transcription of the 
recombinant target genes and a marker gene transiently produces the fluorescent protein 
mCherry. We inserted different versions of WNV gene sequences (WNV-prM/ME, WNV-
ETMC, WNV-ETMV, WNV-Esol,) into pIIIH5red to generate the vector plasmid pIII5red-
WNV derivatives (Figure 1A). Recombinant MVA-WNVs were generated in CEF infected 
with MVA (clonal isolate F6) and transfected with DNA of the four different pIIIH5red-
WNV vector plasmids. The four different MVA-WNVs were isolated in plaque passages by 
screening for transient co-expression of the fluorescent marker gene mCherry under the 
transcriptional control of the vaccinia virus late promoter P11. The repetitive sequences 
(del) served to remove the mCherry marker by intragenomic homologous recombination 
(marker gene deletion) (Figure 1A). To confirm the genetic integrity and proper insertion of 
the different WNV genes within the MVA genome we performed PCR analysis of the viral 
genomic DNA using specific oligonucleotide primers targeting sequences adjacent to the 
MVA deletion site III. As a control for equal amounts of viral DNA, a second PCR 
amplified C7L gene sequences in the MVA genome ([31]; Figure 1B).  
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Figure 1. Generation of recombinant MVA-WNV viruses. (A) A schematic representation of 
the MVA genome with the major deletions sites I-VI shown on the top. Flank-1 and flank-2 
refer to MVA DNA sequences at deletion site III in the MVA genome, which target this site for 
insertion of recombinant genes. MVA vector plasmids pIIIH5red contain recombinant WNV 
gene sequences under transcriptional control of the vaccinia virus promoter PmH5 and a marker 
gene sequence for transient expression of the fluorescent protein mCherry. prM/ME encodes the 
M and E gene sequences including the transmembrane domain (TME), Esol lacks the E 
transmembrane domain  and ETMV and ETMC contain the WNV E gene with substituted 
heterologous transmembrane domains from MVA or chikungunya virus, (see M&M). The 
recombinant viruses were isolated in plaque passages screening for red fluorescent cells. 
Repetitive sequences (del) were designed to remove the mCherry marker by intragenomic 
homologous recombination (marker gene deletion). (B, C) PCR analyses of genomic viral DNA 
to confirm (B) insertion of recombinant genes into deletion III, and (C) the genetic integrity of 
the MVA genome for the C7L gene locus. Genomic template DNA was prepared from 
recombinant MVA-WNV viruses or non-recombinant MVA (MVA). Oligonucleotides from 
gene sequences adjacent to deletion III or within the C7L gene were used to amplify specific 
DNA fragments. PCR products were separated by agarose gel electrophoresis. PCR reactions 
without template DNA (Mock) served as controls. 
 
Growth of recombinant MVA-WNV viruses in cell culture  
Next, we evaluated the in vitro growth behaviour of the MVA-WNV viruses (Figure 2A, 
B). Multiple-step growth analyses were performed with avian cell cultures (CEF and DF-1), 
which are routinely used to propagate recombinant MVA viruses. We also analyzed the 
replicative capacity of recombinant MVA-WNVs in cells of mammalian origin. Non-
recombinant MVA-WT served as a control virus. In both avian cell lines, the growth of the 
recombinant WNV viruses was comparable to that of MVA-WT, since all viruses replicated 
to similar titres within 72 hours, each increasing infectivity by approximately three log10 
steps in CEF and DF-1 cells (Figure 2). In the cells of mammalian origin (human HaCat 
cells and equine fibroblasts, EqF), we could confirm the well-established MVA replication 
deficiency for the four recombinant MVA-WNVs. After 72 hours, and comparable to non-
recombinant MVA-WT virus, amounts of virus recovered remained lower than the titres 
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used as the infection input. These findings corroborated the expected MVA phenotype and 
confirmed that the recombinant viruses could be handled under biosafety level 1 conditions. 
 
 
Figure 2. Multiple-step growth analysis of recombinant MVA-WNV viruses. Growth of 
recombinant viruses MVA-WNV-prME, -Esol, -ETMC, -ETMV, or non-recombinant MVA (MVA-
WT) was monitored upon infection (MOI of 0.01) of (A) chicken fibroblast cells CEF and 
HaCat or (B) DF-1 and equine fibroblasts EqF.   
 
Characterization of recombinant WNV-E proteins  
First, immunofluorescence of MVA-WNV-infected cells was used to assess the synthesis of 
the WNV proteins. Anti-WNV E antibody followed by fluorescent secondary antibody 
specifically stained cells infected with recombinant MVA-WNVs (Figure 3). No 
background staining was observed in control cultures infected with non-recombinant MVA. 
We observed a reticular pattern upon infection with all recombinant viruses, with a 
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juxtanuclear accumulation of all E proteins. As anticipated, the E-specific staining in cells 
infected with MVA-ETMV and MVA-ETMC viruses seemed to include the cell surface, while 
in MVA-prM/ME or the MVA-Esol infected cells the E proteins appeared to be exclusively 
located within the cell. To further investigate the distribution patterns we also performed 
immunostaining of MVA-WNV infected cells without permeabilizing the cells. Here, we 
specifically detected the E protein only in cells infected with MVA-ETMV and MVA-ETMC, 
indicating localization of abundant E protein on the cell surface. 
 
 
Figure 3. Immunofluorescence staining of cells infected with recombinant MVA-WNV. 
Virus infected MA-104 cells were fixed with 4% paraformaldehyde and selected samples were 
treated with 0.2% Triton X-100 for permeabilization. DAPI solution was used to stain nuclear 
DNA.  
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To further analyze the synthesis of WNV envelope proteins upon infection with the 
recombinant MVA-WNV viruses, total cell lysates from infected CEF and HaCat cells were 
analyzed by Western Blot using WNV-E-specific mouse monoclonal antibodies (Figure 4). 
We specifically detected a protein with an estimated molecular mass of about 45 kDa in 
lysates from CEF cells and HaCat cells infected with all the MVA-WNV derivatives. Over 
the time course of 48 hours, the amounts of E protein remained stable in cell lysates from 
CEF and HaCat cells infected with MVA-WNV-prM/ME, MVA-ETMV and MVA-ETMC. 
However, in cell lysates from MVA-Esol-infected cells, the level of WNV E seemed to 
decline by 48 hours post-infection. To monitor the release of WNV proteins from MVA-
infected cells we also analyzed the supernatants of infected CEF and HaCat cell cultures. 
After MVA-prM/ME or MVA-Esol infection we clearly detected the WNV E specific 
protein band, indicating the release of soluble WNV E protein or E protein-containing 
particles from these infected cells. In contrast, we detected only tiny amounts of E proteins 
in the supernatants from cells infected with MVA-ETMV and MVA-ETMC suggesting that 
these E proteins remained associated with the infected cells. Comparable results could be 
detected in EqF (data not shown). 
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Figure 4. Analysis of recombinant WNV proteins. Recombinant viruses MVA-WNV-prME, -
Esol, -ETMV and -ETMC were tested by Western blot analysis using cell lysates and supernatants 
from infected (A) CEF and (B) HaCat cells. Polypeptides were separated by SDS-PAGE and 
tested by immunoblotting using WNV-E specific monoclonal antibodies. Lysates from 
uninfected cells (Mock) or non-recombinant MVA infected cells (MVA) and Western blot 
detection of beta actin served as controls. The ~46 kDa WNV E proteins (WNV-E) and 42 kDa 
polypeptide beta actin (β-Actin) are indicated on the left. 
 
Antibody responses of MVA-WNV vaccines in BALB/c mice 
To assess the immunogenicity of the recombinant MVA-WNV candidate vaccines in vivo, 
we vaccinated BALB/c mice in an initial experiment with 108 PFU by an intramuscular 
route at 0 and 3 weeks. Eighteen days after the first immunization (Prime) and ten days 
after the second immunization (Prime-Boost), serum samples were tested for WNV-binding 
antibodies by ELISA (Figure 5A). Even a single application of all MVA-WNV vaccines 
induced significant levels of WNV-specific antibodies in the mice. After booster 
immunization, all vaccinated animals produced even higher levels of circulating WNV-
specific antibodies, with the antibody titres increasing about ten-fold. 
 
WNV specific CD8+ and CD4+ T cells induced by MVA-WNV vaccines 
To assess whether the MVA-WNV recombinant proteins can activate a WNV-specific T 
cell response, we vaccinated HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-
knockout mice using 108 PFU of recombinant MVA-WNVs via an intramuscular route in 
prime and prime-boost immunizations (Figure 5B). We tested splenocytes for WNV E-
specific (SVG9 peptide epitope) CD8+ T cells by IFN-γ ELISPOT 8 days after the last 
immunization. Single intramuscular immunizations induced substantial levels of SVG9-
 192 
specific CD8+ T cells (with median absolute numbers of >2,000 IFN-γ SFC/106 
splenocytes) for all recombinant MVA-WNVs. Of note, the magnitude of CD8+ T cells did 
not differ significantly when comparing the groups of mice immunized with all 
recombinant MVA-WNVs. Intramuscular booster immunization harmonized the responses 
of individually immunized animals in all groups and increased the median levels of WNV-
specific CD8+ T cells to about 3,500 to 4,000 IFN-γ secreting SVG9-specific CD8+ T 
cells/106 splenocytes.  
At 56 days following a primary immunization with the MVA derivatives, we still 
found 400 to 800 WNV SVG9 specific IFN-γ-producing T-cells/106 splenocytes, 
suggesting an antigen-specific memory CD8+ T-cell response (Figure 5C). Prime-boost 
applications confirmed this data demonstrating significantly increased numbers of WNV-
SVG9 specific IFN-γ-producing memory T-cells in splenocytes. 
In addition, we tested for the activation of WNV-specific CD4+ T cell responses in 
mice that had been vaccinated twice (day 0, day 21) with the different MVA-WNV 
candidate vaccines. Eight days after the last vaccination we prepared the splenocytes, 
depleted CD8+ T cells using MACS Micro Beads and in vitro stimulated the remaining 
spleen cells with purified recombinant E-protein for 48 hours. To measure CD4+ T cell 
activation we counted IFN-γ secreting cells via ELISPOT assay. Two immunizations by 
intramuscular application resulted in readily detectable levels of E-specific CD4 + T cell 
responses (with median absolute numbers of 182 IFN-γ SFC/106 splenocytes) for all 
recombinant MVA-WNV candidate vaccines (Figure 5D). Immunizations with MVA-ETMC 
or MVA-prME elicited WNV-E-specific CD4+ T cells with means of 23 and 73 IFN-γ 
SFC/106 purified splenocytes.  MVA- Esol and MVA-ETMV resulted in activation of higher 
numbers of WNV E-specific IFN-γ SFC/106 purified splenocytes with a mean of 503 for 
MVA-Esol and 98 for MVA-ETMV. 
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Figure 5. Immunogenicity of recombinant MVA-WNV vaccines. Mice were vaccinated by 
intramuscular applications of saline (Mock or PBS), non-recombinant MVA (MVA), or the 
indicated recombinant viruses. Animals received one (prime immunization) or two vaccinations 
(prime-boost immunization) with 108 PFU MVA vaccine. (A) WNV E-binding antibodies in 
BALB/c mice (n=10 per group). Sera were analyzed by ELISA 18 days after the first and 10 
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days after the second immunization. (B) WNV E-specific CD8+ T cell responses in HLA-
A*0201 transgenic mice (n=6-7 per group). Splenocytes were prepared at eight days after prime 
or prime-boost vaccination. SV09 epitope specific, IFN-γ spot forming CD8+ T cells (IFN-γ 
SFC) were quantified by ELISPOT. (C) WNV E-specific CD8+ T cell memory responses in 
HLA-A*0201 transgenic mice (n=2-4 per group). Splenocytes were prepared at 56 days after 
prime or prime-boost vaccination. SV09 epitope specific, IFN-γ spot forming CD8+ T cells 
(IFN-γ SFC) were quantified by ELISPOT. *, P<0.05; **, P<0.01; ns, no statistically significant 
difference. (D) WNV E-specific CD4+ T cell responses in HLA-DR1 transgenic mice. 
Splenocytes were prepared at 8 days after prime-boost vaccination. After depletion of CD8+ T 
cells WNV E-specific, IFN-γ spot forming CD4+ T cells (IFN-γ SFC) were quantified by 
ELISPOT (Mock, MVA-WT, MVA-prME, n=3; MVA-Esol, MVA-ETMV, MVA-ETMC, n=4). *, 
P<0.05.  
 
Induction of WNV neutralizing antibodies 
To monitor the induction of WNV neutralizing antibodies, we vaccinated groups of 
C57BL/6 mice with 108 PFU of the indicated MVA-WNV recombinant viruses (omitting 
MVA-WMV ETMC because its phenotype resembled MVA-WMV ETMV) by intramuscular 
inoculation. Two weeks after the initial immunization all mice mounted detectable levels of 
circulating antibodies that neutralized the heterologous WNV Hungarian lineage 2 strain 
578/10 (with average titres >16; Figure 6A). These titres could be further increased after 
boost immunization on day 21 as measured at day 56 (average titres of 64). Furthermore, 
these sera also neutralized the homologous WNV lineage 1a strain, Ita09 (Figure 6B). 
Already two weeks after the primary immunization all mice produced significant levels of 
neutralizing antibodies in the serum (average titre >64). Booster immunizations given at 
day 21 further consolidated the neutralizing antibody response to WNV-Ita09 (with average 
titres of 128).  
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Figure 6. WNV neutralizing antibody responses. C57BL/6 mice (n=8-10 per group) were 
vaccinated twice (21-day interval) by intramuscular application with non-recombinant MVA 
(MVA) or the indicated recombinant viruses. We analyzed the WNV neutralizing capacity of 
mouse serum samples taken at days 0, 14 and 56 after the first immunization. Serum antibodies 
against (A) WNV lineage 2 strain Hungary 578 (HUN578)  or (B) WNV lineage 1 strain Italy 
09 (Ita09) were tested by virus neutralization assays (VNT). Shown are the mean serum 
antibody titres (log2) of individual animals. **, P<0.01; ***, P<0.001. 
 
Protection of mice against WNV challenge infection 
To evaluate the protective capacity of these MVA-WNV vaccine candidates, C57BL/6 
mice vaccinated by an intramuscular route were challenged intraperitoneally with a dose of 
104 TCID50 of either WNV lineage 1a strain Ita09 or WNV Hungarian lineage 2 strain 
578/10 (Figure 7). The survival rates of each group were monitored after challenge. Upon 
challenge with WNV-Ita09, 5/5 (100%) of animals in the mock-vaccinated (MVA-WT) 
group died, while all mice in the vaccinated groups survived infection (Figure 7A; 
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p<0.0007, curve; p<0.0001, trend). Upon challenge with WNV-578/10, 2/5 (40%) of the 
mock-vaccinated animals died from infection, whereas no animals in the vaccinated groups 
succumbed to the challenge infection (Figure 7B; p<0.1, curve; p<0.056, trend).  
To determine whether vaccination prevents virus from entering the brain, five animals 
per group were sacrificed on day 8 p.i., a time point at which virus has previously been 
shown to have entered the brain of all susceptible animals (data not shown). All mock-
vaccinated (MVA-WT) mice challenged with WNV Ita09 or WNV 578/10 harboured high 
viral loads in the brain at day 8 p.i. (Figure 7C; mean titre: 4.9 log10 RNA copies WNV 
Ita09/g of brain, or 5.5 log10 RNA copies WNV 578/10/g). In sharp contrast, we failed to 
detect any WNV RNA in the brains of all animals euthanized on day 8 p.i. with the 
recombinant MVA-WNV vaccines (Figure 7C). 
 
 
                 197 
 
Figure 7. Protection against WNV challenge infection. C57BL/6 mice (n=10 per group) were 
vaccinated twice (21-day interval) by intramuscular application with non-recombinant MVA 
(MVA) or recombinant viruses MVA-WNV-Esol, -ETMV, or -prME. Six weeks after the last 
immunization all animals were challenged by intraperitoneal inoculation of 104 TCID50 of (A) 
WNV-Ita09, or (B) WNV-578/10. (C) On day eight after challenge, five mice per group were 
sacrificed and brains were collected for analysis of virus loads (RNA copies). At the end-point 
of the experiment (day 14 post challenge) the survival rate was analyzed (A, B). **, P<0.01.  
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DISCUSSION 
Ongoing WNV infections in horses and humans, particularly in the United States, 
demonstrate the continuing need for WNV-specific public health responses 
(http://www.cdc.gov/westnile/index.html). The availability of a WNV vaccine for humans 
should greatly reduce the risk of infection in people; however, the commercial development 
of such a vaccine is expected to be complex [32]. Several requirements must be met for a 
promising candidate WNV vaccine: (i) it should protect against different WNV strains; (ii) 
it must be safe and immunogenic in the most important human target population, i.e. the 
elderly and immunocompromised patients; (iii) it should be suitable for a licensing 
approach using efficacy testing in animal models because of the low incidence of WNV 
infections in humans; (iv) it should be suitable for storage as an emergency vaccine (shelf-
life), and (v) ideally, the same vaccine technology platform should allow for the 
development of a vaccine for veterinary use. All these points supported our strategy to 
evaluate MVA as vector vaccine for delivery of WNV antigens. 
Moreover, our motivation to construct a WNV candidate vaccine based on MVA was 
due to encouraging results with another recombinant MVA vaccine in preclinical and 
clinical evaluation [33-37]. In these studies, a recombinant MVA expressing the HA of 
influenza A/Vietnam/1194/04 (H5N1) virus efficiently induced H5 cross-reactive 
antibodies and prevented virus replication in the upper and lower respiratory tract, as well 
as the development of severe necrotizing bronchointerstitial pneumonia following challenge 
infections with homologous and heterologous influenza A/H5N1 viruses. Moreover, the 
first clinical evaluation in humans demonstrated the safety and immunogenicity of this 
MVA-H5 influenza candidate vaccine [34, 38].    
Here, we focused on the WNV E protein as the immunogen to efficiently activate 
WNV-specific immune responses. Previous studies on the flavivirus life cycle identified the 
E protein as an important activator of WNV-specific antibodies [7, 39]. Moreover in a 
recent study, a Matrix-MTM adjuvanted WNV E protein vaccine successfully protected 
mice against lethal WNV challenge infection by activating WNV-specific humoral and 
cellular immune responses. The E protein is a structural protein mainly involved in the 
attachment of WNV to the receptor of target cells to mediate the cell entry process. 
Therefore, most of the neutralizing antibodies against flaviviruses recognize the structural E 
protein, although another population of antibodies exits that also binds to the prM/M 
protein [40-42].  
Efficient vaccine-mediated activation of immune responses can also be optimized by 
expressing antigens that closely resemble those of the target pathogen during its actual life 
cycle. Previous studies have identified different modalities of antigen presentation that 
efficiently activate flavivirus-specific immune responses. For example, secreted E proteins 
alone in a soluble truncated form lacking the membrane anchor region have been shown to 
be highly immunogenic when expressed by vaccinia virus vectors or recombinant 
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baculoviruses [43-45]. Another study demonstrated the immunogenicity and protective 
capacity of a membrane anchored WNV E protein in BALB/c mice [46].  
Another promising approach for vaccine development is the induction of so-called “virus 
like particles” (VLPs), which are non-infectious virus particles found to be highly 
immunogenic [47]. For WNV, co-expression of the E and M protein resulted in the 
production of VLPs that were able to protect mice and horses against neuroinvasive disease 
upon WNV challenge [18, 48].  
In this study, we successfully constructed four recombinant MVA-WNVs delivering the 
WNV E protein in different forms for antigen presentation to mimic the vaccine 
optimization strategies described above, i.e. E protein lacking the membrane anchor region, 
containing heterologous transmembrane domains, or including the M protein encoding 
sequences. We succeeded in producing all WNV E antigens as stable proteins, alone or in 
combination with M, and achieved high levels of expression using the strong synthetic 
early/late vaccinia virus PmH5 [25]. 
In the case of MVA-Esol, removal of the authentic E membrane anchor sequence 
resulted in secretion of E antigen from MVA-infected cells and predominant accumulation 
of E protein in culture supernatants as shown by Western blot analysis. A similar, efficient 
release of soluble WNV E protein from infected cells has been seen upon expression from 
recombinant measles virus [49]. In contrast, replacement of the E membrane anchor 
sequence by the transmembrane domains of the VACV protein A56 (WNV ETMV) or the 
chikungunya virus E2 protein (WNV ETMC) resulted in stable presentation of WNV E 
protein antigens on the cell surface. The immunostaining and Western blot analysis data 
support the idea that these chimeric E antigens undergo cell membrane-associated 
expression without release from the MVA vector infected cells.  
For MVA-prM/ME, the M protein-encoding sequences are maintained in addition to 
the E gene sequences in order to trigger the synthesis of VLPs [50-52]. Upon cell culture 
infections, we could detect increasing amounts of WNV E protein in cell lysates as well as 
in the supernatants, suggesting the assembly of VLPs in the ER, transport via the trans-
Golgi, and release of the particles from the MVA infected cells [53, 54].  
An important requirement for recombinant MVA candidate vaccines is that the vector 
viruses can be stably grown and produced in CEF cells at an industrial scale [24]. Our 
experiments demonstrated the genetic stability of all the vector viruses and comparative 
growth analyses confirmed that recombinant MVA-WNV replicated in CEF cells as 
efficiently as the non-recombinant wild-type MVA. Moreover, in vivo experiments in mice 
demonstrated the immunogenicity of all the recombinant MVA-WNV vaccines, including 
the production of WNV-specific antibodies and CD8+ T cell responses.  
The use of HLA*A0201 transgenic mice allowed us to monitor activation of SVG9 
epitope-specific IFN-γ secreting CD8+ T cells that mimic an immunodominant T cell 
specificity also found in humans [55].  In addition, we showed the induction of WNV E-
specific CD4+ T cells upon prime-boost immunization in the HLA-DR1 transgenic mice 
with the MVA-WNV vaccines and using recombinant purified E protein for in vitro 
 200 
stimulation. This data goes well along with WNV E-specific CD4+ T cell responses 
reported in a recent study by De Filette and coworkers [56]. Further experiments will be 
needed to characterize the WNV E-specific CD4+ T cell immunity in more detail by 
monitoring for HLA-DR1 restricted peptide epitopes. Of note, WNV-specific CD4+ T cells 
are considered essential for the regulation of antibody and CD8+ T cell responses and for 
protection against lethal WNV infection [57, 58]. 
In addition, we also demonstrated the maintenance of WNV-specific CD8+ memory T 
cell responses until 56 days after the last vaccination. These data are of relevance since 
previous studies have demonstrated that WNV-specific CD8+ T cell responses are critical 
for protection against neuroinvasive disease [59, 60]. Of note, Brien and coworkers 
demonstrated that a deficiency in CD8+ T cell immunity may result in severe neurological 
WNV disease [61].  
Furthermore, the different MVA-WNV vaccines also elicited serum antibodies that 
led to comparable neutralization of the homologous lineage 1 WNV Ita09 and the 
heterologous Hungarian lineage 2 WNV strain 578/10. Activation of virus neutralizing 
antibodies is considered to be the most important correlate for protection against 
flaviviruses [7]. Corroborating the immunogenicity testing, the MVA-ETMV, MVA-Esol and 
MVA-prM/ME candidate vaccines fully protected mice against lethal challenge infections 
with homologous and heterologous WNV.  
In summary, the immunogenicity and efficacy of the MVA-WNV vaccines appeared 
at least similar to that described for other WNV candidate vaccines in preclinical testing 
with regard to the induction of WNV-specific immune responses and the protective 
capacity against lethal WNV challenge infection [18, 55, 56]. The recombinant MVA-
WNV vector viruses we have developed here merit further development as candidate 
vaccines for potential use in humans and our data strongly support their evaluation in other 
preclinical models. 
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The re-emergence of WNV in Europe in 1990 with continuing introductions into new areas 
and the genetic and phenotypic diversity of the virus, have led to the intensification of 
integrated and multidisciplinary research efforts. Where in Europe WNV may emerge and 
whether it will pose a major threat to Europe is hard to predict. The complexities of its 
enzootic transmission cycle, which involves mosquitoes and birds as well as related 
ecological factors, render the geographical spread of WNV unpredictable. More 
information about the pathogenicity of circulating WNV strains for different reservoir 
hosts, their potential vector range and ecological factors may at least in part fill these 
knowledge gaps. This may also shed light on the question why WNV infections in Europe 
have a much more limited or focal distribution than in the United States.  
This thesis therefore aims to address three questions related to the current distribution of 
WNV in Europe:  
1. Are European WNV strains less virulent than their American counterparts?  
2. Are European birds less susceptible to WNV than their American counterparts?  
3. Does a WNV vaccine protect against both lineage 1 and 2 viruses circulating in Europe? 
 
Part 1: Virulence 
Although WNV harbors a single serotype, it exhibits considerable genetic variation within 
the African continent, which is the source of all the strains found around the globe [1, 2]. 
While single introduction events in India, Australia, and the Americas respectively, 
established WNV endemicities, which were followed by spatial categorization of WNV 
strains (clades 1b and lineage 5 in particular) [1], the genetic diversity of WNV in Europe 
and the Middle East is most likely the result of independent introductions by migratory 
birds [1, 3-6]. 
WNV can be subdivided into at least eight separate lineages, of which lineage 1 and 2 
have been responsible for disease outbreaks in humans and equines. Lineage 1 mostly 
encompasses outbreaks in Africa, Europe, the Middle East, Asia, Oceania (Kunjin strain) 
and North America, while lineage 2 primarily consists of strains identified in Africa. 
Lineage 2 strains have historically been considered less pathogenic in humans compared to 
lineage 1. However, since the bird of prey mortality in 2004 (mostly goshawks, Accipiter 
gentilis) caused by a lineage 2 strain found in central Europe (Hungary), this lineage has 
caused several epidemics in humans that subsequently occurred in Greece (2010), Romania 
(2010), Russia (2011), Italy (2011-2013) and Serbia (2012). It therefore appears that the 
plasticity and adaptive capacity of WNV poses a continuous risk of generating genotypes 
virulent in vertebrates that may spread outside of Africa [7]. 
The European strains investigated in this thesis comprise two Italian isolates, FIN and 
Ita09, and one Hungarian isolate, 578/10. Interestingly, of these strains, only Ita09 has 
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caused a substantial outbreak in humans, particularly in 2009. The closely related FIN, on 
the other hand, was obtained from a single case of human neuroinvasive disease, and 
578/10 was isolated from a horse presenting with neuroinvasive disease. Although these 
two strains have displayed their neuroinvasive potential in a single human and a single 
horse, respectively, the actual virulence of FIN and 578/10 still remains to be determined. 
As a result, in Chapter 2 we sought to characterize the neuroinvasive, and indirectly 
neurovirulent potential, of these European strains of WNV after intraperitoneal (i.p.) 
injections of C57BL/6 mice, using Ita09 as the more prototypic virulent European strain. 
We decided to construct a hypothetical virulence profile for these strains based on in vitro 
replication kinetics and fitness, in vivo survival (LD50), brain and spinal cord viral load, and 
response to infection in the brain using markers that play a role in neurodegeneration. 
In our study, we found that in vitro Ita09 replicated faster than FIN and 578/10, and to 
higher titers (LT50, burst size). However, the latent period was the same for the three virus 
strains tested. As a stand-alone in vitro experiment, this data suggests that Ita09 would be 
the more virulent virus. We found that all three virus strains tested were neuroinvasive, as 
virus was found in the brain of a large proportion of the moribund and surviving mice, and 
neurovirulent as infection led to neurological disease and in many cases to death. 
Nonetheless, differences in virulence were observed between the virus strains as 578/10 
clearly showed the lowest LD50. Interestingly, in vivo Ita09 was found to have a 2.5 day 
earlier median mortality compared to the other two viruses (day 8.5 compared to day 11). 
This makes it tempting to speculate that the higher in vitro observed replication kinetics of 
Ita09 is associated with a more rapid onset of disease and mortality. It may be speculated 
that higher viral titers established more rapidly in the periphery, lead to earlier 
neuroinvasion and neuronal cell death. However, the one-step growth curve was carried out 
in neuroblastoma cells only, which makes it difficult to extrapolate the data to events 
occurring in the periphery before neuroinvasion takes place.  
Our in vitro and in vivo experiments yielded information on neuroinvasive and 
neurovirulent capacities of the WNV strains tested. Nonetheless, several questions 
remained. Firstly, we do not specifically know whether the more rapid death of Ita09-
infected mice reflected the ability of the virus to enter the brain more quickly, for example, 
due to higher virus titers that are reached more rapidly in the periphery, or whether it is 
dependent on the ability of the virus to spread more rapidly in the brain and cause more 
rapid neuronal cell death (neurovirulence). A large proportion of mice that survived 
infection with FIN (67%) had viral RNA in the brain, which rather indicates successful 
neuroinvasion, suggesting that this virus is less neurovirulent than the other two strains. In 
order to properly assess and compare the neuroinvasive capacity of our virus strains, it 
would be more instructive to conduct a kinetic experiment in i.p. inoculated mice that are 
examined and sampled daily comparing virus titers in peripheral organs and brain sections. 
As we have now confirmed that our viruses are neuroinvasive, it would be interesting to 
directly compare their neuroinvasive capacities by determining the time required for each 
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virus strain to gain access to the brain (using qRT-PCR), as well as the initial amount that 
enters the brain and in which particular areas (using qRT-PCR and immunohistochemistry). 
An effective method to investigate neurovirulence is to conduct intracranial (i.c.) 
inoculations with several doses of virus, followed by observation of the survival as well as 
a straight kinetic analysis of viral spread by daily sampling of the brain and analyzing the 
separate sections for virus replication. This method determines neurovirulence, as the more 
neurovirulent the virus is, the more rapidly it will kill its host.  
Initially, alongside FIN, Ita09 and 578/10 we had also included NY99 as a virulent 
non-European control that has been extensively characterized in different mouse models. 
We conducted similar experiments for this strain as for the other three strains. We found 
that in vitro infectious NY99 was produced two hours earlier (at 12 hours p.i.) compared to 
the European strains (Figure 1). In addition, the replication rate of NY99 was found to be 
1.97, which is even higher than for Ita09 (1.75). Interestingly, in vivo, the cumulative 
mortality of NY99 (76%) was close to the one of FIN (78%) and Ita09 (74%), while its 
LD50 was found to be the highest out of the four virus strains at 101.43. This data gives the 
indication that in vitro NY99 is potentially the more virulent virus; however, in vivo the 
European strains appear to be more virulent. Nonetheless, as the NY99 strain was of a 
higher passage (P5) than the European strains (P2/3), the comparison with NY99 was 
eventually not published. 
           
Figure 1. Fitted one-step growth curves of infectious virus titers recovered from the supernatant 
of N2a cells infected with several WNV strains at a high MOI. 
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Host tropism determines which cells can be infected by a given pathogen and is a 
combination of susceptibility, (the cell possesses the surface receptors for binding and 
entering the cell), and permissiveness (viral replication occurs). Even though it is possible 
to deduce cell permissiveness by following viral replication and witnessing a substantial 
increase in RNA or infectious virus titers over time, a more direct approach would be to 
directly measure negative-stranded RNA. Therefore, in an effort to obtain an additional tool 
that can aid in the determination and comparison of virulence, in Chapter 3 we developed 
a qRT-PCR that specifically measures and quantifies the amount of positive- and negative-
stranded RNA of WNV. This is useful for measuring the replication rate more specifically 
as well as determining the tropism of a virus for particular host cells.  
In order to test the sensitivity and applicability of the qRT-PCR, we chose to measure 
tropism both in vitro and in vivo. As the tropism of WNV for microglial cells (both in vitro 
and in vivo) is still elusive, we decided to investigate its ability to infect a mouse microglial 
(BV-2) cell line. We found that these cells are susceptible and permissive as we were able 
to measure an increase in both negative-stranded as well as positive-stranded RNA over 48 
hours. To study the in vivo relevance of this data, we chose for a set-up in which bulk 
brains were collected daily from 9-day-old C57BL/6 mice starting at an early time point of 
infection but during which virus was already detectable in the brain (day 3) up to day 6, 
which was close to the humane endpoint and could therefore be considered a late stage of 
disease. We saw that the amount of negative-stranded RNA increased most significantly 
from day 3 to day 4 (4 log10 RNA copies), which could be an indication of active virus 
replication in the brain between these two days and suggests that the positive-stranded virus 
that we found in the brain on day 4 is most likely not derived from the periphery. It is 
interesting, however, that the increase in negative-strand at this point is much larger than 
the increase in positive-stranded RNA at the same time point, especially since the ratio of 
positive- to negative-strand genomic RNA production is 10:1 for flaviviruses [8]. As a 
result, an increase by 4 log10 RNA copies of negative-stranded RNA between day 3 and 4 
should make the amount of positive-stranded RNA detected around this time point about 
10-fold as well; instead the difference is only about 1 log10 RNA copies. Nonetheless, the 
qRT-PCR that we developed proved to be a useful tool for following viral infection over 
time, and should be useful for future virulence studies.  
The non-structural proteins of WNV have been thoroughly studied as possible 
virulence markers. The conventional way of identifying virulence markers is by comparing 
a highly virulent strain with an attenuated strain. Many of the studies attempting to identify 
virulence markers for lineage 1 compared the virulent NY99 strain with the attenuated 
Kunjin strain. Another method of finding virulence markers has been obtained via cell lines 
that contain persistently replicating flaviviral replicon, which have been established by 
selection of cells transfected with replicon RNA expressing an antibiotic resistance gene 
[9]. These cell lines are stable and useful for complementation analysis of replicase [10], 
virion assembly [11, 12] and antiviral drug screening [13, 14]. One notable feature of the 
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flavivirus replicon-containing cells is that the persistent replication of viral RNA does not 
cause CPE, which may be explained by the lack of viral structural protein expression. 
Using this system, particular epidemic strains of WNV eventually acquire an accumulation 
of adaptations in the replicons that favor persistent viral replication [15]. The key, however, 
is to deduce which adaptive mutations are responsible for the non-cytopathic replication, 
and especially, how these adaptive substitutions affect WNV replication and virulence. In 
Chapter 4, we investigated whether particular markers of attenuation found in lineage 1 
WNV were also attenuating a lineage 2 strain, using a molecular cloning strategy via which 
we constructed a lineage 2 molecular clone of the Hungarian strain 578/10 harboring 
lineage 1 attenuating mutations.  
In this study we investigated a number of non-structural proteins at which particular 
mutations proved to be attenuating in lineage 1 NY99, namely NS1-P250L, NS2a-A30P, 
NS3-H249P, NS4B-P38G, NS4B-C102S, NS4B-E249G, and NS5-A804V. We first 
examined the neuroinvasive capacity of molecular clones harboring these particular 
mutations in C57BL/6 mice via i.p. inoculations. Here we found that only the NS1-P250L 
mutant was significantly attenuated as it resulted in the complete abolishment of 
neurovirulence. There is a high probability that this mutant was also no longer 
neuroinvasive, although with the current data we cannot confirm this. To be specific, even 
though the original mutant could not be retrieved from the brains of all mice 14 days p.i., 
which therefore suggests that this mutant was not neuroinvasive, we cannot establish with 
certainty that the virus had never entered the brain, but had simply been cleared by day 14. 
In light of the data generated in Chapter 2, follow-up experiments in which we inject mice 
i.c. with this particular mutant and assess its neurovirulence, as well as collecting daily 
brain samples after i.p. inoculation, could be particularly instructive to establish its 
neuroinvasive capacity. 
Even though the other mutations were not significantly attenuating in mice, a slight 
reduction in mortality (at a high dose that we have previously seen to induce 100% 
mortality in mice for the original 578/10 isolate [16]) was observed after infection with the 
NS3 (6/8), NS4B249 (5/8) and NS2a (7/8) mutants. The same attenuating effect for the 
latter two mutations as was observed in the lineage 1 studies [9, 17] might not have been 
achieved in our study due to the absence of particular co-mutations that are possibly not 
present on the lineage 2 backbone and are in fact required to increase the attenuating effect 
of these mutations in mice. In terms of the NS3 mutation, even though a proline at the NS3-
249 locus has been proven to be an important virulence marker in birds, with in particular 
corvids [18], as we have also highlighted in Chapter 5 and Chapter 6, a proline to 
histidine mutation has actually been found more recently to not be attenuating in American 
crows nor in mice, as viremia and mortality for the birds and LD50 for the mice were highly 
similar upon infection with the NS3-249H mutant compared to the parental NS3-249P [19]. 
Even though the NS3-249H has never been associated with virulence in mice, it is known 
that the goshawk-Hungary-2004 strain harbors a histidine at the NS3-249 locus and that a 
large outbreak of human encephalitis in Greece in 2010 with the closely related Greek 
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strain was in fact associated with a His to Pro substitution at this position [20]. As a result, 
it is possible that a proline at this position could still be a virulence marker of severe disease 
for a lineage 2 strain upon infection of humans, and it was therefore still necessary to 
explore this mutation in a mouse model. 
In our study, we measured viral attenuation in terms of replication in cell culture at 
37°C and reduction of mortality in mice. However, a few studies investigating virulence 
markers have also examined plaque size and temperature sensitivity of mutant viruses by 
conducting multiplication kinetics experiments at 39.5°C or 41°C in comparison to 37°C. 
Some of these mutants appeared to be temperature-sensitive [21-23], while some were not 
[24]. As the outcome of these temperature-sensitivity experiments did not directly relate to 
the presence of an attenuating mutation, in combination with the fact that we have only 
tested our molecular clones in a mouse model and not in birds for which higher 
temperatures might be more relevant, we decided not to include temperature-sensitivity 
experiments in our study. 
 Nonetheless, our multiplication kinetics studies at 37°C showed that several of the 
mutants, namely NS1, NS2a and NS3, yielded significantly lower infectious virus titers as 
compared to the wild-type. However, over the 96 hours, these titers were only consistently 
significantly lower for the NS1 mutant. This in combination with the fact that we did not 
see significantly attenuating results in vivo for any of the mutants except NS1-P250L, we 
decided to only further characterize this mutant in vitro. In an attempt to elucidate the 
mechanisms behind the observed attenuating effect of the NS1-P250L mutant, we found the 
strand-specific qRT-PCR employing tagged primers (Figure 2) developed in Chapter 4 to 
be particularly useful for measuring viral genome replication and assessing whether 
attenuation is caused by an effect exerted during this step of the replication cycle.  
Quantifying the amount of positive and negative stranded RNA using the assay 
described in Chapter 4, we found that significantly less positive and negative stranded 
RNA of the NS1-P250L mutant were synthesized over time. This implied that the given 
mutation had an effect on the efficiency of replication. Under normal circumstances NS1 
exists as a heat labile homodimer that associates with cellular organelle membranes and is 
transported to the cell surface [25, 26]. Cell surface associated NS1 appears to have an 
immunomodulatory function via the decrease of the complement activation by different 
routes [27, 28], but NS1 is also secreted by mammalian cells as a soluble hexamer [29, 30]. 
Interestingly, NS1 has been shown to be involved in the replication process which was 
demonstrated in a study examining the ultrastructure of Kunjin virus-infected cells where 
NS1 was shown to be required for formation of the replication complex and recruitment of 
other non-structural proteins, such as NS3, to the vesicle packets [31] associated with ER 
membranes. NS1 also appears to be required in the replication process of other flaviviruses 
[32], such as dengue virus [33] and yellow fever virus [34], although the precise 
mechanisms are not completely known.  
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Figure 2. Strand-specific amplification of the negative strand of WNV using tagged primers in 
qRT-PCR. 
Nonetheless, a study by Youn et al. further elucidated the role of NS1 as they 
demonstrated in viral lifecycle experiments that WNV NS1 was not required for virus 
attachment or input strand translation of infectious viral RNA, but instead was required for 
replication as WNV RNA lacking intact NS1 genes did not form canonical replication 
complexes early after infection, resulting in a failure to replicate viral RNA and 
consequently significantly lower amounts of positive and negative stranded RNA in the 
cells [35]. We had similar results; however, the reduction in the amount of positive- and 
negative-stranded RNA was less pronounced as compared to the observations by Youn et 
al. [35] but could be related to the fact that in their study the entire NS1 gene was deleted, 
whereas in our study we simply had a proline to leucine mutation.  
The Pro to Leu substitution in the NS1 protein has been shown to ablate dimer 
formation in WNV-KUN [36]. This mutation was specifically discovered by identification 
of a cDNA clone of KUN virus (FLSD) that replicated efficiently in cell culture but 
produced and secreted NS1 in monomeric form, after which sequence analysis of the NS1 
gene in this FLSD revealed a single amino acid substitution (P250L). Proline is quite a 
unique amino acid as the last carbon atom of the side chain is bonded to the main nitrogen 
atom forming a ring structure [36]. As a result, Pro is often found in flexible regions of a 
polypeptide or gives a bend in the peptide chain [37]. For this reason a Pro to Leu 
substitution is likely to significantly affect the structure of the surrounding peptide 
sequence and is therefore consistent with the major structural change indicated by the lack 
of dimerization of the mutated NS1 [36]. This in turn leads to intracellular trafficking and 
secretion of monomeric NS1. However, given that the lack of dimerization did not hamper 
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the distribution of the protein in cells infected with the mutant and that secretion remained 
relatively efficient, it appears that dimerization may not be an absolute requirement for NS1 
function. Nonetheless, the Pro at position 250 in NS1 and a second Pro, six residues 
upstream, have been found to be strictly conserved in all members of the flavivirus genus 
(sequenced up to 1999) and lie in a relatively conserved region of the protein as well [36]. 
As a result, despite the monomeric form of NS1 appearing to be distributed and secreted 
properly, it is possible that this form of the protein still impacts the stability of the 
replication complex, consequently affecting the efficiency of the replication process. It 
remains to be determined whether this mutation also influences the immunomodulatory 
function of this protein. 
Despite our study confirming an already earlier described attenuating effect of the 
NS1-P250L mutation [36], this mutation proved to be significantly more attenuating in our 
study: in the study by Hall et al. [36], the impact on replication was not as large (100-fold 
lower between 12-24 h p.i. compared to the WT) nor was the virus as attenuated in vivo 
(only 10-fold more virus of the WNV-KUN P250L mutant was required to produce disease 
in mice) as compared to our study. The difference in the mouse model used or the age of 
the mice (18- to 20-day-old weanling BALB/c mice vs C57BL/6) may explain the 
discrepancy between these results. However, it is also possible that the presence of certain 
loci in the genome of lineage 2 viruses augmented the attenuating effect of the P250L 
mutation previously demonstrated in WNV-KUN. Studies involving the introduction of this 
mutation into other virulent lineage 1 and 2 WNV strains may provide insight into the 
importance of this mutation in other lineage 2 viruses, and, if the mutation proves to be 
only slightly attenuating in lineage 1 viruses, may also confirm that the augmented 
attenuation seen in our study is related to a co-mutation in the lineage 2 backbone. In fact, it 
may even be a co-mutation in the NS1, potentially located in the stretch of amino acids 
comprising the relatively conserved region of the NS1, as described earlier [36]. 
Even though it appears that we have found a virulence marker in lineage 2 WNVs, 
with the chosen approach, it is more correct to state that we have identified a marker of 
attenuation. Virulence markers are most accurately found by comparing emerging virulent 
isolates with circulating more attenuated strains. In our situation, however, we investigated 
a mutation that was found in a variant of the attenuated Kunjin virus in cell culture. 
Whether this variant is also circulating in nature still needs to be determined. It is likely, 
however, that the majority of emerging virulent strains of WNV have the Pro at the 250 
position on the NS1, and this locus has probably not been under such strong selective 
pressure as the NS3-T249P, which appears to be an evolutionary adaptation driven by avian 
hosts. In fact, a threonine to proline substitution at this locus has occurred on at least three 
independent occasions between lineage 1a WNVs, which preceded human WNV outbreaks 
in Egypt (1950), Romania and Russia (1996) and Israel (1997-98) [19]. To determine 
whether a leucine to proline mutation has occurred at the NS1-250 position in association 
with the emergence of more virulent strains of WNV, some in-depth phylogenetic studies 
of sequenced isolates are required. Only after the identification of strains that harbour the 
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leucine at this position that are only associated with cases of mild or absent disease, in 
combination with mouse experiments proving that mutating the leucine to a proline leads to 
a neuroinvasive phenotype, is it possible to say with more certainty that the NS1-250 is 
indeed a virulence marker. Therefore, to date it may be more accurate to conclude that we 
have found a marker of attenuation and that we have confirmed the association between 
NS1 protein and replication. 
To conclude the section on virulence, we have demonstrated that the selected 
European strains of WNV investigated for this thesis are all neuroinvasive and 
neurovirulent. In addition, we have found that markers of attenuation in lineage 1 do not 
consistently produce the same effect in a lineage 2 virus, which confirms the observed 
difference in virulence of lineage 2 viruses and suggests that different markers of virulence 
may have resulted in the emergence of more pathogenic lineage 2 viruses, which may not 
necessarily mimic the emergence of virulent lineage 1 strains. Furthermore, our study has 
also confirmed the highly virulent phenotype of Ita09 and it is therefore not surprising that 
this virus strain has caused outbreaks of neurological disease in humans. The virulent 
phenotype displayed in mice infected with FIN explains why the virus was isolated from a 
human case of neuroinvasive disease; however, it does not explain the lack of subsequent 
cases of neuroinvasive disease. This can also be said for 578/10, as this strain was shown to 
be highly virulent in mice, yet has only caused one isolated case of neuroinvasive disease in 
a horse in Hungary. These results demonstrate the complexity of the enzootic transmission 
cycle of WNV and therefore also the importance of a One Health approach. Potentially the 
answers to the lack of spread of the FIN and 578/10 isolates can be found by studying the 
reservoir hosts that may be involved in the WNV transmission cycle, as is discussed below. 
 
Part 2: Reservoir Hosts and Vectors 
WNV is maintained in an enzootic transmission cycle between birds and mosquitoes. 
Mosquitoes act as vectors while birds are the amplification hosts. When WNV spreads into 
new territory, it is often first detected in mosquito pools, subsequently in birds (often 
marked by bird mortality), which is quickly followed by the first human cases. In fact, in 
North America, bird mortality, with in particular deaths amongst American crows, were 
often found to precede cases of WNV in humans, and as a result, bird mortality was used to 
track the spread of the virus across many parts of the continent [38-41]. 
In Chapter 5 and Chapter 6 we investigated the susceptibility of two bird species 
ubiquitously found across Europe. We sought to answer the question whether the lack of 
bird mortality and also the limited distribution of WNV in Europe are related to a lower 
susceptibility of European versus American bird species to WNV infection. For the 
experiments we chose the Carrion crow (Corvus corone), which is the European 
counterpart of the American crow, a bird species highly susceptible to WNV in the United 
States, and we also chose the closely related Western jackdaw (Corvus monedula). 
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Western jackdaw (Corvus monedula) 
Hooded crow (Corvus cornix) 
Importantly, both bird species are found ubiquitously across northwestern Europe. 
Although the Hooded crow (Corvus cornix) is found in north- and southeastern Europe and 
may therefore be considered more representative for WNV endemic areas, we had to 
choose for the Carrion crow for practical reasons. Furthermore, the Hooded crow is 
genetically so closely related to the Carrion crow (0.28% at the genome level, difference in 
40 genes involved in factors such as pigmentation, vision and social dominance behavior 
[42], which are probably not directly relevant from a virological point of view), that the 
data generated in experimental infections with Carrion crows are likely to mimic those that 
would be found in Hooded crows. As a result, we believe that experimental infections of 
Carrion crows will provide us with more insight on the current distribution of WNV in both 
northwestern (no WNV activity) and north- and southeastern Europe (focal distribution). 
                             
 
          
                                                                     
                                    
The first study to use a European strain of WNV and the Carrion crow indicated that 
European strains of WNV have a relatively low virulence to crows, as a strain from France 
(Fr2000) resulted in only 33% mortality compared to 100% mortality by Is98, a strain 
closely related to the highly virulent NY99 [43]. This study therefore seemed to suggest 
that the relatively low virulence of European strains of WNV could be the reason for the 
observed low bird mortality in Europe. In order to further investigate this hypothesis, it 
became essential to conduct more experimental bird studies using other strains of WNV 
circulating in Europe. Importantly, these studies would also include strains that have caused 
outbreaks amongst humans (Greece-10, Ita09), as well as those that have shown a very 
limited spread, for example, only isolated from a single human (FIN) or equine (578/10) 
Carrion crow (Corvus corone) 
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case, which would be similar to the French strain (Fr2000) that has only been associated 
with sporadic equine cases in Camargue, France. Besides it being important to investigate 
whether other European strains of WNV could be virulent to crows, it was also interesting 
to examine whether strains that caused large outbreaks in humans also tend to display a 
higher virulence in crows, which may potentially explain the spread of these viruses 
throughout a larger area that eventually led to spill over into humans. In fact, the results of 
Chapters 5 and 6 strongly indicate that the Western jackdaw and Carrion crow are 
susceptible to WNV, as mortality (60% in jackdaws, 83% in Carrion crows) was observed 
after inoculation with NY99, a strain of WNV known to be highly virulent to American 
crows. We also found that the majority of European strains of WNV are virulent to corvids 
as three out of four strains induced viremia and mortality in both bird species. In fact, 
European strains of WNV displayed a similar, if not higher, virulence in the birds than the 
North American strain. Furthermore, in order to measure the ‘absolute’ virulence of these 
European strains of WNV, we conducted parallel studies in the highly susceptible 
American crow. We found that the European strains were at least as virulent in these birds 
as the virulent prototype NY99.  
Interestingly, mortality and viremia after WNV infection were found to be generally 
higher in the Carrion crow compared to the Western jackdaw. Despite the close genetic 
relationship, this suggests that Carrion crows are more susceptible to WNV than Western 
jackdaws, which could be related to differences in host innate immunity. Nonetheless, 
similar results were induced after inoculation with the FIN strain, as both Western jackdaws 
and Carrion crows did not experience mortality nor sustained viremia titers. Here it is 
tempting to speculate that a possible reason for the lack of more cases of WNV-FIN in 
either birds, horses or humans, is because the virus was not able to spread beyond infected 
mosquitoes due to the inability of the virus to be sufficiently amplified in corvid birds. 
However, more susceptibility studies with WNV-FIN in other bird species, possibly under 
more nature-mimicking conditions (e.g. infection by mosquitoes), could verify this 
hypothesis. 
Through bird susceptibility studies information can be obtained that may be useful for 
risk-based approaches and WNV surveillance (Table 1). A risk-based assessment tool such 
as the Hazard Analysis Critical Control Points (HACCP) analysis [44] has proven to be 
particularly useful for infectious diseases such as food-borne illnesses as well as the highly 
pathogenic avian influenza virus (HPAI) strain H5N1. The latter helped to identify the key 
stages within the poultry trade chain that pose risks for the transmission of HPAI viruses 
among human and poultry populations [45]. For WNV it was also possible to identify the 
key stages at which transmission of the virus can take place; however, proposing critical 
limits and adopting mitigation strategies to limit virus transmission risks proved to be 
challenging. The WNV transmission cycle is highly complex and also dependent on many 
extraneous factors pertaining to the environment. For example, it has been hypothesized 
that WNV can be introduced via mosquitoes by airplane, wind, and boat; and via infected 
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humans, human-transported birds or other vertebrates, and migratory birds. The most likely 
and more easily controlled pathway of these can be considered introduction by airplane, as 
it is theoretically possible to fumigate airplanes. In fact, a study conducted at Amsterdam 
Schiphol Airport demonstrated that mosquitoes were occasionally found in aircraft cabins, 
including Culex quinquefasciatus [46], which is a competent vector for WNV in North 
America [47]. However, other introductory pathways, such as infected mosquitoes imported 
by wind, or infected migratory birds are considerably more difficult to influence. As a 
result, a passive but probably more realistic approach would be to conduct surveillance, and 
upon confirmation of WNV circulation, to control human and domestic animal behavior 
that leads to infection by mosquitoes. Therefore, apart from fumigating airplanes and 
controlling mosquito populations, it currently seems more realistic to focus the majority of 
the efforts on WNV surveillance and awareness campaigns.  
The information obtained from our bird experiments may help to direct the nature of 
the surveillance practiced (Table 1). Monitoring susceptible bird species, by e.g. dead bird 
pathology and virological screening, in combination with measuring viremia and antibody 
seroprevalence can provide indications about the role of different bird species in the 
transmission of virus to mosquitoes (amplifier hosts). In addition, viral persistence studies 
may provide additional information about bird species that can participate in oral 
transmission (carcass scavenging). Identifying susceptible birds and virulent strains can 
also help to pinpoint potential risk areas (seroprevalence, amplifier hosts, virulence 
markers), while duration of viremia can give an indication about duration of infectiousness, 
and as a result the potential risk posed by a particular migrating viremic bird species.  
Our data identified the Carrion crow as an important target for WNV live and dead 
bird surveillance. In addition, this bird species may transmit WNV as an amplifier host to 
mosquitoes -although this requires confirmation by reservoir host-mosquito experiments- 
and may also transmit the virus as a subject of carcass scavenging. In contrast, the lower 
susceptibility of the Western jackdaw makes the contribution of this bird to maintenance of 
WNV in the transmission cycle more doubtful, and as a result it is probably more suitable 
as a sentinel for WNV serosurveillance. On the other hand, the relatively high mortality 
observed in experimentally infected Carrion crows may render them less appropriate for 
serosurveillance. Obviously the use of other highly susceptible sentinel birds like domestic 
chickens may be practiced under circumstances of imminent threat. Nonetheless, to 
determine the real use of particular bird species as sentinels, proper antibody longevity 
studies will need to be conducted. 
 
 
 
 
 
 
 
                 219 
Parameter Application to WNV surveillance or transmission 
Mortality Dead bird surveillance 
Peak viremia titers Live bird surveillance  and potential transmission to mosquitoes 
Duration of viremia Estimation of duration of infectiousness (potential for virus introduction) 
Organ viral titers Oral transmission risk via carcass scavenging  
Virus strain-specific virulence Virulence marker surveillance 
Antibody titers Serosurveillance 
Persistence in organs Oral transmission risk via carcass scavenging  
Table 1. The potential application for the data obtained in the bird susceptibility experiments 
For virulence marker surveillance, our Western jackdaw and Carrion crow studies 
have found that a previously described virulence marker identified in the North American 
strain NY99 [18] is also relevant for Europe. To be more specific, the two closely related 
Italian strains, FIN and Ita09 (99.7% nucleotide identity) exhibited a contrasting virulence 
phenotype in both Western jackdaws and Carrion crows. The viral genome revealed the 
presence of a proline for Ita09 at the NS3-249 locus and for FIN a threonine at this position. 
In the study by Brault et al., introduction of a T249P in an attenuated Kenyan strain was 
found to be sufficient to generate a phenotype highly virulent to American crows, while a 
P249T introduction in the virulent NY99 strain resulted in an attenuated phenotype [18]. 
This suggests that the different virulence profile exhibited by FIN and Ita09 is related to the 
presence of the T249P substitution. Interestingly, it has been found that a series of 
hydrophobic residues (NS3-243-254) within the NS3 helicase are highly conserved among 
WNVs, with variation observed only at the NS3-249 residue. This residue is positioned at 
the terminus of the hydrophobic loop and would therefore be in a strategic orientation for 
direct interaction with alternative viral or host proteins, which may explain the influence of 
this locus on viral virulence. Furthermore, the positioning of this residue allows for any 
number of amino acids at this locus, which explains the potential for the variety of lineage-
specific amino acid identities observed at this site [19]. 
 In contrast to the importance of this determinant in avian virulence, the NS3-249 
substitutions produced no different effect on LD50 or neurovirulence in a murine model 
[19]. The reason why this particular mutation has a dramatically attenuating effect in 
corvids but not in mice is not very clear. Interestingly, the NS3-249T even appears to have 
a variable effect in different bird species. To illustrate, this particular locus did not appear 
to be attenuating in house sparrows (Passer domesticus) as inoculation with NY99 (which 
possesses the proline) and KEN-3829 (known to possess a threonine at NS3-249) resulted 
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in similar mortality rates (38% vs 50%) [48]. In addition, the Morocco/2003 strain 
(possesses a threonine at the locus) was more virulent in red-legged partridges (Alectoris 
rufa) compared to the Spain/2007 isolate (possesses a proline) (70% vs 30%) [49]. 
However, it may be possible to explain this (bird) species-dependent effect in terms of 
temperature sensitivity. In fact, a study by Kinney et al. found that WNV-KEN-3829 was 
less efficient than NY99 at replicating at high temperatures (≥43°C), such as those 
measured in viremic American crows [50]. A follow-up study inoculating American crows 
and house sparrows with NS3-249 variants found that the NS3-249T mutant was highly 
attenuating for American crows, as has been demonstrated before, but not for house 
sparrows, as these birds developed mean peak viremia titers only approx. 10-fold lower 
than the NS3-249P variant on day 3 p.i. Replication of the different mutants in duck 
embryo fibroblast (DEF) cells at 44°C demonstrated a consistently temperature-sensitive 
phenotype for the Thr mutant in comparison to the Pro mutant [19]. These results might be 
translated into the ability of the aforementioned animal species to develop fever. To be 
specific, febrile corvids have been shown to develop fever of up to 45°C upon WNV 
infection [50], while house sparrows have been found to rather develop hypothermia 
following WNV infection (unpublished data, mentioned in [19]). As a result, this bird 
species-specific variation in pyrexia could explain the varying results observed with the 
NS3-249T variant. The fact that mice do not develop fever and can even become 
hypothermic during infection [51-54] also supports this theory. It would be interesting to 
see if this theory also holds true for house finches (Haemorhous mexicanus), as their body 
temperature during infection with WNV has been found to average 41.3°C, implying that 
these birds did not exhibit fever during peak viremia. In fact, several birds were even found 
to be hypothermic at this point [55]. In addition, monitoring the temperature of red-legged 
partridges during WNV infection and linking these to the results from the study by Sotelo et 
al. [49] may provide clues as well. 
Many vector competence studies have been conducted using North American (NA) 
mosquitoes, in which mosquitoes such as Culex pipiens, Cx. restuans and Cx. salinarius 
were found to be efficient laboratory vectors [47, 56]. In contrast, European mosquito 
competence studies have only recently been conducted by Fros et al., which have shown 
that north-west European (NWE) Culex pipiens mosquitoes are competent vectors for 
WNV, as both a lineage 1 (NY99) and a lineage 2 (Greece-10) strain of WNV were able to 
effectively infect, replicate and disseminate in NWE mosquitoes from The Netherlands, as 
indicated by infection rate (percentage of infected mosquitoes after feeding on a blood meal 
containing virus from either WNV-lin2 or WNV-lin1) and transmission rate (indicated by 
percentage of mosquitoes in which virus was detected in the saliva) [57]. Using mosquitoes 
from North America (NA) as a control, it was also found that North American mosquitoes 
were a competent vector for the lineage 1 and 2 isolates; however, significant lower 
transmission rates were observed for lineage 2 in these mosquitoes compared to NWE 
mosquitoes. This difference was only apparent after oral injections rather than intrathoracic, 
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which suggests that WNV-lin2 escapes more effectively from the midgut epithelial cells in 
mosquitoes from NWE compared to those from NA. The observation that two 
geographically separated Culex pipiens populations have a notably different vector 
competence for WNV-lin2 suggests that a high degree of genotype-genotype specificity 
exists in the interaction between virus and vector. This was also noted for isolates collected 
from different regions in Florida (FL) in the United States that were assessed for vector 
competence in Culex pipiens quinquefasciatus, where transmission rates, body and leg titers 
appeared to vary between isolates and sometimes even between colonies [58]. This 
highlights that genetic differences may affect replication rates in mosquitoes and that it is 
therefore technically important to evaluate vector competence for each different WNV 
isolate, which in turn may help us understand vector-virus interactions and their role in 
complex transmission cycles in nature. 
 The study of Fros et al. [57] demonstrating that mosquitoes in an area of Europe 
where WNV has not yet been detected are competent to replicate the virus, in combination 
with our data showing that European birds from the same area (Chapters 5 and 6) are 
susceptible to WNV, indicate that intrinsic factors are not likely to be the limiting factor for 
the absence of WNV in the northern areas of Europe. Instead, extrinsic environmental 
factors such as temperature could be more likely players in the current distribution of WNV 
in Europe. Fros et al. [57] hypothesized that temperature is limiting the vector competence 
of European mosquitoes for WNV transmission, and tested this by incubating Lin2-infected 
NWE and NA mosquitoes at three different temperatures, 18, 23 and 28ºC. The first 
temperature matches the average temperature of the Netherlands, the latter the average 
temperature during the warmest period in Greece (July and August), which also 
corresponds to the peak in WNV amplification and transmission [59], and the middle 
temperature is the intermediate temperature of the two. Higher temperatures significantly 
increased the percentage of WNV-infected mosquito vectors, for both the NWE and NA 
mosquitoes. Furthermore, comparison of the spatial arrangement of recent WNV outbreaks 
in Europe per annum and the corresponding mean temperature during peak transmission 
season concurs with the hypothesis, as a strong correlation was found between WNV 
outbreaks and the mean diurnal summer temperature throughout Europe. To be specific, 
WNV outbreaks have occurred at mean temperatures of 24.6ºC, 25.3ºC and 23.5ºC. Taking 
the temperatures of locations where individual outbreaks have occurred gives an indication 
of the average summer temperatures at which there is an elevated risk for WNV activity. 
Nonetheless, this information does not tell us why the spread and circulation of WNV have 
still been relatively limited in the south of Europe. Importantly, the mild winters in southern 
Europe should potentially allow WNV persistence via mosquito overwintering. 
Furthermore, we have also not established that viremic European birds, such as the 
Carrion crow, can transmit the virus to NWE mosquitoes, and that in turn NWE mosquitoes 
can infect susceptible birds. As a result, reservoir competence studies still need to be 
conducted using Carrion crows and potentially common blackbirds (Turdus merula), if they 
may be considered the most likely counterpart of the American robin (Turdus migratorius; 
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see below) and susceptibility experiments prove to be successful, in combination with 
NWE as well as Mediterranean Culex pipiens. Even though we have focused the majority 
of our experiments on northwestern Europe due to the lack of WNV activity in this region, 
we also do not understand the current distribution of WNV in southern Europe. Several 
species of wild birds found in Europe, such as eagles [60], sparrow hawks, goshawks, 
geese, and falcons [61-63] have been shown to be susceptible by analyzing carcasses, while 
experimental infections of red-legged partridges (Alectoris rufa) [49] and house sparrows 
(Passer domesticus) [64, 65] have demonstrated varying (virus strain-dependent) 
susceptibility. Infection of the red-legged partridge with Morocco/2003 showed the highest 
mortality (70%) [49]; however, in general no species of bird from southern Europe have 
shown a similar susceptibility as the Carrion crow, and susceptibility studies in other bird 
species may be warranted. Even though the Carrion crow is not found in southeastern 
Europe, the closely-relatedness of the Hooded crow, a bird that is found in southeastern 
Europe in regions where WNV is often endemic, suggests that our studies may be highly 
applicable to this area as well. Nonetheless, reservoir competence studies with other 
susceptible birds indigenous to Europe are warranted. 
Despite the relevance of bird susceptibility studies, other factors such as mosquito 
behavior and density may also be important in explaining the current limited distribution of 
WNV in Europe. Even though we have shown that Carrion crows are highly susceptible to 
WNV, an important question that remains is whether they are also the preferred host for a 
blood meal for competent mosquitoes in Europe. Analyses of data from the mid-Atlantic to 
Colorado that combined host abundance and mosquito feeding data with host infectiousness 
indicated that even though introduced house sparrows (Passer domesticus) and crows are 
the more abundant and/or highly infectious species, they actually play a minor role in WNV 
transmission [66-68]. This is mainly because 30-80% of mosquito feedings by the dominant 
WNV vectors (C. pipiens, C. restuans, and C. tarsalis) in the US are on American robins 
(Turdus migratorius), despite these birds comprising only 1-20% of the avian communities 
studied. In contrast, the abundant crows only make up a small fraction of all mosquito 
blood meals and house sparrows are rarely fed on by mosquitoes relative to their 
abundance, which results in few bites per individual and inefficient transmission [69].  
Furthermore, a European study conducted by Rizzoli et al. specifically looked at the 
host feeding preference of wild Cx. pipiens in a hotspot of virus emergence, namely 
northern Italy, and found that this mosquito had a clear feeding preference for the common 
blackbird, both collected from the wild and in the lab [70], suggesting a potential important 
role for this species in the WNV epidemiology in Europe, and warranting future 
susceptibility studies and increased monitoring of these birds. Therefore, as mentioned 
earlier, even though we have demonstrated that Carrion crows are highly susceptible and 
could therefore function as a sentinel and potentially also as an amplification host, if the 
majority of the mosquitoes in Europe preferentially feed on other birds, we may be missing 
important birds that should be incorporated into a surveillance plan. As a result, it may be 
more strategic to now first determine the geographical abundance of the respective bird and 
                 223 
mosquito species as well as the feeding preferences of NWE and Mediterranean mosquitoes 
found in areas of WNV activity, for particular bird species. This could be performed with 
field collections of mosquitoes and subsequent determination of their blood meals, followed 
by experimental infections (via needle or mosquito bite) of the preferred bird species 
determined in these studies, in order to determine their susceptibility and potential role as 
an amplification host.  
Moreover, the role of mosquitoes such as Culex pipiens and Culex molestus hybrids as 
potential bridge vectors should not be neglected. In fact, a study by Vogels et al. has so far 
shown that Culex molestus, a mosquito with a strong preference for mammalian blood, 
including that of humans, is more abundant during winter than previously thought, and also 
displays feeding behavior towards humans. In addition, a large percentage of molestus 
hybridization is occurring in The Netherlands (6-15%), meaning that the potential bridge 
vector for WNV is present here [71]. More studies on Dutch mosquito populations are 
required, which should include more extensive mapping of the different mosquito species, 
as well as examining their blood meal preference, including specific bird species. Studying 
the feeding behavior of a potentially high-risk mosquito species, such as the bridge vectors, 
could direct proper surveillance methods and strategies for Europe. 
To conclude this section, results obtained from our bird studies combined with 
published mosquito data tells us that northwestern Europe is an area that could be at risk for 
the introduction of WNV. In the Netherlands, only reactive surveillance exists due to the 
associated high costs, and proactive surveillance will probably only be initiated after 
identification of an animal or human case. It is currently therefore unclear whether WNV is 
already circulating in the Netherlands. A study conducted by Reusken et al. in which seven 
potential WNV vector species were collected at a potential high-risk area 
(Oostvaardersplassen) found no evidence for WNV circulation in mosquitoes [72]. 
However, more mosquito surveillance studies would be needed to give a better indication 
of the presence of WNV in the Netherlands. We first propose to conduct serological studies 
for WNV on wild and migratory birds that are already sampled as part of the avian 
influenza A surveillance network established by the Erasmus Medical Centre (EMC) in 
Rotterdam. If serologically positive birds are found we next propose to collect mosquitoes 
in the areas from which those seropositive birds were collected. In addition, WNV RNA 
surveillance among mosquitoes should be considered, along with identification of the 
origins of mosquito blood meals, and this also in combination with future bird susceptibility 
studies. Even though our bird studies may prove to be useful in reactive or proactive WNV 
surveillance development for mosquitoes and birds, they have elucidated several remaining 
research gaps in the complex enzootic transmission cycle of WNV. 
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Part 3: Vaccine 
The neutralizing antibody response against the WNV E protein is most frequently used as 
the correlate of protection. The E protein is a structural protein involved in the attachment 
of WNV to the receptor of target cells as well as membrane fusion for mediation of cell 
entry [73]. Most of the neutralizing antibodies against flaviviruses recognize the E protein, 
and studies using mouse monoclonal antibodies suggest that those against DIII have a 
higher neutralizing potency than those against other sites of the molecule [74, 75]. 
However, another population of antibodies exists that also bind to the prM/M protein [75-
77]. Different modalities of antigen presentation have been identified, such as the E protein 
in a soluble truncated form lacking the membrane anchor region, which was found to be 
highly immunogenic when expressed by vaccinia virus vectors or recombinant 
baculoviruses [78-80]. On the other hand, another study demonstrated the immunogenicity 
and protective capacity of a membrane-anchored WNV protein in BALB/c mice [81]. 
Lastly, coexpression of the E and M protein has been found to result in the production of 
virus-like particles (VLPs), which are highly immunogenic non-infectious virus particles 
[82], that were able to protect mice and horses from neuroinvasive disease after WNV 
challenge [83, 84]. 
 Although currently different effective WNV vaccines for horses have been developed 
(for review see [85]), to date, no vaccine for use in humans has been approved after 
rigorous testing in clinical trials. However, recently the NIH has announced that an 
experimental vaccine that should protect against West Nile virus will enter human clinical 
trials. This vaccine is a hydrogen peroxide-inactivated virus that has been shown to protect 
both young and aged C57BL/6 as well as aged BALB/c mice after intracranial challenge 
with a heterologous virulent North American WNV strain. In addition, using both wild-type 
and human HLA-A2 transgenic C57BL/6 and BALB/c adult mice, it was shown that the 
H2O2-WNV-KUNV vaccine also generates a polyfunctional antigen-specific CD8+ T cell 
response [86]. 
Nonetheless, one vaccine platform that is being increasingly tested in animal and 
human clinical trials is based on the orthopox virus vector Modified Vaccinia virus Ankara 
(MVA), which is a highly attenuated strain of vaccinia virus (VACV), originating from the 
chorioallantois membrane vaccinia virus Ankara (CVA) via an extensive series of 
infections in primary chicken embyrofibroblasts (CEF). Propagating this virus through 
more than 570 CEF passages resulted in a massive loss of genetic information that affected 
many of the VACV virulence and immune evasion genes [87, 88] and resulted in MVA 
becoming highly restricted to cells of avian origin and unable to productively replicate in 
most mammalian cell cultures [88-90]. This growth deficiency is due to a late block in 
virion assembly, resulting in the production of immature virus particles. As viral early, 
intermediate, and late gene products are readily synthesized in non-permissive mammalian 
cells, recombinant MVA has been proposed as an antigen-expressing vector with an 
excellent safety profile [90] that currently is being tested for many applications, having 
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shown promising preclinical and clinical results for candidate vaccines against viruses, 
cancers and even allergies [91-102].  
For the production of stable heterologous antigens using MVA as a vector virus, genes 
are placed under transcriptional control of poxvirus-specific promoters. The subsequent 
presentation of antigenic peptides by professional antigen presenting cells via the MHC 
class I pathway leads to the activation of CD8+ T cells [103]. The synthesis of long-lived 
antigens is an advantageous feature since stable proteins as immunogens are superior at 
efficiently activating immune responses in vivo. This in fact appears to be the case in the 
induction of antibody responses to typical pathogen surface proteins, such as influenza 
virus hemagglutinin, as well as for eliciting MHC class I restricted antigen-specific T cells 
to internal antigens [104-106]. Another feature of MVA that is highly advantageous for 
future vaccine applications is the notable immunogenicity when compared directly to 
replication-competent VACV [107, 108]. This observation is most likely related to the 
particular ability of MVA to induce or upregulate important host responses that activate the 
immune system early on [109-112]. 
In Chapter 7, we assessed the efficacy of an MVA based candidate vaccine in 
protecting against WNV infection. We used the WNV E protein as immunogen for 
activation of the immune response. Therefore we generated four recombinant MVA-WNVs 
(prM/ME, Esol, ETMV, ETMC) delivering the WNV E protein in different forms in order to 
mimic previously described vaccine optimization strategies [78-81]. In our study, we found 
that all wild-type C57BL/6 mice vaccinated with each of the recombinant MVA’s exhibited 
homologous and heterologous neutralizing antibody titers on day 56 post-vaccination and 
survived subsequent lethal challenge with both lineage 1 and 2 WNVs. In addition, no virus 
was detected in the brain of mice euthanized on day 8 p.i. Furthermore, vaccinations of 
HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II mice elicited SV9 epitope-specific 
IFN-γ-secreting CD8+ T cell responses. This immunodominant HLA-A2-restricted epitope 
that falls within the E protein SVG9 [SVGGVFTSV]) has also been found during WNV 
infections in humans [113-115] and is conserved between members of the Flaviviridae 
family, including WNV-NY99 and WNV-KUNV. The use of these transgenic mice can 
give a good indication of whether humans are also likely to elicit protective CD8+ T cell 
responses upon WNV infection. 
It is important to consider that the specificity of an antibody response for a single 
epitope may not be sufficient to neutralize all epitope (antigenic) variations of a challenge 
virus strain and sometimes even a number of quasispecies within a single virus stock [116]. 
This also appeared to be the case for our study, as despite the presence of high homologous 
neutralizing antibody titers against WNV-Ita09, the heterologous neutralizing antibody 
titers elicited against WNV-578/10 were approx. 2-fold lower. This is something that we 
also observed previously using sera from mice that survived infection (collected on day 14 
p.i.) with WNV-NY99, FIN and Ita09 versus WNV-578 (data not shown). Such a 
phenomenon is not unusual, however, as, for example, a rabies vaccination study in which 
serum titers of human subjects measured in vitro against rabies challenge virus strains 
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found that in the majority of subjects, higher titers were detected against the homologous 
strain [117]. Several studies have explored the cross-protective efficacy of several WNV 
vaccine candidates; however, some of these, such as the study by Magnusson et al. did not 
specifically investigate the cross-protective capacity of their vaccine against their two 
lineage 1 and 2 viruses via in vitro cross-neutralization assays [118]. Nonetheless, lower 
heterologous neutralizing antibody titers have been described between WNV lineage 1 
(Eg101) and several proposed lineage 5 isolates from India due to substantial genetic 
variation [119]. In addition, it is an even more common phenomenon across flaviviruses, 
where for example, Martina et al. witnessed lower heterologous neutralizing antibody titers 
against JEV upon vaccination with WNV-DIII [120]. It therefore appears that genetic 
variation between lineage 1 Ita09 and lineage 2 578/10 renders these viruses substantially 
different to the extent that it leads to lower heterologous neutralizing antibody titers. 
The peak of vaccine induced IgG antibodies is often reached within 4-6 weeks after 
primary immunization and is controlled by the intensity of B cell differentiation into plasma 
cells, and therefore also by the magnitude of germinal center responses, i.e., the quantity 
and quality of the complex interactions between DC, B cell, follicular helper T cells (Tfh) 
and follicular dendritic cells (FDCs) interactions. The short life span of these plasma cells 
results in a rapid decline of antibody titers, but booster exposure to antigen will reactivate 
the immune memory and result in a rapid (<7 days) increase of IgG antibodies. Short-lived 
plasma cells will reach and maintain peak antibody levels until approx. 4 weeks later, after 
which serum antibody titers decline as rapidly as following primary immunization. 
However, long-lived plasma cells that have reached survival niches in the bone marrow will 
continue to produce antigen-specific antibodies, which decline with slower kinetics. Given 
the kinetics of antibody responses, we chose to measure neutralizing antibody titers on day 
56, as well as challenging the mice on this day. This allowed us to measure antibody titers 
after they have reached their postulated peak values, representing a realistic indication of 
the elicited immune response.  
MVA have induced unprecedented frequencies of vaccine-induced antigen-specific T 
cells during recent human clinical trials. These were observed after priming with Bacille 
Calmette-Guérian (BCG) and boosting with MVA-85A [101, 121], after priming with 
natural A virus infection and boosting with MVA-NP+M1 [122]; and priming with a 
recombinant non-replicating chimpanzee adenovirus vector [123] and boosting with rMVA. 
These heterologous prime-boost regimens are the only vaccines that induced mean IFN-ɣ 
ELIspot responses above 1000 spot-forming cells per million peripheral blood mononuclear 
cells (sfc/million PBMC) in humans, which include some of the highest responses ever 
measured in humans and well above what has been achieved using individual vectors, such 
as recombinant adenovirus alone [124, 125] or recombinant canarypox virus (ALVAC) 
with protein-in-adjuvant [126, 127]. Moreover, our study indicated a specific CD8+ T cell 
response as prime-boost applications were found to greatly increase the magnitude of 
WNV-SV9 specific IFN-γ-producing memory T-cells in splenocytes. 
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Nonetheless, many studies have been published testing the efficacy of various types of 
vaccines in animal models for the prevention of WNV infection. After the first cases of 
WNV were detected in New York more than 15 years ago, a large amount of money was 
invested into understanding and potentially controlling this virus. A lot of progress has been 
made since then, but interestingly, measures to prevent or treat WNV infection have stalled. 
In fact, a chimeric vaccine based on the backbone of Yellow-Fever 17D human vaccine 
expressing the prM and E genes of the NY99 strain (ChimeriVax-WN01) made it through a 
phase II trial [128] but was suspended when Sanofi Pasteur bought Acambis in 2008. 
During this year, West Nile cases had dropped from 2006 to 2008, and the company had 
decided to focus on other priorities, including a dengue vaccine. Clinical trials on treatment, 
including a monoclonal antibody, interferon, and immunoglobulin, have also been delayed 
for similar reasons; researchers were not able to enroll enough trial volunteers [129].  
As a result, one important question related to vaccine development for WNV is 
whether there is actually a market. Clinical trials are very costly and the sporadic nature of 
WNV outbreaks makes it very difficult to get enough volunteers for trials. In addition, the 
virus usually causes flu-like symptoms and less than 1% of those infected actually develop 
serious neuroinvasive disease. Due to this, it might only be useful to vaccinate the elderly 
and perhaps highly exposed groups such as outdoor workers. However, even in this case it 
is still difficult to do any kind of patient studies when outbreak sites are uncertain [129].  
Nonetheless, recent evidence suggests that WNV can cause kidney disease in younger 
people. A study by Nolan et al. found that in a cohort of 139 people with a mean age of 57 
who had tested positive for WNV, 40% had evidence of kidney disease years after infection 
[130]. If this is indeed the case, then developing an effective vaccine for WNV could 
become more of a priority, and might also involve vaccinations of younger populations. 
Whether this will improve the market certainty for a WNV vaccine remains to be 
determined. As a result, the most cost-effective remedy against WNV infection may 
continue to be mosquito repellent and screen doors. 
This thesis provides invaluable information on the virulence of European WNV 
strains in corvids as well as in a mammalian model, and demonstrates the efficacy of a 
vaccine that would be applicable to Europe where both lineage 1 and 2 WNV strains are 
circulating. In the end, through either surveillance, risk-based approaches or immunization, 
Europe is now slightly more prepared for WNV outbreaks that may arise in the future. 
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Het West Nile virus (WNV) is een flavivirus dat de West-Nijl ziekte veroorzaakt. 
Zoogdieren zoals mensen en paarden kunnen ziek worden van dit virus, en bij een klein 
percentage van de gevallen kan dit tot dodelijke encefalitis of meningitis leiden. Dit virus 
wordt door muggen verspreid die geinfecteerd worden met het virus voornamelijk door zich 
te voeden op geïnfecteerde vogels, die het virus amplificeren. Vogels zijn daarbij ook vaak 
het slachtoffer van dit virus. WNV was voor het eerst geïsoleerd in 1937 uit een zieke 
vrouw die woonachtig was in de West Nile provincie van Uganda. Het virus werd echter als 
apathogeen beschouwd omdat het in de meeste gevallen niet leidde tot klinische 
symptomen. In 1999 werd het virus voor het eerst gedetecteerd in de Verenigde Staten en 
dit leidde uiteindelijk tot een uitbraak waarbij veel menselijke slachtoffers vielen. Deze 
uitbraak ging gepaard met hoge mortaliteit onder vogels, met name de kraaiachtigen. 
Doordat kraaien in de VS erg gevoelig zijn voor WNV, wordt mortaliteit onder deze vogels 
vaak gebruikt om WNV activiteit vroegtijdig op te sporen.  
Het virus heeft zich uiteindelijk razendsnel weten te verspreiden over de gehele 
Verenigde Staten binnen een periode van 5 jaar. In Europa is het WNV tot voor kort nooit 
de oorzaak van uitbraken geweest en waren de meeste ziektegevallen mild. Sinds 1996 
heeft het virus echter verscheidene uitbraken veroorzaakt in Europa, in landen zoals 
Roemenië, Tsjechië, Hongarije, Italië en Griekenland, die gepaard gingen met gevallen van 
neuroinvasieve ziekte in mensen of paarden. Deze uitbraken hebben echter nooit geleid tot 
een uitgebreide verspreiding van het virus over Europa en de distributie van het virus is 
eerder focaal. Omdat de transmissie cyclus van het WNV opgemaakt is uit zowel een vector 
(de mug) en een gewervelde gastheer (de vogel) is deze uitermate complex, en is het 
bestuderen van de verspreiding van het virus een uitdaging. Het doel van dit 
promotieonderzoek was om te onderzoeken waarom de verspreiding van WNV binnen 
Europa gering is en of dit virus een mogelijk risico vormt voor verdere verspreiding binnen 
Europa. De volgende vragen kwamen hierbij aan de orde: 
1) Zijn de Europese stammen van WNV minder virulent dan de Amerikaanse 
variant? 
2) Zijn vogels in Europa minder gevoelig voor infectie met WNV? 
3) Zou een vaccin bescherming kunnen bieden tegen infectie met beiden lineage 1 en 
lineage 2 virus stammen?  
Hoofdstuk 2, 3 en 4 vallen onder het gedeelte “pathogenese” van dit proefschrift. 
Hoofdstuk 2 beschrijft de virulentie en het neuroinvasieve vermogen van een selectie 
Europese stammen van het WNV (twee uit Italië, een uit Hongarije) die gemeten werden 
aan de hand van een aantal parameters, namelijk in vitro replicatie en fitness in 
neuroblastoma cellen, gevolgd door intraperitoneale infectie in C57BL/6 muizen en meting 
van in vivo mortaliteit (LD50), hoeveelheid virus in de hersenen en ruggenmerg, en respons 
op infectie in de hersenen met betrekking tot markers die een rol spelen in 
neurodegeneratie. Alle stammen bleken neuroinvasief en neurovirulent te zijn in deze 
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muizen. De stam uit Italië die verantwoordelijk is geweest voor een grote uitbraak in 2009, 
Ita09, vertoonde de hoogste fitness in vitro. De stam uit Hongarije, 578/10, was het meest 
virulent in muizen, met de laagste LD50 waarde en grootste hoeveelheid RNA in de 
hersenen. De stam FIN uit Italië vertoonde de minste lethaliteit in muizen vergeleken met 
de andere twee stammen. Sequentie-analyse toonde aan dat op nucleotide niveau Ita09 en 
FIN slechts 99.7% verschillen; echter is Ita09 iets virulenter gebleken dan FIN in onze 
studie.  
Om virulentie beter te kunnen meten, werd in Hoofdstuk 3 een qRT-PCR opgezet die 
nauwkeuriger dan bestaande tests het negatief- en positief-strengs RNA van het WNV kan 
quantificeren. Hiermee zouden we de replicatie snelheid van verschillende virusstammen 
beter kunnen meten en ook het cel tropisme kunnen bepalen. Om de bruikbaarheid en 
specificiteit van deze qRT-PCR vast te leggen is deze gebruikt om de toename van het 
WNV in de microglia cellijn BV-2 te meten over een periode van 48 uur, omdat het 
tropisme van het WNV voor microglia nog onduidelijk is. Er was een duidelijke toename 
van negatief- en positief-strengs RNA te zien, wat aangaf dat deze cellijn permissief is voor 
het WNV. De qRT-PCR is ook toegepast op een muisexperiment waarin 9-dagen oude 
muizen zijn geinfecteerd met WNV-NY99 en op dag 3, 4, 5 en 6 zijn hiervan de hersenen 
verwijderd voor RNA-isolatie. Ook hier was een toename van negatief- en positief-strengs 
RNA te zien in de tijd. Een mogelijk nadeel van deze qRT-PCR zou de gevoeligheid voor 
het negatief-strengs RNA kunnen zijn, omdat deze varieerde van 102 tot 103. Deze qRT-
PCR zou hierdoor mogelijk niet geschikt kunnen zijn voor het meten van negatief-strengs 
RNA in de vroege stadia van infectie.  
Het doel van Hoofdstuk 4 was om virulentie markers voor een lineage 2 WNV te 
identificeren. Deze zijn geselecteerd uit de literatuur aan de hand van in vitro en/of in vivo 
attenuatiemarkers die eerder gevonden zijn voor lineage 1. Vijf verschillende moleculaire 
clones waren ontworpen op basis van de Hongaarse virusstam 578/10, met elk een mutatie 
in een nonstructureel eiwit (NS1-P250L, NS2A-A30P, NS3-P249H, NS4B-P38G, en 
NS4B-E249G). Na intraperitoneale infectie van deze mutanten in C57BL/6 muizen bleek 
de NS1-P250L mutatie hevig attenuerend te zijn (0% mortaliteit). Ook in vitro infectie van 
een Vero E6 cellijn met deze mutant leidde tot significant lagere infectieuse virus titers dan 
met het wilde-type. Om deze attenuatie beter in kaart te brengen is hier de qRT-PCR die 
ontwikkeld is in Hoofdstuk 3 op toegepast. De NS1 mutant bleek significant minder 
negatief-strengs RNA te produceren waardoor ook de hoeveelheid positief-strengs RNA 
minder was. Dit zou kunnen bijdragen aan de attenuatie van deze mutant in vivo.  
Hoofdstuk 5 en 6 vallen onder het gedeelte “gastheer” van dit proefschrift en 
onderzoeken de vatbaarheid van kraaiachtigen in Nederland voor WNV-infectie. Kauwen 
(Hoofdstuk 5) en zwarte kraaien (Hoofdstuk 6) werden geinfecteerd met vijf verschillende 
stammen, WNV-NY99, Greece-10, FIN, Ita09 en 578/10. Zwarte kraaien bleken gevoeliger 
te zijn voor het WNV dan de kauwen omdat deze een hogere mortaliteit vertoonden (tussen 
de 83-100% voor kraaien vergeleken met 30-60% voor kauwen), hogere virustiters in het 
bloed (ong. 103 RNA kopieën/mL) en meer verspreiding van het virus naar de organen (102 
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RNA kopieën/g). Een van de virusstammen, WNV-FIN, veroorzaakte geen mortaliteit in 
beiden de kauw en de kraai en ook significant lagere virus titers in het bloed. Een alignment 
van de nauw verwante FIN en Ita09 gaf een marker voor virulentie weer die mogelijk een 
rol heeft gespeeld in dit experiment; NS3-249. Deze virulentie marker was al eerder 
geidentificeerd omdat een mutatie in deze locus de virulentie van een geattenueerde stam 
verhoogde in de Amerikaanse kraai. Deze marker zou mogelijk ook een rol kunnen spelen 
in de verspreiding van bepaalde stammen van het WNV binnen Europa. De experimenten 
in Hoofdstuk 5 en 6 geven de indicatie dat de zwarte kraai gebruikt zou kunnen worden 
voor WNV surveillance binnen Europa aan de hand van vogelsterfte, terwijl de kauw 
gebruikt zou kunnen worden als ‘signaalvogel’. De daadwerkelijke rol van deze vogels in 
amplificatie van het WNV is nog niet duidelijk, maar deze studies suggereren dat de zwarte 
kraai een goede amplificatie gastheer zou kunnen zijn, terwijl de titers die het WNV 
teweegbrengt in kauwen waarschijnlijk niet hoog genoeg zullen zijn hiervoor. 
Het een na laatste hoofdstuk, Hoofdstuk 7, valt onder “interventie strategieën”. Hierin 
is de effectiviteit van een MVA-gebaseerd vaccin getest voor bescherming tegen infectie 
met lineage 1 en 2 WNVs in C57BL/6 muizen. Het WNV envelop eiwit werd gebruikt als 
basis voor de ontwikkeling van vier recombinante MVAs; een die het membraan en 
envelop eiwit afschrijft (prM/ME), twee die de envelop met een transmembraan gedeelte 
afschrijven (van het Vaccinia Ankara virus (ETMV) of het Chikungunya virus (ETMC)) en een 
die een oplosbare versie van het E eiwit afschrijft (Esol). Alle muizen gevaccineerd met een 
van de vier constructen waren beschermd tegen mortaliteit na infectie met een lethale dosis 
van beiden WNV-Ita09 en 578/10. Bovendien was virus ook afwezig in de hersenen op dag 
8 na infectie van alle gevaccineerde muizen. Op dag 56 na vaccinatie hadden alle 
gevaccineerde muizen neutralizerende antilichamen in het bloed tegen Ita09, maar ook 
tegen 578/10, wat heterologe bescherming aangeeft en de bescherming van de muizen tegen 
infectie met WNV-578/10 verklaart. Echter waren de neutralizerende (heterologe) 
antilichaam titers wel lager. Verder induceerde vaccinatie van HLA-A2.1-/HLA-DR1-
transgene H-2 class I-/class II muizen een SV9 epitoop-specifieke IFN-γ secreterende 
CD8+ T cel respons. Dit is een immunodominante epitoop dat is gevonden na WNV 
infectie in mensen en deze muizen geven hierdoor een goede indicatie dat de WNV-MVAs 
ook een beschermende CD8+ T cel respons in mensen zou kunnen induceren. 
Samenvattend heeft het onderzoek in dit proefschrift geleid tot een aantal nieuwe 
inzichten betreft de aanwezigheid van en de risico’s geassocieerd met WNV in Europa. De 
drie bestudeerde Europese stammen van WNV zijn allen neuroinfasief en neurovirulent in 
muizen en zouden hierdoor waarschijnlijk een even grote bedreiging kunnen vormen voor 
de mens als de NY99 stam in Amerika. Dit geldt ook voor het lineage 2 virus uit Hongarije 
dat bestudeerd is en geeft weer dat lineage 2 stammen van het WNV die mogelijk in de 
toekomst opkomen ook virulent kunnen zijn. Dit proefschrift heeft ook aangetoond dat twee 
van de kraaiachtigen die in Nederland voorkomen vatbaar zijn voor infectie met het WNV 
en dat de zwarte kraai een mogelijke rol zou kunnen spelen in de verspreiding van het virus. 
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Het WNV zou dus een bedreiging kunnen blijven vormen voor Europa en de resultaten 
zouden onder andere gebruikt kunnen worden voor het sturen van WNV surveillance 
methodes binnen Europa. Mocht het WNV een nog groter probleem worden voor Europa in 
de toekomst, dan zou het kandidaat MVA-vaccin dat bestudeerd is in deze thesis mogelijk 
verder ontwikkeld kunnen worden aangezien het bescherming heeft geboden tegen infectie 
van zowel een lineage 1 als 2 virusstam. 
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West Nile virus (WNV) is a flavivirus that causes West Nile disease and affects mammals 
such as humans and horses, of which a small percentage develops WN neuroinvasive 
disease that may lead to fatal encephalitis or meningitis. The virus is transmitted by 
mosquitoes that obtain the virus from infected birds, which are the amplification hosts. 
WNV was first isolated in 1937 from a febrile woman in the West Nile province of Uganda. 
Despite a small number of cases in Africa, the virus was generally considered non-
pathogenic as it led to asymptomatic infection in most cases. However, in 1999, the virus 
was detected for the first time in the United States in New York where it caused a large 
outbreak of neuroinvasive disease and several deaths. Within 5 years’ time, the virus spread 
across the entire United States. Several outbreaks of WNV in the US were also 
characterized by a high mortality among birds, in particular corvids. As crows were found 
to be very susceptible to WNV and bird mortality often preceded human outbreaks, 
mortality among these birds is often still used to detect and predict WNV activity in the US.  
In Europe, WNV has never been the cause of large outbreaks and most clinical cases 
were of mild disease. However, since the first outbreak in Romania in 1996, WNV has 
spread and been responsible for cases or outbreaks in countries such as Czech Republic, 
Hungary, Italy and Greece, which also included cases of neuroinvasive disease in humans 
or horses. Nonetheless, these outbreaks have never led to an extensive spread of the virus 
across Europe and its distribution is more focal and contained to the south and eastern parts 
of the continent. As the enzootic transmission cycle of WNV is comprised of both a vector 
(mosquito) and a vertebrate amplification host (birds) it is rather complex, and also a 
challenge to completely understand.  
The aim of this thesis was to investigate the limited spread of WNV within Europe and to 
assess whether this virus could actually present a greater risk to Europe in the future. As a 
result, the following questions were addressed: 
1) Are European strains of WNV less virulent than the American strains? 
2) Are birds in Europe less susceptible to infection with WNV? 
3) Would a vaccine be able to protect against infection with both lineage 1 and 2 
WNVs? 
The section “pathogenesis” of this thesis comprises Chapters 2, 3 and 4. Chapter 2 
characterizes the virulence and neuroinvasive potential of a selection of European strains of 
WNV (two from Italy, one from Hungary) using parameters such as in vitro replication and 
fitness on neuroblastoma cells, followed by intraperitoneal infection of C57BL/6 mice and 
measuring the mortality (LD50), viral burden in the brain and spinal cord, as well as 
response to infection in the brain using genetic markers that are known to play a role in 
neurodegenerative disease. The results indicated that all the WNV strains were 
neuroinvasive and neurovirulent in the mice. The Ita09 strain, which was responsible for a 
large outbreak in Italy in 2009, demonstrated the highest fitness in vitro. The strain from 
Hungary, 578/10 was the most virulent in mice as it had the lowest LD50 value as well as 
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the highest viral RNA burden in the brain. The other Italian strain, FIN, showed the lowest 
mortality in mice compared to the other two strains. Despite a 99.7% similarity at the 
nucleotide level between these two strains, Ita09 appeared to be slightly more virulent 
compared to FIN in this study. 
In order to improve the ability to measure virulence, a qRT-PCR assay was set-up in 
Chapter 3 that more accurately quantifies the negative and positive RNA strands of WNV. 
By this means, this assay is able to measure the replication rate of WNV as well as 
determining its cellular tropism. To assess the in vitro applicability and utility of this qRT-
PCR, it was used to measure the increase in WNV-specific RNA strands over the course of 
48 hours in the microglial cell line BV-2, as infection of microglial cells by WNV is 
elusive. A clear increase in both positive- and negative-stranded RNA was seen over time, 
which indicated that this cell line is permissive to WNV. The qRT-PCR was also used in a 
mouse experiment in which 9-day-old mice were infected with NY99, and mouse brains 
were sampled on days 3, 4, 5, and 6 for RNA isolation. In this experiment an increase in 
both negative- and positive-stranded RNA was also seen over time, suggesting that this tool 
might also be appropriate for studying in vivo replication. A potential drawback of this 
assay, however, might be its sensitivity, as in this study the detection limit was found to 
vary between 102-103 RNA copies. As a result, this assay might not be useful for measuring 
negative-stranded RNA in the early stages of infection. 
The aim of Chapter 4 was to identify virulence markers of a lineage 2 strain of WNV. 
Markers were selected from the literature which have already been shown to attenuate 
lineage 1 WNV strains, either in vitro or in vivo. Five different molecular clones were 
designed based on the Hungarian lineage 2 strain 578/10, each harboring a mutation in a 
nonstructural protein (NS1-P250L, NS2A-A30P, NS3-P249H, NS4B-P38G, and NS4B-
E249G). After intraperitoneal infection of these mutants in C57BL/6 mice, the NS1-P250L 
mutant appeared to be the most attenuated giving 0% mortality of these mice at both the 
low and high dose. In vitro infection of a Vero E6 cell line with this mutant also showed 
significantly lower infectious virus titers compared to the wildtype. This directed the focus 
to studying the replication competence of the NS1 mutant by measuring the amount of 
positive- and negative-stranded RNA produced in Vero E6 cells in 48 hours using the qRT-
PCR developed in Chapter 3. It was found that the NS1 mutant produced significantly less 
positive and negative strands of RNA as compared to the wildtype, which might explain 
why this mutant was attenuated in vivo as well. 
Chapters 5 and 6 are part of the section “host” of this thesis, which investigates the 
susceptibility of corvids to WNV in the Netherlands. Jackdaws (Chapter 5) and carrion 
crows (Chapter 6) were experimentally infected with five different strains of WNV, 
namely NY99, Greece-10, FIN, Ita09 and 578-10, of which Greece-10 is the strain that was 
responsible for the large outbreak in humans with many cases of neuroinvasive disease in 
Greece in 2010. Carrion crows appeared to be more susceptible to WNV than the jackdaws 
as they demonstrated higher mortality (83-100% for crows compared to 30-60% for 
jackdaws), higher peak viremia titers in the blood (approx. 103 RNA copies/mL) and more 
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dissemination of virus to the organs (102 RNA copies/g). However, FIN did not induce any 
mortality in both the jackdaws and crows, and birds infected with this strain had 
significantly lower viremia titers as well. An amino acid alignment of FIN and Ita09 
identified a differential marker between the two strains, NS3-T249P, which has already 
been linked to augmented virulence in the American crow. This virulence marker may 
therefore play a role in the spread of particular strains of WNV within Europe as well. The 
experiments in Chapters 5 and 6 indicate that the carrion crow could potentially be used 
for WNV surveillance within Europe as part of ‘dead bird surveillance’, while the jackdaw 
could be used as a sentinel in serosurveillance. Even though the role of these birds in 
amplification of the virus still needs to be experimentally confirmed, our studies suggest 
that the carrion crow could be an efficient amplification host while jackdaws might not 
sustain viremia titers above the threshold required for efficient infection of mosquitoes 
(105.2 TCID50). 
The last chapter, Chapter 7, is part of the thesis section “intervention strategies”. 
Herein, the effectiveness of an MVA-based vaccine for the protection against infection with 
both lineage 1 and 2 WNVs is evaluated in C57BL/6 mice. The envelope protein of WNV 
was used as a basis for the development of four recombinant MVAs; one that transcribes 
the (pre)-membrane and envelope proteins, two that code for the envelope harboring the 
transmembrane part of either the wildtype Vaccinia Ankara virus (ETMV) or Chikungunya 
virus and one that transcribes the soluble part of the E protein (Esol). All constructs 
protected mice from infection with a lethal dose of either Ita09 (lineage 1) or 578/10 
(lineage 2) 56 days after vaccination. In addition, no virus was detected in the brains of 
vaccinated mice as compared to the control group on day 8 post-infection. Furthermore, 
neutralizing antibodies against Ita09, but also against 578/10 were found in the blood on 
day 56 post-vaccination, which may explain the heterologous cross-protection witnessed in 
vivo. However, heterologous neutralizing antibodies titers were found to be lower compared 
to the homologous titers. Lastly, vaccination of HLA-A2.1-/HLA-DR1-transgenic H-2 class 
I-/class II mice induced an SV9 epitope-specific IFN-γ-secreting CD8+ T cell response, an 
immunodominant epitope found after WNV infection in humans, which indicates that the 
vaccines could also induce a CD8+ T cell-specific response in humans that may be 
protective against WNV.  
In summary, this thesis has led to several insights regarding the presence of WNV in 
Europe. The WNV strains utilized in our studies were all three found to be neuroinvasive 
and neurovirulent in mice and European strains may therefore present an equal threat to 
Europe as the NY99 strain did to the inhabitants of the US. Our studies have also 
demonstrated the virulence of a lineage 2 strain of WNV, despite the limited amount of 
cases that have been associated with this strain. This suggests that lineage 2 strains of WNV 
that may arise in the future in Europe could also be virulent. Furthermore, this thesis has 
shown that infection of the carrion crow with WNV may play a role in the (future) spread 
of this virus within Europe and could serve as an indicator of WNV activity. As a result, 
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WNV could remain a threat for Europe and the results may prove to be useful for directing 
WNV surveillance methods. Lastly, if WNV becomes a future epidemic burden to Europe, 
the MVA-based vaccine that we have investigated may be useful in protecting against 
infection with both lineage 1 and 2 WNVs. 
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behulpzaamheid voelde ik me snel thuis op Ee1714 en ik kan me nog steeds herinneren dat 
je op mijn eerste werkdag mijn bureau (lees: bijzettafeltje) voor me had schoongemaakt en 
dat ik je login en wachtwoord mocht gebruiken toen ik nog niet mijn eigen account had. Ik 
hoop je nog vaker te zien in Utrecht voor een kletspraatje! 
De volgende andere mede-collega’s wil ik graag bedanken voor hun gezelligheid, zoals bij 
borrels, etentjes, op het lab of in de trein: Stefan V, Werner, Ramona, Carolien, 
Mathilde, Miranda, Claudia, Stalin, Stefan N, Gijs, Stella, Sander, Rachel, Eefje, 
Lidewij, Johanna, Mart, Rory, Alwin. Ook collega’s die zijn gekomen nadat ik al klaar 
was, Wesley, Laura en Stephanie.  
Josanne – Pas na de echte PhD periode kwamen we met elkaar in contact! Maar omdat we 
ongeveer in dezelfde fase van afronding zaten wat betreft ons proefschrift hebben we veel 
hierover kunnen bespreken en kon je mij vaak al vertellen over de volgende stap. Ik hoop 
dat we elkaar nog vaak zullen treffen in Utrecht of Hannover en samen nog veel TBEV 
besprekingen en hopelijk ook experimenten zullen hebben.  
My UCU friends: Cheryl, Emily, Stijn, Wouter, Xandra, Britt, Frederieke, Niels, Phil, 
Sietske, Ruben and Illy (UCU-adopted;) (en bijgekomen aanhang zoals Jurriaan, Peter, 
Lex, Lisa, Ingunn, Indira, David, Charlotte, Ioannis, Marion). I am so glad I had you 
guys for fun, distractions, conversations, drinks and trips and also being able to share PhD 
or research perils with some of you! We have been friends for at least 10 years (even 
though we don’t feel much older) and I hope we will remain friends for many years to 
come.  
Britta en Nina – Tijdens onze stage bij het EWI heb ik jullie gevonden en hebben we 
daarna ook nog vele leuke tijden doorgebracht in oa Utrecht, Neede (tentfeest;), Duinrell, 
Haarlem, Amsterdam. Het feit dat jullie tegelijkertijd bezig waren met jullie PhD (of iig 
met labwerk) heeft ons uiteraard nog meer bij elkaar gebracht. Ik zou nog steeds willen dat 
jullie vaker plek hadden in jullie overvolle agenda’s;). Britta, ik vind het erg jammer dat je 
naar Stockholm gaat verhuizen en ik ga je zeker missen, vooral nu we onze HSP 
gelijkenissen hebben gevonden, maar Nina en ik komen jullie zeker opzoeken! 
George and Alanna – Nothing, incl Leiden or my PhD period would have been the same 
without you guys! I found you on a cold, winter’s night in 2011 when I was moody from 
walking through the snow We immediately became a great quartet and saw each other 
almost every weekend. Great dinners, experiMentationS, bbqs, beach, the lake, chilling in 
the park, Science club, movies, Paris, New York, Giethoorn....! Life truly changed when 
you guys left for the USA and becoming JAGS again is probably now more a dream than 
ever. Thanks for your friendship! 
I would also like to thank other Leiden friends that made Leiden truly feel like home and 
gave me some great company; Mira, Daniel, Mia, David, Geoffrey, Marlène, Phat, 
Stefanie, Youssry, Samira, Job, Marjolein, Eva, Sebastian, Sanjay, Anna, Pim, 
Miriam,  Iris, Yessica, Bas. 
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Some French friends such as Anastasia, Anne-Laure and Niels, and Anais and Rocco for 
some wonderful dinners and fun! 
Huidige (ex-)Artemis collega’s zoals Leslie, Linda, Susan, Loubiela, Mirelle, Guido, 
Anne, Ruud; ook al niet direct betrokken geweest bij mijn promotietraject, wel aanwezig 
tijdens mijn (lange) afrondings phase. Jullie zijn/waren hele fijne collega’s! Loubiela en 
Mirelle, bedaknt voor al jullie werk op het lab, en door jullie te mogen begeleiden heb ik 
veel geleerd! 
Lieve Lim familieleden (alfabetisch): Gavin, Gunilla, James, Jasper, Jon, Lance, 
Tiara, Tita, Twyla en de kids. En Goedraad familieleden, Pucky, Iris, Ad, Remke, 
Willem-Jan, Sanne en Thije. Ik vind het altijd zo fijn om bij jullie te zijn en we hebben 
altijd zoveel lol. Hopelijk kunnen we elkaar nog vaker zien in de toekomst. 
Papa en mama: Ik ben zo blij dat jullie in 2011 naar Nederland zijn gekomen! Elkaar maar 
2× per jaar zien (mama wel wat vaker natuurlijk ) voor 7 jaar lang begon steeds zwaarder te 
wegen en ik ben blij dat papa het mogelijk gemaakt heeft om overgeplaatst te worden. Nu 
zien we elkaar 2× per maand en hebben jullie een belangrijke periode eindelijk van 
“dichtbij”  mee kunnen maken (zoals papa altijd voelde dat hij veel dingen heeft gemist). 
Van bijna pathologisch verlegen tweelingmeisjes hebben jullie ons toch om weten te 
toveren naar iets redelijk geslaagds;) Bedankt voor alles wat jullie voor ons gedaan hebben 
(“alles” in 30 jaar is echt heel veel!)! Hopelijk kan ik jullie nog steeds trots maken in de 
toekomst! 
Zusje Jamie. Het heeft zeker geholpen dat we samen naar Nederland zijn gekomen en dat 
we iig elkaar hadden. (Bijvoorbeeld, op UC kon ik altijd mijn kleren bij jou komen strijken 
als ik me eenzaam voelde;)) Dat we bijna tegelijkertijd begonnen met onze PhD en beiden 
iets gerelateerd aan de hersenen deden kon eigenlijk niet missen! Vier jaar lang hebben we 
veel verhalen uitgewisseld en daardoor veel aan elkaar gehad. Het was voor mij altijd een 
geruststelling en aanmoediging, “als jij iets kan dan kan ik het ook”, en ik denk dat dat nog 
lang zal gelden. Ook al doe je nu geen research meer vind ik het leuk dat het zo goed gaat 
bij je nieuwe baan en gaan we de komende tijd misschien toch echt een keer iets niet 
hetzelfde doen Ik hoop dat we nog lang dicht bij elkaar in de buurt zullen blijven! 
Chers beaux-parents Luc et Micheline, merci de m'avoir toujours accueillie à Lyon ou au 
chalet et de m'avoir permis de me détendre pendant les vacances avec des randonnées 
exceptionnelles, de la bonne nourriture et des conversations agréables! Tom, even though 
we should have seen each other more often (for example in France or England), the two 
times we saw you in London as well as the two times you came to visit us in Leiden were 
great! 
Julien: C'est à mon tour, à présent (en français et presque 6 ans après toi!). Tu m’as suivie 
jusqu’aux Pays-Bas et ma période de thèse n’aurait jamais été la même sans toi! Tu es mon 
meilleur ami et mon “roc” et tu m’as toujours soutenue pendant cette période. J’admire ton 
intelligence et tes connaissances, tu m’as aussi aidée avec certains calculs et graphiques. 
Ton esprit calme, appaisant, rationnel mais positif, a toujours été très important pour moi, et 
passer du temps avec toi les soirs et les weekends m’a tellement aidée à me détendre et à 
oublier le mauvais temps au boulot. Tu m’as bien initiée aux sorties au grand air (les 
randonnées et l'escalade) et je n’oublierai jamais nos excellentes vacances aux États-Unis et 
en France! En ce moment nous nous trouvons dans une période très difficile mais j’en suis 
sûre qu’on va se battre et s'en sortir! 
